{"PMC7118644": [["IntroductionThe first human coronaviruses (HCoVs) were identified in the 1960s [1], and for the majority of the past six decades, HCoVs have generally maintained a relatively innocuous reputation as a cause of the common cold [2].", [["human", "ORGANISM", 22, 27], ["coronaviruses", "ORGANISM", 28, 41], ["HCoVs", "CANCER", 43, 48], ["HCoVs", "GENE_OR_GENE_PRODUCT", 130, 135], ["human", "SPECIES", 22, 27], ["human coronaviruses", "SPECIES", 22, 41], ["HCoVs", "SPECIES", 43, 48]]], ["However, public perception and awareness of HCoVs has shifted considerably in the last twenty years, with the onset of three high profile outbreaks that have garnered international attention and have subsequently led to renewed interest in potential therapeutic options for HCoV-related illnesses.", [["HCoVs", "CHEMICAL", 44, 49], ["HCoV", "CHEMICAL", 274, 278], ["HCoVs", "GENE_OR_GENE_PRODUCT", 44, 49], ["HCoV", "SPECIES", 274, 278], ["HCoVs", "PROBLEM", 44, 49], ["HCoV", "PROBLEM", 274, 278], ["related illnesses", "PROBLEM", 279, 296]]], ["In 2002\u20132003, severe acute respiratory syndrome coronavirus (SARS-CoV) infected more than 8000 people, reaching 26 countries and resulting in a 10% case fatality rate [3].", [["acute respiratory syndrome coronavirus", "DISEASE", 21, 59], ["SARS-CoV) infected", "DISEASE", 61, 79], ["severe acute respiratory syndrome coronavirus", "ORGANISM", 14, 59], ["SARS-CoV", "ORGANISM", 61, 69], ["people", "ORGANISM", 95, 101], ["people", "SPECIES", 95, 101], ["severe acute respiratory syndrome coronavirus", "SPECIES", 14, 59], ["SARS-CoV", "SPECIES", 61, 69], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 14, 59], ["severe", "OBSERVATION_MODIFIER", 14, 20], ["acute", "OBSERVATION_MODIFIER", 21, 26], ["respiratory syndrome coronavirus", "OBSERVATION", 27, 59]]], ["In the ~7 years between April 2012 and November 2019, there were 2494 laboratory-confirmed cases of infection with Middle East respiratory syndrome coronavirus (MERS-CoV) that reached 27 countries and had a mortality rate of approximately 34% [4], though serologic studies have implied that the prevalence of MERS-CoV may have been underestimated [5].", [["infection", "DISEASE", 100, 109], ["Middle East respiratory syndrome coronavirus", "DISEASE", 115, 159], ["Middle East respiratory syndrome coronavirus", "ORGANISM", 115, 159], ["MERS-CoV", "ORGANISM", 161, 169], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 309, 317], ["Middle East respiratory syndrome coronavirus", "SPECIES", 115, 159], ["MERS-CoV", "SPECIES", 161, 169], ["MERS-CoV", "SPECIES", 309, 317], ["infection", "PROBLEM", 100, 109], ["Middle East respiratory syndrome coronavirus", "PROBLEM", 115, 159], ["a mortality rate", "TEST", 205, 221], ["serologic studies", "TEST", 255, 272], ["infection", "OBSERVATION", 100, 109], ["Middle", "ANATOMY_MODIFIER", 115, 121], ["respiratory syndrome", "OBSERVATION", 127, 147]]], ["Most recently, the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in December 2019 in Wuhan and its subsequent spread to over 160 countries across the world has generated intense interest in vaccine development and treatment options for coronavirus disease 2019 (COVID-19) [6,7].IntroductionRemdesivir (GS-5734, Fig. 1a) is an investigational broad-spectrum small-molecule antiviral drug that has demonstrated activity against RNA viruses in several families, including Coronaviridae (such as SARS-CoV, MERS-CoV, and strains of bat coronaviruses capable of infecting human respiratory epithelial cells), Paramyxoviridae (such as Nipah virus, respiratory syncytial virus, and Hendra virus), and Filoviridae (such as Ebola virus) [[8], [9], [10], [11], [12]].", [["respiratory epithelial cells", "ANATOMY", 600, 628], ["acute respiratory syndrome coronavirus", "DISEASE", 39, 77], ["coronavirus disease", "DISEASE", 264, 283], ["IntroductionRemdesivir", "CHEMICAL", 306, 328], ["GS-5734", "CHEMICAL", 330, 337], ["Nipah virus", "DISEASE", 656, 667], ["respiratory syncytial virus", "DISEASE", 669, 696], ["GS-5734", "CHEMICAL", 330, 337], ["severe acute respiratory syndrome coronavirus 2", "ORGANISM", 32, 79], ["SARS-CoV-2", "ORGANISM", 81, 91], ["GS-5734", "SIMPLE_CHEMICAL", 330, 337], ["SARS-CoV", "ORGANISM", 520, 528], ["MERS-CoV", "ORGANISM", 530, 538], ["bat coronaviruses", "ORGANISM", 555, 572], ["human", "ORGANISM", 594, 599], ["respiratory epithelial cells", "CELL", 600, 628], ["Nipah virus", "ORGANISM", 656, 667], ["respiratory syncytial virus", "ORGANISM", 669, 696], ["Hendra virus", "ORGANISM", 702, 714], ["Ebola virus", "ORGANISM", 742, 753], ["[9], [10], [11], [12]]", "SIMPLE_CHEMICAL", 761, 783], ["human respiratory epithelial cells", "CELL_TYPE", 594, 628], ["bat coronaviruses", "SPECIES", 555, 572], ["human", "SPECIES", 594, 599], ["Nipah virus", "SPECIES", 656, 667], ["respiratory syncytial virus", "SPECIES", 669, 696], ["Hendra virus", "SPECIES", 702, 714], ["Ebola virus", "SPECIES", 742, 753], ["severe acute respiratory syndrome coronavirus", "SPECIES", 32, 77], ["SARS-CoV-2", "SPECIES", 81, 91], ["SARS-CoV", "SPECIES", 520, 528], ["MERS-CoV", "SPECIES", 530, 538], ["bat coronaviruses", "SPECIES", 555, 572], ["human", "SPECIES", 594, 599], ["Nipah virus", "SPECIES", 656, 667], ["respiratory syncytial virus", "SPECIES", 669, 696], ["Hendra virus", "SPECIES", 702, 714], ["Ebola virus", "SPECIES", 742, 753], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 32, 77], ["vaccine development", "TREATMENT", 218, 237], ["treatment options", "TREATMENT", 242, 259], ["coronavirus disease", "PROBLEM", 264, 283], ["COVID", "TEST", 290, 295], ["IntroductionRemdesivir", "TEST", 306, 328], ["GS", "TEST", 330, 332], ["an investigational broad-spectrum small-molecule antiviral drug", "TREATMENT", 351, 414], ["RNA viruses", "PROBLEM", 454, 465], ["Coronaviridae", "TREATMENT", 497, 510], ["SARS", "PROBLEM", 520, 524], ["MERS", "PROBLEM", 530, 534], ["CoV", "PROBLEM", 535, 538], ["strains", "PROBLEM", 544, 551], ["bat coronaviruses", "PROBLEM", 555, 572], ["infecting human respiratory epithelial cells", "TREATMENT", 584, 628], ["Paramyxoviridae", "TREATMENT", 631, 646], ["Nipah virus", "PROBLEM", 656, 667], ["respiratory syncytial virus", "PROBLEM", 669, 696], ["Hendra virus", "PROBLEM", 702, 714], ["Filoviridae", "TREATMENT", 721, 732], ["Ebola virus", "TEST", 742, 753], ["severe", "OBSERVATION_MODIFIER", 32, 38], ["acute", "OBSERVATION_MODIFIER", 39, 44], ["respiratory syndrome", "OBSERVATION", 45, 65], ["molecule antiviral drug", "OBSERVATION", 391, 414], ["epithelial cells", "OBSERVATION", 612, 628]]], ["Originally developed to treat Ebola virus infection [8], remdesivir is a prodrug of the parent adenosine analog, GS-441524 (Fig. 1b), both of which are metabolized into an active nucleoside triphosphate (NTP) by the host (Fig. 1c) [13].", [["Ebola virus infection", "DISEASE", 30, 51], ["remdesivir", "CHEMICAL", 57, 67], ["adenosine", "CHEMICAL", 95, 104], ["GS-441524", "CHEMICAL", 113, 122], ["nucleoside triphosphate", "CHEMICAL", 179, 202], ["NTP", "CHEMICAL", 204, 207], ["remdesivir", "CHEMICAL", 57, 67], ["adenosine", "CHEMICAL", 95, 104], ["GS-441524", "CHEMICAL", 113, 122], ["nucleoside triphosphate", "CHEMICAL", 179, 202], ["NTP", "CHEMICAL", 204, 207], ["Ebola virus", "ORGANISM", 30, 41], ["remdesivir", "SIMPLE_CHEMICAL", 57, 67], ["adenosine", "SIMPLE_CHEMICAL", 95, 104], ["GS-441524", "SIMPLE_CHEMICAL", 113, 122], ["Fig. 1b", "GENE_OR_GENE_PRODUCT", 124, 131], ["nucleoside triphosphate", "SIMPLE_CHEMICAL", 179, 202], ["NTP", "SIMPLE_CHEMICAL", 204, 207], ["Ebola virus", "SPECIES", 30, 41], ["Ebola virus", "SPECIES", 30, 41], ["Ebola virus infection", "PROBLEM", 30, 51], ["GS", "TEST", 113, 115], ["an active nucleoside triphosphate (NTP", "TREATMENT", 169, 207], ["Ebola virus", "OBSERVATION", 30, 41], ["active", "OBSERVATION_MODIFIER", 172, 178], ["nucleoside triphosphate", "OBSERVATION", 179, 202]]], ["The parent nucleoside, GS-441524, has displayed antiviral activity against SARS-CoV, Marburg virus, and feline infectious peritonitis virus, among others [9,[14], [15], [16]].", [["nucleoside", "CHEMICAL", 11, 21], ["GS-441524", "CHEMICAL", 23, 32], ["SARS-CoV, Marburg virus", "DISEASE", 75, 98], ["feline infectious peritonitis", "DISEASE", 104, 133], ["nucleoside", "CHEMICAL", 11, 21], ["GS-441524", "CHEMICAL", 23, 32], ["nucleoside", "SIMPLE_CHEMICAL", 11, 21], ["GS-441524", "SIMPLE_CHEMICAL", 23, 32], ["SARS-CoV", "ORGANISM", 75, 83], ["Marburg virus", "ORGANISM", 85, 98], ["feline infectious peritonitis virus", "ORGANISM", 104, 139], ["Marburg virus", "SPECIES", 85, 98], ["feline infectious peritonitis virus", "SPECIES", 104, 139], ["SARS-CoV", "SPECIES", 75, 83], ["Marburg virus", "SPECIES", 85, 98], ["feline infectious peritonitis virus", "SPECIES", 104, 139], ["The parent nucleoside, GS", "TEST", 0, 25], ["SARS", "PROBLEM", 75, 79], ["CoV", "PROBLEM", 80, 83], ["Marburg virus", "PROBLEM", 85, 98], ["feline infectious peritonitis virus", "PROBLEM", 104, 139], ["infectious", "OBSERVATION_MODIFIER", 111, 121], ["peritonitis", "OBSERVATION", 122, 133]]], ["A number of studies have examined the effects of these two drugs on coronaviruses (CoVs) both in vitro and in vivo using mouse and non-human primate animal models [[9], [10], [11],13,17,18].IntroductionThere are currently no antiviral drugs approved for the treatment of CoV-specific illnesses.", [["CoV-specific illnesses", "DISEASE", 271, 293], ["coronaviruses", "ORGANISM", 68, 81], ["CoVs", "CELL", 83, 87], ["mouse", "ORGANISM", 121, 126], ["[10], [11],13,17,18].", "SIMPLE_CHEMICAL", 169, 190], ["CoV", "ORGANISM", 271, 274], ["mouse", "SPECIES", 121, 126], ["mouse", "SPECIES", 121, 126], ["these two drugs", "TREATMENT", 49, 64], ["coronaviruses (CoVs)", "TREATMENT", 68, 88], ["antiviral drugs", "TREATMENT", 225, 240], ["CoV-specific illnesses", "PROBLEM", 271, 293], ["antiviral drugs", "OBSERVATION", 225, 240]]], ["Given the rapidly evolving pandemic of COVID-19, it is crucial for public health practitioners and the One Health community to stay up to date on potential therapeutic options that are under investigation [19].", [["COVID-19", "CELL", 39, 47], ["COVID", "TEST", 39, 44]]], ["Based on existing data, remdesivir is a promising candidate, and multi-site clinical trials of remdesivir are now underway among hospitalized adults with COVID-19 [20].", [["remdesivir", "CHEMICAL", 24, 34], ["remdesivir", "CHEMICAL", 95, 105], ["remdesivir", "CHEMICAL", 24, 34], ["remdesivir", "CHEMICAL", 95, 105], ["COVID-19", "CHEMICAL", 154, 162], ["remdesivir", "SIMPLE_CHEMICAL", 24, 34], ["remdesivir", "SIMPLE_CHEMICAL", 95, 105], ["remdesivir", "TREATMENT", 95, 105], ["COVID", "TEST", 154, 159]]], ["This review summarizes the knowledge to date on remdesivir as a therapeutic option for CoVs.Overview of coronavirusesViruses classified under the Coronaviridae family are enveloped positive-sense, single-stranded RNA viruses that exhibit high genetic diversity [21].", [["remdesivir", "CHEMICAL", 48, 58], ["coronaviruses", "DISEASE", 104, 117], ["remdesivir", "CHEMICAL", 48, 58], ["remdesivir", "SIMPLE_CHEMICAL", 48, 58], ["CoVs", "SIMPLE_CHEMICAL", 87, 91], ["coronaviruses", "ORGANISM", 104, 117], ["Coronaviridae", "GENE_OR_GENE_PRODUCT", 146, 159], ["Coronaviridae family", "DNA", 146, 166], ["remdesivir", "TREATMENT", 48, 58], ["CoVs", "PROBLEM", 87, 91], ["coronaviruses", "PROBLEM", 104, 117], ["Viruses", "PROBLEM", 117, 124], ["single-stranded RNA viruses", "PROBLEM", 197, 224], ["high genetic diversity", "PROBLEM", 238, 260], ["coronaviruses", "OBSERVATION", 104, 117]]], ["Within the Orthocoronavirinae subfamily, there are four genera: alphacoronavirus, betacoronavirus, gammacoronavirus, and deltacoronavirus.", [["alphacoronavirus", "GENE_OR_GENE_PRODUCT", 64, 80], ["betacoronavirus", "GENE_OR_GENE_PRODUCT", 82, 97], ["gammacoronavirus", "GENE_OR_GENE_PRODUCT", 99, 115], ["Orthocoronavirinae subfamily", "PROTEIN", 11, 39], ["alphacoronavirus", "TREATMENT", 64, 80], ["betacoronavirus", "TREATMENT", 82, 97], ["gammacoronavirus", "TREATMENT", 99, 115], ["deltacoronavirus", "TREATMENT", 121, 137]]], ["Viruses in this family can infect a wide variety of host species, such as birds, humans, and non-human mammals, including dromedary camels, alpacas, domestic pigs, dogs, cats, ferrets, minks, and bats [5,11,12,16,[22], [23], [24]].", [["humans", "ORGANISM", 81, 87], ["dromedary camels", "ORGANISM", 122, 138], ["alpacas", "ORGANISM", 140, 147], ["pigs", "ORGANISM", 158, 162], ["dogs", "ORGANISM", 164, 168], ["cats", "ORGANISM", 170, 174], ["ferrets", "ORGANISM", 176, 183], ["5,11,12,16,[22], [23", "SIMPLE_CHEMICAL", 202, 222], ["humans", "SPECIES", 81, 87], ["pigs", "SPECIES", 158, 162], ["dogs", "SPECIES", 164, 168], ["cats", "SPECIES", 170, 174], ["ferrets", "SPECIES", 176, 183], ["humans", "SPECIES", 81, 87], ["pigs", "SPECIES", 158, 162], ["Viruses", "PROBLEM", 0, 7], ["host species", "OBSERVATION", 52, 64]]], ["However, to our knowledge, only viruses of the alpha- and betacoronavirus genera infect humans [2], though those in the gamma- and deltacoronavirus genera have indirect effects through economic impacts on the agricultural production of poultry and pigs [12].", [["alpha", "GENE_OR_GENE_PRODUCT", 47, 52], ["betacoronavirus genera", "ORGANISM", 58, 80], ["humans", "ORGANISM", 88, 94], ["poultry", "ORGANISM_SUBDIVISION", 236, 243], ["pigs", "ORGANISM", 248, 252], ["gamma", "PROTEIN", 120, 125], ["humans", "SPECIES", 88, 94], ["pigs", "SPECIES", 248, 252], ["humans", "SPECIES", 88, 94], ["the alpha", "TEST", 43, 52], ["betacoronavirus genera infect humans", "PROBLEM", 58, 94], ["the gamma", "TEST", 116, 125], ["deltacoronavirus genera", "TREATMENT", 131, 154], ["alpha", "ANATOMY", 47, 52], ["gamma", "ANATOMY", 120, 125]]], ["Host specificity is believed to be largely dependent upon variation in the CoV spike attachment glycoprotein [23].", [["CoV spike attachment glycoprotein", "PROTEIN", 75, 108], ["the CoV spike attachment glycoprotein", "TREATMENT", 71, 108], ["believed to be", "UNCERTAINTY", 20, 34], ["largely", "OBSERVATION_MODIFIER", 35, 42], ["dependent", "OBSERVATION", 43, 52]]], ["Although the infectivity of most strains is host species-specific, host range is wide across different CoVs, and some bat CoVs rely on the same host receptor (angiotensin-converting enzyme-2; ACE-2) as human CoVs to facilitate entry into cells [11,25,26].", [["cells", "ANATOMY", 238, 243], ["angiotensin", "CHEMICAL", 159, 170], ["CoVs", "GENE_OR_GENE_PRODUCT", 103, 107], ["bat CoVs", "ORGANISM", 118, 126], ["angiotensin-converting enzyme-2", "GENE_OR_GENE_PRODUCT", 159, 190], ["ACE-2", "GENE_OR_GENE_PRODUCT", 192, 197], ["human", "ORGANISM", 202, 207], ["CoVs", "GENE_OR_GENE_PRODUCT", 208, 212], ["cells", "CELL", 238, 243], ["CoVs", "PROTEIN", 122, 126], ["angiotensin-converting enzyme-2; ACE-2", "PROTEIN", 159, 197], ["human CoVs", "PROTEIN", 202, 212], ["human", "SPECIES", 202, 207], ["human", "SPECIES", 202, 207], ["host species", "PROBLEM", 44, 56], ["wide across different CoVs", "PROBLEM", 81, 107], ["some bat CoVs", "PROBLEM", 113, 126], ["angiotensin", "TEST", 159, 170], ["enzyme", "TEST", 182, 188], ["ACE", "TEST", 192, 195], ["most strains", "OBSERVATION_MODIFIER", 28, 40]]], ["It has been hypothesized that the CoV propensity for host-switching may partly be attributable to recombination events that alter the spike protein, which, in turn, affects interactions with host receptors (e.g., ACE-2) [27,28].Overview of coronavirusesHistorically, HCoVs were largely considered to be relatively low virulence viruses that produced less severe, self-limiting disease, and were predominantly known as the second most prevalent cause of colds and upper respiratory infections (URIs), after rhinoviruses [2,29].", [["respiratory", "ANATOMY", 469, 480], ["colds", "DISEASE", 453, 458], ["upper respiratory infections", "DISEASE", 463, 491], ["URIs", "DISEASE", 493, 497], ["CoV", "GENE_OR_GENE_PRODUCT", 34, 37], ["ACE-2", "GENE_OR_GENE_PRODUCT", 213, 218], ["coronaviruses", "ORGANISM", 240, 253], ["HCoVs", "GENE_OR_GENE_PRODUCT", 267, 272], ["colds", "ORGANISM_SUBDIVISION", 453, 458], ["spike protein", "PROTEIN", 134, 147], ["host receptors", "PROTEIN", 191, 205], ["ACE", "PROTEIN", 213, 216], ["recombination events", "PROBLEM", 98, 118], ["the spike protein", "PROBLEM", 130, 147], ["ACE", "TEST", 213, 216], ["coronaviruses", "PROBLEM", 240, 253], ["relatively low virulence viruses", "PROBLEM", 303, 335], ["self-limiting disease", "PROBLEM", 363, 384], ["colds", "PROBLEM", 453, 458], ["upper respiratory infections (URIs)", "PROBLEM", 463, 498], ["rhinoviruses", "PROBLEM", 506, 518], ["less", "OBSERVATION_MODIFIER", 350, 354], ["severe", "OBSERVATION_MODIFIER", 355, 361], ["self-limiting", "OBSERVATION_MODIFIER", 363, 376], ["disease", "OBSERVATION", 377, 384], ["colds", "OBSERVATION", 453, 458], ["upper", "ANATOMY_MODIFIER", 463, 468], ["respiratory", "ANATOMY", 469, 480], ["infections", "OBSERVATION", 481, 491]]], ["The endemic human CoVs that cumulatively account for about 10\u201330% of URIs are HCoV-229E and HCoV-NL63, which are both alphacoronaviruses, and HCoV-OC43 and HCoV-HKU1, which are both betacoronaviruses [2].", [["human", "ORGANISM", 12, 17], ["CoVs", "GENE_OR_GENE_PRODUCT", 18, 22], ["HCoV-229E", "GENE_OR_GENE_PRODUCT", 78, 87], ["HCoV-NL63", "GENE_OR_GENE_PRODUCT", 92, 101], ["alphacoronaviruses", "GENE_OR_GENE_PRODUCT", 118, 136], ["HCoV-OC43", "CELL", 142, 151], ["HCoV-HKU1", "GENE_OR_GENE_PRODUCT", 156, 165], ["HCoV", "DNA", 156, 160], ["HKU1", "DNA", 161, 165], ["human", "SPECIES", 12, 17], ["human", "SPECIES", 12, 17], ["HCoV-229E", "SPECIES", 78, 87], ["HCoV-OC43", "SPECIES", 142, 151], ["The endemic human CoVs", "PROBLEM", 0, 22], ["URIs", "TEST", 69, 73], ["HCoV", "TEST", 78, 82], ["HCoV", "TEST", 92, 96], ["alphacoronaviruses", "TEST", 118, 136], ["HCoV", "TEST", 142, 146], ["OC43", "TEST", 147, 151], ["HCoV", "TEST", 156, 160], ["HKU1", "TEST", 161, 165], ["endemic", "OBSERVATION_MODIFIER", 4, 11], ["human CoVs", "OBSERVATION", 12, 22]]], ["Among patients with URIs severe enough to warrant hospitalization, one study found that approximately 5% of cases were attributable to rhinoviruses or HCoVs, but a substantial proportion of these hospitalized patients had underlying pulmonary or cardiac comorbidities that may have exacerbated their conditions [29].Overview of coronavirusesThe virus underlying COVID-19 (SARS-CoV-2) is a betacoronavirus that is closely related to SARS-CoV.", [["pulmonary", "ANATOMY", 233, 242], ["cardiac", "ANATOMY", 246, 253], ["rhinoviruses", "DISEASE", 135, 147], ["HCoVs", "DISEASE", 151, 156], ["pulmonary or cardiac comorbidities", "DISEASE", 233, 267], ["coronaviruses", "DISEASE", 328, 341], ["SARS", "DISEASE", 432, 436], ["patients", "ORGANISM", 6, 14], ["rhinoviruses", "ORGANISM", 135, 147], ["patients", "ORGANISM", 209, 217], ["pulmonary", "ORGAN", 233, 242], ["cardiac", "ORGAN", 246, 253], ["coronaviruses", "ORGANISM", 328, 341], ["COVID-19", "ORGANISM", 362, 370], ["SARS-CoV-2", "ORGANISM", 372, 382], ["betacoronavirus", "CANCER", 389, 404], ["SARS-CoV", "ORGANISM", 432, 440], ["patients", "SPECIES", 6, 14], ["patients", "SPECIES", 209, 217], ["COVID-19", "SPECIES", 362, 370], ["SARS-CoV-2", "SPECIES", 372, 382], ["SARS-CoV", "SPECIES", 432, 440], ["URIs severe", "PROBLEM", 20, 31], ["one study", "TEST", 67, 76], ["rhinoviruses", "PROBLEM", 135, 147], ["HCoVs", "PROBLEM", 151, 156], ["underlying pulmonary or cardiac comorbidities", "PROBLEM", 222, 267], ["coronaviruses", "PROBLEM", 328, 341], ["The virus underlying COVID", "TEST", 341, 367], ["SARS", "TEST", 372, 376], ["CoV", "TEST", 377, 380], ["a betacoronavirus", "PROBLEM", 387, 404], ["rhinoviruses", "OBSERVATION", 135, 147], ["pulmonary", "ANATOMY", 233, 242], ["cardiac", "ANATOMY", 246, 253], ["comorbidities", "OBSERVATION", 254, 267], ["coronaviruses", "OBSERVATION", 328, 341], ["virus", "OBSERVATION", 345, 350]]], ["These CoVs share ~80% RNA sequence identity [30,31].", [["CoVs", "GENE_OR_GENE_PRODUCT", 6, 10], ["CoVs", "DNA", 6, 10], ["These CoVs", "TEST", 0, 10], ["RNA sequence identity", "TEST", 22, 43]]], ["The similarity is even greater between the viruses when comparing the sequences specific to a key drug target, the RNA-dependent RNA polymerase (RdRP) (>90% sequence identity) [30].", [["RNA-dependent RNA polymerase", "GENE_OR_GENE_PRODUCT", 115, 143], ["RNA-dependent RNA polymerase", "PROTEIN", 115, 143], ["RdRP", "PROTEIN", 145, 149], ["the RNA", "TEST", 111, 118], ["RdRP", "TEST", 145, 149], ["greater", "OBSERVATION_MODIFIER", 23, 30], ["viruses", "OBSERVATION", 43, 50]]], ["By contrast, MERS-CoV shares about 50% genomic sequence identity with SARS-CoV-2 [31], and with the exception of some bat strains, many animal CoVs are even less similar [12].Remdesivir mechanism of actionAs a nucleoside analog, remdesivir acts as an RdRp inhibitor, targeting the viral genome replication process.", [["nucleoside", "CHEMICAL", 210, 220], ["remdesivir", "CHEMICAL", 229, 239], ["nucleoside", "CHEMICAL", 210, 220], ["remdesivir", "CHEMICAL", 229, 239], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 13, 21], ["SARS-CoV-2", "ORGANISM", 70, 80], ["CoVs", "CANCER", 143, 147], ["Remdesivir", "SIMPLE_CHEMICAL", 175, 185], ["nucleoside", "SIMPLE_CHEMICAL", 210, 220], ["remdesivir", "SIMPLE_CHEMICAL", 229, 239], ["MERS-CoV", "DNA", 13, 21], ["MERS-CoV", "SPECIES", 13, 21], ["SARS-CoV", "SPECIES", 70, 78], ["SARS", "TEST", 70, 74], ["CoV", "TEST", 75, 78], ["some bat strains", "PROBLEM", 113, 129], ["many animal CoVs", "PROBLEM", 131, 147], ["a nucleoside analog", "TREATMENT", 208, 227], ["remdesivir acts", "TREATMENT", 229, 244], ["an RdRp inhibitor", "TREATMENT", 248, 265], ["the viral genome replication process", "TREATMENT", 277, 313], ["bat strains", "OBSERVATION", 118, 129], ["animal CoVs", "OBSERVATION", 136, 147], ["viral genome replication", "OBSERVATION", 281, 305]]], ["The RdRp is the protein complex CoVs use to replicate their RNA-based genomes.", [["CoVs", "GENE_OR_GENE_PRODUCT", 32, 36], ["RdRp", "PROTEIN", 4, 8], ["CoVs", "PROTEIN", 32, 36], ["The RdRp", "TREATMENT", 0, 8], ["RdRp", "OBSERVATION", 4, 8]]], ["After the host metabolizes remdesivir into active NTP, the metabolite competes with adenosine triphosphate (ATP; the natural nucleotide normally used in this process) for incorporation into the nascent RNA strand [32].", [["remdesivir", "CHEMICAL", 27, 37], ["NTP", "CHEMICAL", 50, 53], ["adenosine triphosphate", "CHEMICAL", 84, 106], ["ATP", "CHEMICAL", 108, 111], ["nucleotide", "CHEMICAL", 125, 135], ["remdesivir", "CHEMICAL", 27, 37], ["NTP", "CHEMICAL", 50, 53], ["adenosine triphosphate", "CHEMICAL", 84, 106], ["ATP", "CHEMICAL", 108, 111], ["nucleotide", "CHEMICAL", 125, 135], ["remdesivir", "SIMPLE_CHEMICAL", 27, 37], ["NTP", "SIMPLE_CHEMICAL", 50, 53], ["adenosine triphosphate", "SIMPLE_CHEMICAL", 84, 106], ["ATP", "SIMPLE_CHEMICAL", 108, 111], ["active NTP", "TREATMENT", 43, 53], ["adenosine triphosphate (ATP", "TREATMENT", 84, 111], ["the natural nucleotide", "TREATMENT", 113, 135], ["RNA strand", "OBSERVATION", 202, 212]]], ["The incorporation of this substitute into the new strand results in premature termination of RNA synthesis, halting the growth of the RNA strand after a few more nucleotides are added.", [["nucleotides", "CHEMICAL", 162, 173], ["RNA strand", "RNA", 134, 144], ["premature termination of RNA synthesis", "PROBLEM", 68, 106], ["the RNA strand", "TREATMENT", 130, 144], ["a few more nucleotides", "TREATMENT", 151, 173], ["premature", "OBSERVATION_MODIFIER", 68, 77], ["RNA synthesis", "OBSERVATION", 93, 106]]], ["Although CoVs have a proofreading process that is able to detect and remove other nucleoside analogs, rendering them resistant to many of these drugs, remdesivir seems to outpace this viral proofreading activity, thus maintaining antiviral activity [30].", [["nucleoside", "CHEMICAL", 82, 92], ["remdesivir", "CHEMICAL", 151, 161], ["nucleoside", "CHEMICAL", 82, 92], ["remdesivir", "CHEMICAL", 151, 161], ["CoVs", "GENE_OR_GENE_PRODUCT", 9, 13], ["nucleoside analogs", "SIMPLE_CHEMICAL", 82, 100], ["remdesivir", "SIMPLE_CHEMICAL", 151, 161], ["CoVs", "PROTEIN", 9, 13], ["CoVs", "PROBLEM", 9, 13], ["nucleoside analogs", "TREATMENT", 82, 100], ["these drugs", "TREATMENT", 138, 149], ["remdesivir", "TREATMENT", 151, 161]]], ["Unsurprisingly, Agostini et al. reported that a mutant murine hepatitis virus (MHV) devoid of proofreading ability was more sensitive to remdesivir [13].", [["murine hepatitis virus", "DISEASE", 55, 77], ["remdesivir", "CHEMICAL", 137, 147], ["remdesivir", "CHEMICAL", 137, 147], ["mutant", "ORGANISM", 48, 54], ["murine hepatitis virus", "ORGANISM", 55, 77], ["MHV", "ORGANISM", 79, 82], ["murine", "SPECIES", 55, 61], ["hepatitis virus", "SPECIES", 62, 77], ["murine hepatitis virus", "SPECIES", 55, 77], ["MHV", "SPECIES", 79, 82], ["a mutant murine hepatitis virus", "PROBLEM", 46, 77], ["proofreading ability", "PROBLEM", 94, 114]]], ["The opposite is also possible\u2014that mutations that improve proofreading or otherwise increase fidelity of the base-pairing process may result in remdesivir resistance [33].", [["remdesivir", "CHEMICAL", 144, 154], ["remdesivir", "SIMPLE_CHEMICAL", 144, 154], ["mutations", "PROBLEM", 35, 44], ["increase", "OBSERVATION_MODIFIER", 84, 92], ["fidelity", "OBSERVATION_MODIFIER", 93, 101], ["base", "ANATOMY_MODIFIER", 109, 113]]], ["In fact, Agostini et al. also induced mutations in MHV (through passage in remdesivir) that conferred strong resistance against the drug, but these mutated strains were outcompeted by wild-type MHV in coinfected cell cultures that were not exposed to remdesivir [13].", [["cell cultures", "ANATOMY", 212, 225], ["remdesivir", "CHEMICAL", 251, 261], ["remdesivir", "CHEMICAL", 251, 261], ["MHV", "ORGANISM", 51, 54], ["remdesivir", "GENE_OR_GENE_PRODUCT", 75, 85], ["wild-type MHV", "ORGANISM", 184, 197], ["cell cultures", "CELL", 212, 225], ["coinfected cell cultures", "CELL_LINE", 201, 225], ["MHV", "SPECIES", 51, 54], ["MHV", "SPECIES", 194, 197], ["induced mutations in MHV", "PROBLEM", 30, 54], ["these mutated strains", "PROBLEM", 142, 163], ["type MHV in coinfected cell cultures", "PROBLEM", 189, 225], ["mutations", "OBSERVATION", 38, 47], ["MHV", "OBSERVATION_MODIFIER", 51, 54]]], ["How well this experiment would represent a situation in which a resistance mutation developed naturally, though, is unclear.", [["a resistance mutation", "PROBLEM", 62, 83]]], ["Nonetheless, some evidence suggests that remdesivir could have an additional mechanism of action that has yet to be discovered, which, if true, may allow for partial antiviral activity to continue despite viral mutations that enhance replication fidelity [[11], [12], [13]].In vitro studies ::: Summary of studies on remdesivir and coronavirusesThe majority of in vitro efficacy studies conducted to date have reported positive results on the anti-CoV activity of remdesivir and GS-441524 (Table 1).", [["remdesivir", "CHEMICAL", 41, 51], ["remdesivir", "CHEMICAL", 317, 327], ["remdesivir", "CHEMICAL", 464, 474], ["GS-441524", "CHEMICAL", 479, 488], ["remdesivir", "CHEMICAL", 41, 51], ["remdesivir", "CHEMICAL", 464, 474], ["GS-441524", "CHEMICAL", 479, 488], ["remdesivir", "SIMPLE_CHEMICAL", 41, 51], ["[11], [12], [13]]", "SIMPLE_CHEMICAL", 256, 273], ["remdesivir", "SIMPLE_CHEMICAL", 317, 327], ["coronaviruses", "ORGANISM", 332, 345], ["anti-CoV", "SIMPLE_CHEMICAL", 443, 451], ["remdesivir", "SIMPLE_CHEMICAL", 464, 474], ["GS-441524", "SIMPLE_CHEMICAL", 479, 488], ["partial antiviral activity", "TREATMENT", 158, 184], ["viral mutations", "PROBLEM", 205, 220], ["remdesivir", "TEST", 317, 327], ["coronaviruses", "PROBLEM", 332, 345], ["vitro efficacy studies", "TEST", 364, 386], ["GS", "TEST", 479, 481]]], ["Commonly used metrics in these studies are the half maximal effective concentration (EC50), which is the drug concentration at which half of the maximum response is attained after exposure, or the half maximal inhibitory concentration (IC50), which is the drug concentration at which half of the peak inhibiting effect of the drug against a specific viral function is achieved.", [["these studies", "TEST", 25, 38], ["the drug concentration", "TREATMENT", 101, 123], ["the drug concentration", "TREATMENT", 252, 274], ["the drug", "TREATMENT", 322, 330], ["a specific viral function", "TEST", 339, 364]]], ["Lower EC50 and IC50 values indicate higher potency.", [["Lower EC50", "TEST", 0, 10], ["IC50 values", "TEST", 15, 26], ["higher potency", "OBSERVATION_MODIFIER", 36, 50]]], ["Typical outcomes measured in such studies include the amount of viral RNA (e.g., copies of certain open reading frames) in the culture, the number of virus-infected cells in the culture, or changes in viral replication rates.In vitro studies ::: Summary of studies on remdesivir and coronavirusesIn studies of SARS-CoV and MERS-CoV in human respiratory epithelial cell cultures, remdesivir has demonstrated strong antiviral activity (EC50 \u2248 0.07 \u03bcM for either virus) with relative consistency, and has been shown to be capable of inhibiting MERS-CoV replication at levels below those that would result in unacceptable cytotoxicity [11,13].", [["cells", "ANATOMY", 165, 170], ["respiratory epithelial cell cultures", "ANATOMY", 341, 377], ["remdesivir", "CHEMICAL", 268, 278], ["SARS", "DISEASE", 310, 314], ["remdesivir", "CHEMICAL", 379, 389], ["remdesivir", "CHEMICAL", 379, 389], ["cells", "CELL", 165, 170], ["remdesivir", "SIMPLE_CHEMICAL", 268, 278], ["coronaviruses", "ORGANISM", 283, 296], ["SARS-CoV", "ORGANISM", 310, 318], ["MERS-CoV", "ORGANISM", 323, 331], ["human", "ORGANISM", 335, 340], ["respiratory epithelial cell cultures", "CELL", 341, 377], ["remdesivir", "SIMPLE_CHEMICAL", 379, 389], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 541, 549], ["viral RNA", "RNA", 64, 73], ["open reading frames", "DNA", 99, 118], ["virus-infected cells", "CELL_TYPE", 150, 170], ["human respiratory epithelial cell cultures", "CELL_LINE", 335, 377], ["human", "SPECIES", 335, 340], ["SARS-CoV", "SPECIES", 310, 318], ["MERS-CoV", "SPECIES", 323, 331], ["human", "SPECIES", 335, 340], ["MERS-CoV", "SPECIES", 541, 549], ["Typical outcomes", "PROBLEM", 0, 16], ["such studies", "TEST", 29, 41], ["viral RNA", "PROBLEM", 64, 73], ["the culture", "TEST", 123, 134], ["virus", "PROBLEM", 150, 155], ["infected cells", "PROBLEM", 156, 170], ["the culture", "TEST", 174, 185], ["viral replication rates", "TREATMENT", 201, 224], ["remdesivir", "TEST", 268, 278], ["coronaviruses", "PROBLEM", 283, 296], ["SARS", "PROBLEM", 310, 314], ["CoV", "TEST", 315, 318], ["MERS", "TEST", 323, 327], ["CoV in human respiratory epithelial cell cultures", "TEST", 328, 377], ["remdesivir", "TEST", 379, 389], ["EC50", "TEST", 434, 438], ["virus", "PROBLEM", 460, 465], ["inhibiting MERS", "PROBLEM", 530, 545], ["CoV replication", "TREATMENT", 546, 561], ["unacceptable cytotoxicity", "PROBLEM", 605, 630], ["viral RNA", "OBSERVATION", 64, 73], ["infected cells", "OBSERVATION", 156, 170], ["viral replication", "OBSERVATION", 201, 218], ["SARS", "OBSERVATION", 310, 314], ["respiratory epithelial", "ANATOMY", 341, 363], ["cell", "OBSERVATION", 364, 368], ["strong", "OBSERVATION_MODIFIER", 407, 413], ["antiviral activity", "OBSERVATION", 414, 432]]], ["Interestingly, a study published in February 2020 by Wang et al. was the first, to our knowledge, to examine the effect of remdesivir against SARS-CoV-2, the HCoV involved in the current pandemic [17].", [["remdesivir", "CHEMICAL", 123, 133], ["SARS", "DISEASE", 142, 146], ["remdesivir", "CHEMICAL", 123, 133], ["remdesivir", "SIMPLE_CHEMICAL", 123, 133], ["SARS-CoV-2", "ORGANISM", 142, 152], ["HCoV", "CANCER", 158, 162], ["SARS-CoV", "SPECIES", 142, 150], ["HCoV", "SPECIES", 158, 162], ["a study", "TEST", 15, 22], ["remdesivir", "TREATMENT", 123, 133], ["SARS", "PROBLEM", 142, 146], ["CoV", "TEST", 147, 150]]], ["This study investigated the impact of seven different drugs on viral titers, cytotoxicity, and infection rates, using Vero E6 cells (a cell line originating from African green monkey kidney epithelial cells).", [["Vero E6 cells", "ANATOMY", 118, 131], ["cell line", "ANATOMY", 135, 144], ["kidney epithelial cells", "ANATOMY", 183, 206], ["infection", "DISEASE", 95, 104], ["Vero E6 cells", "CELL", 118, 131], ["cell line", "CELL", 135, 144], ["monkey", "ORGANISM", 176, 182], ["kidney epithelial cells", "CELL", 183, 206], ["Vero E6 cells", "CELL_LINE", 118, 131], ["cell line", "CELL_LINE", 135, 144], ["African green monkey kidney epithelial cells", "CELL_TYPE", 162, 206], ["green monkey", "SPECIES", 170, 182], ["Vero E6", "SPECIES", 118, 125], ["African green monkey", "SPECIES", 162, 182], ["This study", "TEST", 0, 10], ["seven different drugs", "TREATMENT", 38, 59], ["viral titers", "TREATMENT", 63, 75], ["cytotoxicity", "PROBLEM", 77, 89], ["infection rates", "PROBLEM", 95, 110], ["Vero E6 cells", "TREATMENT", 118, 131], ["a cell line", "TREATMENT", 133, 144], ["viral titers", "OBSERVATION", 63, 75], ["infection", "OBSERVATION", 95, 104], ["epithelial cells", "OBSERVATION", 190, 206]]], ["They found low potency of most of these drugs for inhibiting SARS-CoV-2.", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 61, 71], ["SARS-CoV", "SPECIES", 61, 69], ["these drugs", "TREATMENT", 34, 45], ["low potency", "OBSERVATION_MODIFIER", 11, 22]]], ["EC50 values ranged widely from 109.5 \u03bcM for ribavirin to 1.13 \u03bcM for choloquine and 0.77 \u03bcM for remdesivir, which were the two drugs that required the lowest concentrations for blocking viral infection.In vitro studies ::: Summary of studies on remdesivir and coronavirusesA few in vitro studies have also investigated the utility of remdesivir against non-human CoVs.", [["ribavirin", "CHEMICAL", 44, 53], ["choloquine", "CHEMICAL", 69, 79], ["remdesivir", "CHEMICAL", 96, 106], ["viral infection", "DISEASE", 186, 201], ["remdesivir", "CHEMICAL", 334, 344], ["ribavirin", "CHEMICAL", 44, 53], ["choloquine", "CHEMICAL", 69, 79], ["remdesivir", "CHEMICAL", 96, 106], ["remdesivir", "CHEMICAL", 334, 344], ["choloquine", "SIMPLE_CHEMICAL", 69, 79], ["remdesivir", "SIMPLE_CHEMICAL", 96, 106], ["remdesivir", "SIMPLE_CHEMICAL", 334, 344], ["non-human", "ORGANISM", 353, 362], ["CoVs", "GENE_OR_GENE_PRODUCT", 363, 367], ["EC50 values", "TEST", 0, 11], ["ribavirin", "TREATMENT", 44, 53], ["choloquine", "TREATMENT", 69, 79], ["remdesivir", "TREATMENT", 96, 106], ["the two drugs", "TREATMENT", 119, 132], ["the lowest concentrations", "TREATMENT", 147, 172], ["blocking viral infection", "PROBLEM", 177, 201], ["studies", "TEST", 234, 241], ["remdesivir", "TEST", 245, 255], ["coronaviruses", "PROBLEM", 260, 273], ["vitro studies", "TEST", 282, 295], ["remdesivir", "TREATMENT", 334, 344], ["non-human CoVs", "PROBLEM", 353, 367], ["viral infection", "OBSERVATION", 186, 201]]], ["For example, a study by Murphy et al. reported anti-CoV activity of remdesivir's parent nucleoside, GS-441524, against an alphacoronavirus that only infects wild and domestic cats, the feline infectious peritonitis (FIP) virus (EC50 = 0.78 \u03bcM; Table 1) [14].", [["remdesivir", "CHEMICAL", 68, 78], ["nucleoside", "CHEMICAL", 88, 98], ["GS-441524", "CHEMICAL", 100, 109], ["alphacoronavirus", "CHEMICAL", 122, 138], ["feline infectious peritonitis", "DISEASE", 185, 214], ["FIP", "DISEASE", 216, 219], ["remdesivir", "CHEMICAL", 68, 78], ["nucleoside", "CHEMICAL", 88, 98], ["GS-441524", "CHEMICAL", 100, 109], ["anti-CoV", "SIMPLE_CHEMICAL", 47, 55], ["remdesivir", "SIMPLE_CHEMICAL", 68, 78], ["nucleoside", "SIMPLE_CHEMICAL", 88, 98], ["GS-441524", "SIMPLE_CHEMICAL", 100, 109], ["cats", "ORGANISM", 175, 179], ["feline infectious peritonitis", "ORGANISM", 185, 214], ["cats", "SPECIES", 175, 179], ["feline", "SPECIES", 185, 191], ["alphacoronavirus", "SPECIES", 122, 138], ["feline infectious peritonitis (FIP) virus", "SPECIES", 185, 226], ["a study", "TEST", 13, 20], ["GS", "TEST", 100, 102], ["an alphacoronavirus", "PROBLEM", 119, 138], ["the feline infectious peritonitis", "PROBLEM", 181, 214], ["EC50", "TEST", 228, 232], ["infectious", "OBSERVATION_MODIFIER", 192, 202], ["peritonitis", "OBSERVATION", 203, 214]]], ["In 2019, Brown et al. observed some antiviral effects of remdesivir against SARS-like bat CoVs (specifically, Bat-CoV HKU3, Bat-CoV SCH014, and Bat-CoV WIV1) and MERS-like bat CoVs (specifically, Bat-CoV HKU5) [12].In vitro studies ::: Summary of studies on remdesivir and coronavirusesFurther, this study detected a weaker antiviral effect against porcine deltacoronavirus (PDCoV; Table 1), particularly when tested in porcine cell lines.", [["cell lines", "ANATOMY", 428, 438], ["remdesivir", "CHEMICAL", 57, 67], ["SARS", "DISEASE", 76, 80], ["remdesivir", "CHEMICAL", 258, 268], ["remdesivir", "CHEMICAL", 57, 67], ["remdesivir", "CHEMICAL", 258, 268], ["remdesivir", "SIMPLE_CHEMICAL", 57, 67], ["SARS-like bat CoVs", "ORGANISM", 76, 94], ["Bat-CoV HKU3", "ORGANISM", 110, 122], ["Bat-CoV SCH014", "ORGANISM", 124, 138], ["Bat-CoV WIV1", "ORGANISM", 144, 156], ["MERS-like bat CoVs", "GENE_OR_GENE_PRODUCT", 162, 180], ["Bat-CoV HKU5", "GENE_OR_GENE_PRODUCT", 196, 208], ["remdesivir", "SIMPLE_CHEMICAL", 258, 268], ["porcine deltacoronavirus", "ORGANISM", 349, 373], ["porcine", "ORGANISM", 420, 427], ["cell lines", "CELL", 428, 438], ["CoV HKU3", "PROTEIN", 114, 122], ["Bat", "PROTEIN", 124, 127], ["CoV SCH014", "PROTEIN", 128, 138], ["Bat", "PROTEIN", 144, 147], ["CoV WIV1", "PROTEIN", 148, 156], ["MERS", "PROTEIN", 162, 166], ["CoVs", "PROTEIN", 176, 180], ["porcine cell lines", "CELL_LINE", 420, 438], ["porcine", "SPECIES", 349, 356], ["porcine", "SPECIES", 420, 427], ["Bat-CoV", "SPECIES", 110, 117], ["Bat-CoV", "SPECIES", 124, 131], ["Bat-CoV WIV1", "SPECIES", 144, 156], ["Bat-CoV", "SPECIES", 196, 203], ["porcine deltacoronavirus", "SPECIES", 349, 373], ["porcine", "SPECIES", 420, 427], ["remdesivir", "TREATMENT", 57, 67], ["SARS", "PROBLEM", 76, 80], ["bat CoVs", "PROBLEM", 86, 94], ["Bat", "TEST", 110, 113], ["CoV", "TEST", 114, 117], ["HKU3", "TEST", 118, 122], ["Bat", "TEST", 124, 127], ["SCH014", "TEST", 132, 138], ["Bat", "TEST", 144, 147], ["remdesivir", "TEST", 258, 268], ["this study", "TEST", 295, 305], ["a weaker antiviral effect", "PROBLEM", 315, 340], ["porcine deltacoronavirus (PDCoV", "TREATMENT", 349, 380], ["porcine cell lines", "TREATMENT", 420, 438], ["antiviral effects", "OBSERVATION", 36, 53], ["cell lines", "OBSERVATION", 428, 438]]], ["Among currently known CoVs, PDCoV has the least similar RdRp sequence compared to SARS-CoV and MERS-CoV (only 67\u201369% similarity in amino acid sequence) [12].", [["PDCoV", "CHEMICAL", 28, 33], ["SARS", "DISEASE", 82, 86], ["amino acid", "CHEMICAL", 131, 141], ["amino acid", "CHEMICAL", 131, 141], ["CoVs", "GENE_OR_GENE_PRODUCT", 22, 26], ["PDCoV", "GENE_OR_GENE_PRODUCT", 28, 33], ["SARS-CoV", "ORGANISM", 82, 90], ["MERS-CoV", "ORGANISM", 95, 103], ["amino acid", "AMINO_ACID", 131, 141], ["CoVs", "DNA", 22, 26], ["PDCoV", "DNA", 28, 33], ["RdRp sequence", "DNA", 56, 69], ["MERS-CoV", "DNA", 95, 103], ["SARS-CoV", "SPECIES", 82, 90], ["MERS-CoV", "SPECIES", 95, 103], ["known CoVs", "PROBLEM", 16, 26], ["PDCoV", "TREATMENT", 28, 33], ["SARS", "TEST", 82, 86], ["CoV", "TEST", 87, 90], ["MERS", "TEST", 95, 99], ["CoV", "TEST", 100, 103], ["amino acid sequence", "TEST", 131, 150], ["CoVs", "OBSERVATION", 22, 26]]], ["In fact, the RdRp of PDCoV has a different amino acid at a specific site (phenylalanine to leucine at residue 483), a dissimilarity that has been previously associated with increased resistance to remdesivir in other CoVs [12,13].", [["PDCoV", "CHEMICAL", 21, 26], ["amino acid", "CHEMICAL", 43, 53], ["phenylalanine", "CHEMICAL", 74, 87], ["leucine", "CHEMICAL", 91, 98], ["remdesivir", "CHEMICAL", 197, 207], ["amino acid", "CHEMICAL", 43, 53], ["phenylalanine", "CHEMICAL", 74, 87], ["leucine", "CHEMICAL", 91, 98], ["remdesivir", "CHEMICAL", 197, 207], ["PDCoV", "GENE_OR_GENE_PRODUCT", 21, 26], ["amino acid", "AMINO_ACID", 43, 53], ["phenylalanine", "AMINO_ACID", 74, 87], ["leucine", "AMINO_ACID", 91, 98], ["residue 483", "AMINO_ACID", 102, 113], ["remdesivir", "SIMPLE_CHEMICAL", 197, 207], ["RdRp", "PROTEIN", 13, 17], ["PDCoV", "PROTEIN", 21, 26], ["a different amino acid", "PROBLEM", 31, 53], ["phenylalanine to leucine at residue", "TREATMENT", 74, 109], ["increased resistance", "PROBLEM", 173, 193], ["increased", "OBSERVATION_MODIFIER", 173, 182], ["resistance", "OBSERVATION", 183, 193]]], ["Therefore, it was important to attempt to disentangle whether the lower antiviral activity observed could be related to a viral characteristic of PDCoV or if it could be attributable to differences in the cell lines used.", [["cell lines", "ANATOMY", 205, 215], ["PDCoV", "CANCER", 146, 151], ["cell lines", "CELL", 205, 215], ["cell lines", "CELL_LINE", 205, 215], ["the lower antiviral activity", "PROBLEM", 62, 90], ["a viral characteristic of PDCoV", "PROBLEM", 120, 151], ["the cell lines", "TREATMENT", 201, 215], ["antiviral activity", "OBSERVATION", 72, 90], ["cell lines", "OBSERVATION", 205, 215]]], ["While diminished potency of remdesivir against PDCoV was noted in cultures of porcine kidney epithelial cells (LLC-PK1), in a human liver cell line (Huh7), the EC50 was relatively low (EC50 not reached in LLC-PK1 vs. EC50 = 0.02 \u03bcM in Huh7; Table 1).", [["cultures", "ANATOMY", 66, 74], ["kidney epithelial cells", "ANATOMY", 86, 109], ["LLC-PK1", "ANATOMY", 111, 118], ["liver cell line", "ANATOMY", 132, 147], ["Huh7", "ANATOMY", 149, 153], ["Huh7", "ANATOMY", 235, 239], ["remdesivir", "CHEMICAL", 28, 38], ["PDCoV", "CHEMICAL", 47, 52], ["remdesivir", "CHEMICAL", 28, 38], ["remdesivir", "SIMPLE_CHEMICAL", 28, 38], ["PDCoV", "SIMPLE_CHEMICAL", 47, 52], ["porcine", "ORGANISM", 78, 85], ["kidney epithelial cells", "CELL", 86, 109], ["LLC-PK1", "CELL", 111, 118], ["human", "ORGANISM", 126, 131], ["liver cell line", "CELL", 132, 147], ["Huh7", "CELL", 149, 153], ["Huh7", "CELL", 235, 239], ["porcine kidney epithelial cells", "CELL_LINE", 78, 109], ["LLC", "CELL_LINE", 111, 114], ["PK1", "CELL_LINE", 115, 118], ["human liver cell line", "CELL_LINE", 126, 147], ["Huh7", "CELL_LINE", 149, 153], ["Huh7", "CELL_LINE", 235, 239], ["porcine", "SPECIES", 78, 85], ["human", "SPECIES", 126, 131], ["porcine", "SPECIES", 78, 85], ["human", "SPECIES", 126, 131], ["remdesivir", "TREATMENT", 28, 38], ["PDCoV", "PROBLEM", 47, 52], ["cultures", "TEST", 66, 74], ["porcine kidney epithelial cells", "PROBLEM", 78, 109], ["LLC", "TEST", 111, 114], ["a human liver cell line", "TREATMENT", 124, 147], ["the EC50", "TEST", 156, 164], ["EC50", "TEST", 185, 189], ["LLC", "TEST", 205, 208], ["PK1", "TEST", 209, 212], ["EC50", "TEST", 217, 221], ["Huh7", "TEST", 235, 239], ["diminished", "OBSERVATION_MODIFIER", 6, 16], ["potency", "OBSERVATION_MODIFIER", 17, 24], ["kidney", "ANATOMY", 86, 92], ["epithelial cells", "OBSERVATION", 93, 109], ["liver", "ANATOMY", 132, 137], ["cell line", "OBSERVATION", 138, 147], ["low", "OBSERVATION_MODIFIER", 180, 183], ["LLC", "ANATOMY", 205, 208]]], ["Similarly, the EC50 was substantially higher for antiviral activity against an endemic HCoV (229E) in the porcine cell line (3.8 \u03bcM compared to 0.02 \u03bcM in Huh7), again indicating the likely lower potency of the drug in this context.", [["cell line", "ANATOMY", 114, 123], ["Huh7", "ANATOMY", 155, 159], ["EC50", "CHEMICAL", 15, 19], ["porcine", "ORGANISM", 106, 113], ["cell line", "CELL", 114, 123], ["Huh7", "CELL", 155, 159], ["porcine cell line", "CELL_LINE", 106, 123], ["Huh7", "CELL_LINE", 155, 159], ["porcine", "SPECIES", 106, 113], ["HCoV", "SPECIES", 87, 91], ["the EC50", "TEST", 11, 19], ["an endemic HCoV", "PROBLEM", 76, 91], ["the porcine cell line", "TREATMENT", 102, 123], ["Huh7", "TEST", 155, 159], ["antiviral activity", "OBSERVATION", 49, 67], ["endemic", "OBSERVATION_MODIFIER", 79, 86], ["porcine cell line", "OBSERVATION", 106, 123], ["indicating the likely", "UNCERTAINTY", 168, 189], ["lower potency", "OBSERVATION_MODIFIER", 190, 203]]], ["Thus, the observed variations in remdesivir potency against the same viruses in the different cell lines may imply that there is some factor associated with the cell line, rather than the virus, that may be affecting the drug's antiviral activity.", [["cell lines", "ANATOMY", 94, 104], ["cell line", "ANATOMY", 161, 170], ["remdesivir", "CHEMICAL", 33, 43], ["remdesivir", "CHEMICAL", 33, 43], ["remdesivir", "SIMPLE_CHEMICAL", 33, 43], ["cell lines", "CELL", 94, 104], ["cell line", "CELL", 161, 170], ["cell lines", "CELL_LINE", 94, 104], ["the observed variations in remdesivir potency", "PROBLEM", 6, 51], ["the same viruses", "PROBLEM", 60, 76], ["the cell line", "PROBLEM", 157, 170], ["the virus", "PROBLEM", 184, 193], ["viruses", "OBSERVATION", 69, 76], ["different cell lines", "OBSERVATION", 84, 104], ["cell line", "OBSERVATION", 161, 170], ["may be", "UNCERTAINTY", 200, 206], ["antiviral activity", "OBSERVATION", 228, 246]]], ["In fact, the authors state that these findings may imply that LLC-PK1 cells lack a cellular process necessary for remdesivir antiviral activity, which could also support the hypothesis that remdesivir may have another mechanism of action that is not presently understood.In vivo studies: animal models & veterinary studies ::: Summary of studies on remdesivir and coronavirusesAnimal studies on remdesivir efficacy against CoVs have utilized transgenic mice and rhesus macaques [10,11,13,18].", [["LLC-PK1 cells", "ANATOMY", 62, 75], ["cellular", "ANATOMY", 83, 91], ["remdesivir", "CHEMICAL", 190, 200], ["remdesivir", "CHEMICAL", 349, 359], ["remdesivir", "CHEMICAL", 395, 405], ["CoVs", "CHEMICAL", 423, 427], ["remdesivir", "CHEMICAL", 190, 200], ["remdesivir", "CHEMICAL", 395, 405], ["LLC-PK1 cells", "CELL", 62, 75], ["cellular", "CELL", 83, 91], ["remdesivir", "GENE_OR_GENE_PRODUCT", 114, 124], ["remdesivir", "SIMPLE_CHEMICAL", 190, 200], ["remdesivir", "SIMPLE_CHEMICAL", 349, 359], ["coronaviruses", "ORGANISM", 364, 377], ["remdesivir", "SIMPLE_CHEMICAL", 395, 405], ["CoVs", "SIMPLE_CHEMICAL", 423, 427], ["mice", "ORGANISM", 453, 457], ["rhesus macaques", "ORGANISM", 462, 477], ["LLC-PK1 cells", "CELL_LINE", 62, 75], ["mice", "SPECIES", 453, 457], ["rhesus macaques", "SPECIES", 462, 477], ["mice", "SPECIES", 453, 457], ["rhesus macaques", "SPECIES", 462, 477], ["LLC", "TEST", 62, 65], ["PK1 cells", "PROBLEM", 66, 75], ["a cellular process", "PROBLEM", 81, 99], ["remdesivir antiviral activity", "TREATMENT", 114, 143], ["remdesivir", "TEST", 349, 359], ["coronaviruses", "PROBLEM", 364, 377], ["Animal studies", "TEST", 377, 391], ["remdesivir efficacy", "TREATMENT", 395, 414], ["CoVs", "PROBLEM", 423, 427]]], ["For example, using a mouse model with a Ces1c-knockout (which better emulates human metabolism of remdesivir compared to wild-type mice) and a humanized MERS-CoV receptor, Sheahan et al. found that both prophylactic and therapeutic remdesivir had protective effects against MERS-CoV replication and associated pathology, generally resulting in less lung damage and better pulmonary function compared to controls [10].", [["lung", "ANATOMY", 349, 353], ["pulmonary", "ANATOMY", 372, 381], ["remdesivir", "CHEMICAL", 98, 108], ["remdesivir", "CHEMICAL", 232, 242], ["lung damage", "DISEASE", 349, 360], ["remdesivir", "CHEMICAL", 98, 108], ["remdesivir", "CHEMICAL", 232, 242], ["mouse", "ORGANISM", 21, 26], ["Ces1c", "GENE_OR_GENE_PRODUCT", 40, 45], ["human", "ORGANISM", 78, 83], ["remdesivir", "GENE_OR_GENE_PRODUCT", 98, 108], ["mice", "ORGANISM", 131, 135], ["MERS-CoV receptor", "GENE_OR_GENE_PRODUCT", 153, 170], ["remdesivir", "SIMPLE_CHEMICAL", 232, 242], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 274, 282], ["lung", "ORGAN", 349, 353], ["pulmonary", "ORGAN", 372, 381], ["Ces1c", "PROTEIN", 40, 45], ["humanized MERS-CoV receptor", "PROTEIN", 143, 170], ["mouse", "SPECIES", 21, 26], ["human", "SPECIES", 78, 83], ["mice", "SPECIES", 131, 135], ["mouse", "SPECIES", 21, 26], ["human", "SPECIES", 78, 83], ["mice", "SPECIES", 131, 135], ["MERS-CoV", "SPECIES", 153, 161], ["MERS-CoV", "SPECIES", 274, 282], ["remdesivir", "TREATMENT", 98, 108], ["a humanized MERS-CoV receptor", "TREATMENT", 141, 170], ["therapeutic remdesivir", "TREATMENT", 220, 242], ["protective effects", "TREATMENT", 247, 265], ["MERS", "PROBLEM", 274, 278], ["CoV replication", "TREATMENT", 279, 294], ["associated pathology", "PROBLEM", 299, 319], ["less lung damage", "PROBLEM", 344, 360], ["less", "OBSERVATION_MODIFIER", 344, 348], ["lung", "ANATOMY", 349, 353], ["damage", "OBSERVATION", 354, 360], ["pulmonary", "ANATOMY", 372, 381]]], ["Interestingly, among mice that were infected with a higher virus quantity (i.e., more plaque-forming units), those receiving prophylactic remdesivir one day before infection had significantly better 6-day survival than infected control mice that did not receive remdesivir.", [["plaque", "ANATOMY", 86, 92], ["remdesivir", "CHEMICAL", 138, 148], ["infection", "DISEASE", 164, 173], ["remdesivir", "CHEMICAL", 262, 272], ["remdesivir", "CHEMICAL", 262, 272], ["mice", "ORGANISM", 21, 25], ["mice", "ORGANISM", 236, 240], ["remdesivir", "SIMPLE_CHEMICAL", 262, 272], ["mice", "SPECIES", 21, 25], ["mice", "SPECIES", 236, 240], ["mice", "SPECIES", 21, 25], ["mice", "SPECIES", 236, 240], ["a higher virus quantity", "PROBLEM", 50, 73], ["prophylactic remdesivir", "TREATMENT", 125, 148], ["infection", "PROBLEM", 164, 173], ["remdesivir", "TREATMENT", 262, 272]]], ["However, the mice were sacrificed before longer follow-up data could be obtained.", [["mice", "ORGANISM", 13, 17], ["mice", "SPECIES", 13, 17], ["mice", "SPECIES", 13, 17]]], ["Similarly, in a rhesus macaque model of MERS-CoV pathogenesis, prophylactic and therapeutic administration of remdesivir demonstrated favorable results, reducing respiratory tract viral titers and pulmonary pathology [18].", [["respiratory tract", "ANATOMY", 162, 179], ["pulmonary", "ANATOMY", 197, 206], ["remdesivir", "CHEMICAL", 110, 120], ["respiratory tract viral titers", "DISEASE", 162, 192], ["remdesivir", "CHEMICAL", 110, 120], ["macaque", "ORGANISM", 23, 30], ["MERS-CoV", "ORGANISM", 40, 48], ["remdesivir", "SIMPLE_CHEMICAL", 110, 120], ["respiratory tract", "ORGANISM_SUBDIVISION", 162, 179], ["pulmonary", "ORGAN", 197, 206], ["rhesus macaque", "SPECIES", 16, 30], ["rhesus macaque", "SPECIES", 16, 30], ["MERS-CoV", "SPECIES", 40, 48], ["CoV pathogenesis", "PROBLEM", 45, 61], ["prophylactic", "TREATMENT", 63, 75], ["therapeutic administration of remdesivir", "TREATMENT", 80, 120], ["reducing respiratory tract viral titers", "PROBLEM", 153, 192], ["pulmonary pathology", "PROBLEM", 197, 216], ["respiratory tract", "ANATOMY", 162, 179], ["pulmonary", "ANATOMY", 197, 206]]], ["Prophylactic use was initiated 24 h prior to viral challenge, whereas therapeutic use was initiated 12 h after challenge.", [["viral challenge", "TREATMENT", 45, 60]]], ["While respiratory rate was not substantially different between the prophylactic, therapeutic, and control groups, x-ray scores, representing the severity of pulmonary infiltrates, were significantly better in the prophylactic and therapeutic groups, comparing each to controls [18].", [["respiratory", "ANATOMY", 6, 17], ["pulmonary infiltrates", "ANATOMY", 157, 178], ["pulmonary", "ORGAN", 157, 166], ["respiratory rate", "TEST", 6, 22], ["the prophylactic", "TREATMENT", 63, 79], ["x-ray scores", "TEST", 114, 126], ["pulmonary infiltrates", "PROBLEM", 157, 178], ["pulmonary", "ANATOMY", 157, 166], ["infiltrates", "OBSERVATION", 167, 178], ["significantly", "OBSERVATION_MODIFIER", 185, 198], ["better", "OBSERVATION_MODIFIER", 199, 205]]], ["Incidentally, remdesivir has also been associated with beneficial effects, including reduced severity of respiratory signs and improved survival, against challenge with Nipah virus, which is a non-CoV virus in the Paramyxoviridae family, in African green monkeys [21].In vivo studies: animal models & veterinary studies ::: Summary of studies on remdesivir and coronavirusesIn a Ces1c-knockout mouse model of SARS-CoV infection, prophylactic and therapeutic remdesivir treatment resulted in lower lung viral titers, and if therapy was administered 1 day post-infection (which is before peak viral replication), it was associated with greater pulmonary function, compared to controls [11].", [["respiratory", "ANATOMY", 105, 116], ["lung", "ANATOMY", 497, 501], ["pulmonary", "ANATOMY", 642, 651], ["remdesivir", "CHEMICAL", 14, 24], ["respiratory signs", "DISEASE", 105, 122], ["Nipah virus", "DISEASE", 169, 180], ["remdesivir", "CHEMICAL", 346, 356], ["SARS-CoV infection", "DISEASE", 409, 427], ["remdesivir", "CHEMICAL", 458, 468], ["remdesivir", "CHEMICAL", 14, 24], ["remdesivir", "SIMPLE_CHEMICAL", 14, 24], ["Nipah virus", "ORGANISM", 169, 180], ["non-CoV virus", "ORGANISM", 193, 206], ["green monkeys", "ORGANISM", 249, 262], ["remdesivir", "SIMPLE_CHEMICAL", 346, 356], ["coronaviruses", "ORGANISM", 361, 374], ["Ces1c", "GENE_OR_GENE_PRODUCT", 379, 384], ["mouse", "ORGANISM", 394, 399], ["SARS-CoV", "ORGANISM", 409, 417], ["remdesivir", "SIMPLE_CHEMICAL", 458, 468], ["lung", "ORGAN", 497, 501], ["pulmonary", "ORGAN", 642, 651], ["Ces1c", "PROTEIN", 379, 384], ["Nipah virus", "SPECIES", 169, 180], ["green monkeys", "SPECIES", 249, 262], ["mouse", "SPECIES", 394, 399], ["Nipah virus", "SPECIES", 169, 180], ["non-CoV virus", "SPECIES", 193, 206], ["African green monkeys", "SPECIES", 241, 262], ["mouse", "SPECIES", 394, 399], ["SARS-CoV", "SPECIES", 409, 417], ["reduced severity of respiratory signs", "PROBLEM", 85, 122], ["Nipah virus", "PROBLEM", 169, 180], ["a non-CoV virus", "PROBLEM", 191, 206], ["remdesivir", "TEST", 346, 356], ["coronaviruses", "PROBLEM", 361, 374], ["SARS", "PROBLEM", 409, 413], ["CoV infection", "PROBLEM", 414, 427], ["prophylactic", "TREATMENT", 429, 441], ["therapeutic remdesivir treatment", "TREATMENT", 446, 478], ["lower lung viral titers", "PROBLEM", 491, 514], ["therapy", "TREATMENT", 523, 530], ["peak viral replication", "TREATMENT", 586, 608], ["greater pulmonary function", "PROBLEM", 634, 660], ["respiratory", "ANATOMY", 105, 116], ["SARS", "OBSERVATION", 409, 413], ["CoV", "OBSERVATION_MODIFIER", 414, 417], ["infection", "OBSERVATION", 418, 427], ["lower", "ANATOMY_MODIFIER", 491, 496], ["lung", "ANATOMY", 497, 501], ["viral titers", "OBSERVATION", 502, 514], ["pulmonary", "ANATOMY", 642, 651]]], ["However, there were no differences in disease pathology or survival if treatment was administered 2 days post-infection.In vivo studies: animal models & veterinary studies ::: Summary of studies on remdesivir and coronavirusesSome veterinary studies have also examined the effects of the parent nucleoside, GS-441524, in cats with FIP, a condition associated with very high mortality in cats [14,16].", [["nucleoside", "CHEMICAL", 295, 305], ["GS-441524", "CHEMICAL", 307, 316], ["FIP", "DISEASE", 331, 334], ["nucleoside", "CHEMICAL", 295, 305], ["GS-441524", "CHEMICAL", 307, 316], ["remdesivir", "SIMPLE_CHEMICAL", 198, 208], ["nucleoside", "SIMPLE_CHEMICAL", 295, 305], ["GS-441524", "SIMPLE_CHEMICAL", 307, 316], ["cats", "ORGANISM", 321, 325], ["cats", "ORGANISM", 387, 391], ["cats", "SPECIES", 321, 325], ["differences in disease pathology", "PROBLEM", 23, 55], ["treatment", "TREATMENT", 71, 80], ["remdesivir", "TEST", 198, 208], ["veterinary studies", "TEST", 231, 249], ["the parent nucleoside", "TREATMENT", 284, 305], ["GS", "TEST", 307, 309], ["no", "UNCERTAINTY", 20, 22]]], ["Subsequently, GS-441524 became an intermediate in the production of the prodrug, remdesivir, which has superior ability to transport the active compound into cells [9,18].", [["cells", "ANATOMY", 158, 163], ["GS-441524", "CHEMICAL", 14, 23], ["remdesivir", "CHEMICAL", 81, 91], ["GS-441524", "CHEMICAL", 14, 23], ["remdesivir", "CHEMICAL", 81, 91], ["GS-441524", "SIMPLE_CHEMICAL", 14, 23], ["prodrug", "SIMPLE_CHEMICAL", 72, 79], ["remdesivir", "SIMPLE_CHEMICAL", 81, 91], ["cells", "CELL", 158, 163], ["GS-441524", "SPECIES", 14, 23], ["GS", "TEST", 14, 16], ["remdesivir", "TREATMENT", 81, 91], ["intermediate", "OBSERVATION_MODIFIER", 34, 46]]], ["Because both drugs yield the same active metabolite in host cells, some prior studies on the antiviral activity of remdesivir also investigate GS-441524 [15,18], and/or discuss its relevance in the veterinary studies [9,12].In vivo studies: animal models & veterinary studies ::: Summary of studies on remdesivir and coronavirusesIn 2018, Murphy et al. examined the efficacy of GS-441524 against FIP in 12 experimentally infected cats [14].", [["cells", "ANATOMY", 60, 65], ["GS-441524", "CHEMICAL", 143, 152], ["GS-441524", "CHEMICAL", 378, 387], ["FIP", "DISEASE", 396, 399], ["remdesivir", "CHEMICAL", 115, 125], ["GS-441524", "CHEMICAL", 143, 152], ["GS-441524", "CHEMICAL", 378, 387], ["host cells", "CELL", 55, 65], ["remdesivir", "SIMPLE_CHEMICAL", 115, 125], ["GS-441524", "SIMPLE_CHEMICAL", 378, 387], ["FIP", "ORGANISM", 396, 399], ["cats", "ORGANISM", 430, 434], ["host cells", "CELL_TYPE", 55, 65], ["cats", "SPECIES", 430, 434], ["both drugs", "TREATMENT", 8, 18], ["some prior studies", "TEST", 67, 85], ["GS", "TEST", 143, 145], ["the veterinary studies", "TEST", 194, 216], ["GS", "TEST", 378, 380], ["FIP", "PROBLEM", 396, 399], ["host cells", "OBSERVATION", 55, 65]]], ["Controls were not included, as historical data on untreated cats were available, demonstrating a mortality rate close to 100% [14,36].", [["cats", "ORGANISM", 60, 64], ["a mortality rate", "TEST", 95, 111]]], ["After experimental challenge with the FIP virus, 2 cats did not develop FIP-related signs and remained untreated [14].", [["FIP", "DISEASE", 72, 75], ["FIP virus", "ORGANISM", 38, 47], ["cats", "ORGANISM", 51, 55], ["cats", "SPECIES", 51, 55], ["FIP virus", "SPECIES", 38, 47], ["the FIP virus", "PROBLEM", 34, 47], ["FIP", "PROBLEM", 72, 75]]], ["In the 10 infected cats, treatment was initiated upon onset of FIP-associated clinical signs (~10\u201318 days post infection), and continued for 2 weeks.", [["FIP", "DISEASE", 63, 66], ["infection", "DISEASE", 111, 120], ["cats", "ORGANISM", 19, 23], ["cats", "SPECIES", 19, 23], ["treatment", "TREATMENT", 25, 34], ["FIP", "PROBLEM", 63, 66], ["clinical signs", "PROBLEM", 78, 92], ["infection", "PROBLEM", 111, 120], ["infected", "OBSERVATION_MODIFIER", 10, 18], ["cats", "OBSERVATION", 19, 23]]], ["Of these cats, half (n = 5) were treated with a 5 mg/kg dose of GS-441524 administered subcutaneously once per day, and the other half (n = 5) were treated with 2 mg/kg daily.", [["subcutaneously", "ANATOMY", 87, 101], ["GS-441524", "CHEMICAL", 64, 73], ["GS-441524", "CHEMICAL", 64, 73], ["cats", "ORGANISM", 9, 13], ["GS-441524", "SIMPLE_CHEMICAL", 64, 73], ["cats", "SPECIES", 9, 13], ["a 5 mg/kg dose of GS", "TREATMENT", 46, 66], ["cats", "OBSERVATION", 9, 13]]], ["If disease recurred after initial treatment, cats were re-treated using the same regimen for another 2 weeks.", [["cats", "ORGANISM", 45, 49], ["disease", "PROBLEM", 3, 10], ["initial treatment", "TREATMENT", 26, 43], ["cats", "TREATMENT", 45, 49], ["the same regimen", "TREATMENT", 72, 88]]], ["All treated cats demonstrated favorable responses to GS-441524 treatment within 24\u201348 h, regardless of dose, and were still alive and clinically unremarkable 8 months post infection.", [["GS-441524", "CHEMICAL", 53, 62], ["infection", "DISEASE", 172, 181], ["GS-441524", "CHEMICAL", 53, 62], ["cats", "ORGANISM", 12, 16], ["GS-441524", "SIMPLE_CHEMICAL", 53, 62], ["cats", "SPECIES", 12, 16], ["GS", "TEST", 53, 55], ["treatment", "TREATMENT", 63, 72], ["infection", "PROBLEM", 172, 181], ["infection", "OBSERVATION", 172, 181]]], ["Two cats (one from each dose group) experienced disease recurrence at 4 weeks and 6 weeks after initial treatment and were re-treated.", [["cats", "ORGANISM", 4, 8], ["cats", "SPECIES", 4, 8], ["disease recurrence", "PROBLEM", 48, 66], ["initial treatment", "TREATMENT", 96, 113], ["disease", "OBSERVATION_MODIFIER", 48, 55], ["recurrence", "OBSERVATION", 56, 66]]], ["Adverse events related to treatment, other than temporary discomfort at the injection site, were not observed.", [["Adverse events", "PROBLEM", 0, 14], ["treatment", "TREATMENT", 26, 35], ["temporary discomfort at the injection site", "PROBLEM", 48, 90]]], ["This study was based on a small number of animals, and it is unclear whether experimental infection is a relevant representation of naturally-occurring FIPV infection in cats.", [["infection", "DISEASE", 90, 99], ["infection", "DISEASE", 157, 166], ["FIPV", "ORGANISM", 152, 156], ["cats", "ORGANISM", 170, 174], ["cats", "SPECIES", 170, 174], ["FIPV", "SPECIES", 152, 156], ["This study", "TEST", 0, 10], ["experimental infection", "PROBLEM", 77, 99], ["FIPV infection in cats", "PROBLEM", 152, 174], ["small", "OBSERVATION_MODIFIER", 26, 31], ["unclear whether", "UNCERTAINTY", 61, 76], ["experimental", "OBSERVATION_MODIFIER", 77, 89], ["infection", "OBSERVATION", 90, 99], ["FIPV", "OBSERVATION_MODIFIER", 152, 156], ["infection", "OBSERVATION", 157, 166]]], ["Future studies with additional follow-up time would be helpful for assessing whether unexpected long-term sequelae are observed in the cats, since such information on surviving animals is sparse given the high fatality rate.In vivo studies: animal models & veterinary studies ::: Summary of studies on remdesivir and coronavirusesIn a field trial of treatment with GS-441524 for naturally occurring FIP, Pedersen et al. treated 31 cats with an initial dose of 2 mg/kg daily [16].", [["remdesivir", "CHEMICAL", 302, 312], ["GS-441524", "CHEMICAL", 365, 374], ["FIP", "DISEASE", 399, 402], ["GS-441524", "CHEMICAL", 365, 374], ["cats", "ORGANISM", 135, 139], ["remdesivir", "SIMPLE_CHEMICAL", 302, 312], ["coronaviruses", "ORGANISM", 317, 330], ["GS-441524", "SIMPLE_CHEMICAL", 365, 374], ["cats", "ORGANISM", 431, 435], ["cats", "SPECIES", 135, 139], ["cats", "SPECIES", 431, 435], ["Future studies", "TEST", 0, 14], ["unexpected long-term sequelae", "PROBLEM", 85, 114], ["the high fatality rate", "PROBLEM", 201, 223], ["remdesivir", "TEST", 302, 312], ["coronaviruses", "PROBLEM", 317, 330], ["treatment", "TREATMENT", 350, 359], ["GS", "TEST", 365, 367], ["naturally occurring FIP", "PROBLEM", 379, 402], ["long-term sequelae", "OBSERVATION_MODIFIER", 96, 114]]], ["Within the first week of treatment, 4 cats (13%) with severe disease died or were euthanized, a fifth cat died after 26 days, and another was euthanized about 2-weeks post relapse due to the development of neurological signs and a lack of response to treatment.", [["neurological", "ANATOMY", 206, 218], ["neurological signs", "DISEASE", 206, 224], ["cats", "ORGANISM", 38, 42], ["cat", "ORGANISM", 102, 105], ["cats", "SPECIES", 38, 42], ["treatment", "TREATMENT", 25, 34], ["severe disease", "PROBLEM", 54, 68], ["neurological signs", "PROBLEM", 206, 224], ["treatment", "TREATMENT", 251, 260], ["severe", "OBSERVATION_MODIFIER", 54, 60], ["disease", "OBSERVATION", 61, 68]]], ["The remaining cats completed at least 12 weeks of treatment, but 8 experienced relapses requiring re-treatment with GS-441524.", [["GS-441524", "CHEMICAL", 116, 125], ["GS-441524", "CHEMICAL", 116, 125], ["cats", "ORGANISM", 14, 18], ["GS-441524", "SIMPLE_CHEMICAL", 116, 125], ["treatment", "TREATMENT", 50, 59], ["GS", "TEST", 116, 118]]], ["Dose escalation from 2 mg/kg to 4 mg/kg daily was required for 5 cats.", [["cats", "ORGANISM", 65, 69], ["Dose escalation", "TREATMENT", 0, 15]]], ["A total of 25 treated cats (81%) survived FIP for at least 44 weeks of follow up, indicating that GS-441524 (and presumably, its prodrug remdesivir) is also a promising therapeutic candidate for treatment of alphacoronavirus-related disease in cats.", [["FIP", "DISEASE", 42, 45], ["GS-441524", "CHEMICAL", 98, 107], ["remdesivir", "CHEMICAL", 137, 147], ["alphacoronavirus", "CHEMICAL", 208, 224], ["GS-441524", "CHEMICAL", 98, 107], ["remdesivir", "CHEMICAL", 137, 147], ["cats", "ORGANISM", 22, 26], ["GS-441524", "SIMPLE_CHEMICAL", 98, 107], ["remdesivir", "SIMPLE_CHEMICAL", 137, 147], ["cats", "ORGANISM", 244, 248], ["cats", "SPECIES", 22, 26], ["cats", "SPECIES", 244, 248], ["A total of 25 treated cats", "TREATMENT", 0, 26], ["GS", "TEST", 98, 100], ["alphacoronavirus", "PROBLEM", 208, 224], ["related disease in cats", "PROBLEM", 225, 248]]], ["Most cats in this study had \u201cwet\u201d or effusive FIP, the hallmark of which is the accumulation of fluids in the abdominal or thoracic cavities.", [["abdominal", "ANATOMY", 110, 119], ["thoracic cavities", "ANATOMY", 123, 140], ["FIP", "DISEASE", 46, 49], ["cats", "ORGANISM", 5, 9], ["abdominal", "ORGANISM_SUBDIVISION", 110, 119], ["thoracic cavities", "MULTI-TISSUE_STRUCTURE", 123, 140], ["cats", "SPECIES", 5, 9], ["this study", "TEST", 13, 23], ["wet\u201d or effusive FIP", "PROBLEM", 29, 49], ["the accumulation of fluids in the abdominal or thoracic cavities", "PROBLEM", 76, 140], ["effusive FIP", "OBSERVATION", 37, 49], ["hallmark", "OBSERVATION_MODIFIER", 55, 63], ["accumulation", "OBSERVATION_MODIFIER", 80, 92], ["fluids", "OBSERVATION", 96, 102], ["abdominal", "ANATOMY", 110, 119], ["thoracic", "ANATOMY", 123, 131], ["cavities", "ANATOMY_MODIFIER", 132, 140]]], ["There were only 3 cats in the study with abdominal non-effusive (\u201cdry\u201d) FIP, which is a more chronic condition, and another 4 cats initially had dry FIP that progressed into wet FIP.", [["abdominal", "ANATOMY", 41, 50], ["FIP", "DISEASE", 72, 75], ["FIP", "DISEASE", 149, 152], ["FIP", "DISEASE", 178, 181], ["cats", "ORGANISM", 18, 22], ["abdominal", "ORGANISM_SUBDIVISION", 41, 50], ["cats", "ORGANISM", 126, 130], ["the study", "TEST", 26, 35], ["abdominal non-effusive (\u201cdry\u201d) FIP", "PROBLEM", 41, 75], ["a more chronic condition", "PROBLEM", 86, 110], ["dry FIP", "PROBLEM", 145, 152], ["abdominal", "ANATOMY", 41, 50], ["FIP", "OBSERVATION", 72, 75], ["chronic", "OBSERVATION_MODIFIER", 93, 100], ["condition", "OBSERVATION", 101, 110], ["FIP", "OBSERVATION", 149, 152], ["wet FIP", "OBSERVATION", 174, 181]]], ["One cat in the dry FIP group and one in the dry-to-wet group did not survive.", [["FIP", "DISEASE", 19, 22], ["cat", "ORGANISM", 4, 7], ["dry", "OBSERVATION_MODIFIER", 15, 18], ["FIP", "OBSERVATION", 19, 22], ["dry", "OBSERVATION", 44, 47]]], ["Because of the small number of cats with dry FIP, conclusions cannot be drawn about whether remdesivir has greater efficacy in the treatment of some clinical manifestations of FIP than others.", [["FIP", "DISEASE", 45, 48], ["remdesivir", "CHEMICAL", 92, 102], ["FIP", "DISEASE", 176, 179], ["remdesivir", "CHEMICAL", 92, 102], ["cats", "ORGANISM", 31, 35], ["remdesivir", "SIMPLE_CHEMICAL", 92, 102], ["dry FIP", "PROBLEM", 41, 48], ["some clinical manifestations of FIP", "PROBLEM", 144, 179], ["small", "OBSERVATION_MODIFIER", 15, 20], ["number", "OBSERVATION_MODIFIER", 21, 27], ["dry FIP", "OBSERVATION", 41, 48], ["FIP", "OBSERVATION", 176, 179]]], ["A strength of this study is that it was conducted among animals with naturally-occurring CoV infection as a field trial, better representing real-world circumstances.Human data ::: Summary of studies on remdesivir and coronavirusesThe first patient to present with COVID-19 in the U.S. was treated with intravenous remdesivir under the compassionate use clause after developing pneumonia in January 2020 [37].", [["intravenous", "ANATOMY", 303, 314], ["CoV infection", "DISEASE", 89, 102], ["remdesivir", "CHEMICAL", 203, 213], ["remdesivir", "CHEMICAL", 315, 325], ["pneumonia", "DISEASE", 378, 387], ["remdesivir", "CHEMICAL", 315, 325], ["CoV", "ORGANISM", 89, 92], ["Human", "ORGANISM", 166, 171], ["remdesivir", "SIMPLE_CHEMICAL", 203, 213], ["coronaviruses", "ORGANISM", 218, 231], ["patient", "ORGANISM", 241, 248], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 303, 314], ["remdesivir", "SIMPLE_CHEMICAL", 315, 325], ["Human", "SPECIES", 166, 171], ["patient", "SPECIES", 241, 248], ["Human", "SPECIES", 166, 171], ["this study", "TEST", 14, 24], ["CoV infection", "PROBLEM", 89, 102], ["remdesivir", "TEST", 203, 213], ["coronaviruses", "PROBLEM", 218, 231], ["COVID", "TEST", 265, 270], ["intravenous remdesivir", "TREATMENT", 303, 325], ["pneumonia", "PROBLEM", 378, 387], ["infection", "OBSERVATION", 93, 102], ["pneumonia", "OBSERVATION", 378, 387]]], ["This 35-year-old male had been infected during travel to Wuhan and returned to the U.S. where he was hospitalized for more than 12 days.", [["male", "ORGANISM", 17, 21], ["infected", "OBSERVATION", 31, 39]]], ["He was treated with intravenous remdesivir on the seventh day, and his condition was reportedly improving on the eighth day.", [["intravenous", "ANATOMY", 20, 31], ["remdesivir", "CHEMICAL", 32, 42], ["remdesivir", "CHEMICAL", 32, 42], ["He", "ORGANISM", 0, 2], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 20, 31], ["remdesivir", "SIMPLE_CHEMICAL", 32, 42], ["intravenous remdesivir", "TREATMENT", 20, 42]]], ["No adverse events related to remdesivir use were noted.", [["remdesivir", "CHEMICAL", 29, 39], ["remdesivir", "CHEMICAL", 29, 39], ["remdesivir", "SIMPLE_CHEMICAL", 29, 39], ["adverse events", "PROBLEM", 3, 17]]], ["The case report was written prior to the patient's discharge.Human data ::: Summary of studies on remdesivir and coronavirusesHuman data on remdesivir use for COVID-19 will likely continue to become available from compassionate use cases before the clinical trial is completed.", [["remdesivir", "CHEMICAL", 98, 108], ["remdesivir", "CHEMICAL", 140, 150], ["patient", "ORGANISM", 41, 48], ["Human", "ORGANISM", 61, 66], ["remdesivir", "SIMPLE_CHEMICAL", 98, 108], ["coronaviruses", "ORGANISM", 113, 126], ["Human", "ORGANISM", 126, 131], ["patient", "SPECIES", 41, 48], ["Human", "SPECIES", 61, 66], ["Human", "SPECIES", 126, 131], ["Human", "SPECIES", 61, 66], ["Human", "SPECIES", 126, 131], ["remdesivir", "TEST", 98, 108], ["coronaviruses", "PROBLEM", 113, 126], ["COVID", "TREATMENT", 159, 164]]], ["In fact, there are many anecdotal reports already circulating about treatment of COVID-19 patients with remdesivir.", [["remdesivir", "CHEMICAL", 104, 114], ["remdesivir", "CHEMICAL", 104, 114], ["patients", "ORGANISM", 90, 98], ["remdesivir", "SIMPLE_CHEMICAL", 104, 114], ["patients", "SPECIES", 90, 98], ["COVID", "TREATMENT", 81, 86], ["remdesivir", "TREATMENT", 104, 114]]], ["According to a recent newspaper article, 17 passengers on the Diamond Princess cruise ship were treated with intravenous remdesivir for 10 days and were alive at the time of article release.", [["intravenous", "ANATOMY", 109, 120], ["remdesivir", "CHEMICAL", 121, 131], ["remdesivir", "CHEMICAL", 121, 131], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 109, 120], ["remdesivir", "SIMPLE_CHEMICAL", 121, 131], ["intravenous remdesivir", "TREATMENT", 109, 131]]], ["One of the physicians involved in their treatment, who is affiliated with the U.S. National Institutes of Health (NIH), felt that the patients were less dependent on ventilators after receiving the drug.", [["patients", "ORGANISM", 134, 142], ["patients", "SPECIES", 134, 142], ["ventilators", "TREATMENT", 166, 177], ["the drug", "TREATMENT", 194, 202]]], ["Nevertheless, no conclusions can be drawn based on such reports.Human data ::: Summary of studies on remdesivir and coronavirusesA preprint of a case series on the first 12 COVID-19 patients in the U.S. (who had disease onset between January 14 and 29, 2020) recently became available, though it had not been peer-reviewed at the time of writing [38].", [["Human", "ORGANISM", 64, 69], ["patients", "ORGANISM", 182, 190], ["Human", "SPECIES", 64, 69], ["patients", "SPECIES", 182, 190], ["Human", "SPECIES", 64, 69]]], ["This report, authored by a team from the Centers for Disease Control (CDC), described the demographic and clinical characteristics of the patients, as well as information on course of disease and clinical management.", [["patients", "ORGANISM", 138, 146], ["patients", "SPECIES", 138, 146], ["disease", "PROBLEM", 184, 191], ["clinical management", "TREATMENT", 196, 215]]], ["Seven of the 12 patients (58%) were hospitalized, and three of these patients received remdesivir intravenously at the onset of worsening symptoms (two on the eleventh day of illness and one on the seventh day).", [["remdesivir", "CHEMICAL", 87, 97], ["illness", "DISEASE", 175, 182], ["remdesivir", "CHEMICAL", 87, 97], ["patients", "ORGANISM", 16, 24], ["patients", "ORGANISM", 69, 77], ["remdesivir", "SIMPLE_CHEMICAL", 87, 97], ["patients", "SPECIES", 16, 24], ["patients", "SPECIES", 69, 77], ["remdesivir intravenously", "TREATMENT", 87, 111], ["worsening symptoms", "PROBLEM", 128, 146], ["worsening", "OBSERVATION_MODIFIER", 128, 137], ["symptoms", "OBSERVATION", 138, 146]]], ["Treatment with remdesivir was tolerated, though temporary gastrointestinal upset and elevated aminotransferase levels were observed in all three patients after administration.", [["gastrointestinal", "ANATOMY", 58, 74], ["remdesivir", "CHEMICAL", 15, 25], ["remdesivir", "CHEMICAL", 15, 25], ["remdesivir", "SIMPLE_CHEMICAL", 15, 25], ["gastrointestinal", "ORGANISM_SUBDIVISION", 58, 74], ["aminotransferase", "SIMPLE_CHEMICAL", 94, 110], ["patients", "ORGANISM", 145, 153], ["patients", "SPECIES", 145, 153], ["remdesivir", "TREATMENT", 15, 25], ["temporary gastrointestinal upset", "PROBLEM", 48, 80], ["elevated aminotransferase levels", "PROBLEM", 85, 117]]], ["Treatment was discontinued after respiratory symptoms improved (total treatment durations of 4 days, 5 days, and 10 days).", [["respiratory", "ANATOMY", 33, 44], ["Treatment", "TREATMENT", 0, 9], ["respiratory symptoms", "PROBLEM", 33, 53]]], ["It should be noted that one of these three patients is the same patient described in the case report discussed above [37].Human data ::: Summary of studies on remdesivir and coronavirusesSome safety data were formally collected during a clinical trial conducted in the Democratic Republic of Congo that randomized 175 patients to be treated with remdesivir for Ebola [39].", [["remdesivir", "CHEMICAL", 346, 356], ["Ebola", "DISEASE", 361, 366], ["remdesivir", "CHEMICAL", 346, 356], ["patients", "ORGANISM", 43, 51], ["patient", "ORGANISM", 64, 71], ["Human", "ORGANISM", 122, 127], ["remdesivir", "SIMPLE_CHEMICAL", 159, 169], ["coronaviruses", "ORGANISM", 174, 187], ["patients", "ORGANISM", 318, 326], ["patients", "SPECIES", 43, 51], ["patient", "SPECIES", 64, 71], ["Human", "SPECIES", 122, 127], ["patients", "SPECIES", 318, 326], ["Human", "SPECIES", 122, 127], ["studies", "TEST", 148, 155], ["remdesivir", "TEST", 159, 169], ["remdesivir", "TREATMENT", 346, 356], ["Ebola", "PROBLEM", 361, 366]]], ["Incidentally, randomization to remdesivir treatment was discontinued in this trial after an interim analysis showed superior survival for two other trial drugs, despite preclinical and compassionate use data having been favorable for remdesivir against the Ebola virus prior to the trial [9].", [["remdesivir", "CHEMICAL", 31, 41], ["remdesivir", "CHEMICAL", 234, 244], ["Ebola virus", "DISEASE", 257, 268], ["remdesivir", "CHEMICAL", 31, 41], ["remdesivir", "CHEMICAL", 234, 244], ["remdesivir", "SIMPLE_CHEMICAL", 31, 41], ["remdesivir", "SIMPLE_CHEMICAL", 234, 244], ["Ebola virus", "ORGANISM", 257, 268], ["Ebola virus", "SPECIES", 257, 268], ["Ebola virus", "SPECIES", 257, 268], ["randomization to remdesivir treatment", "TREATMENT", 14, 51], ["an interim analysis", "TEST", 89, 108], ["other trial drugs", "TREATMENT", 142, 159], ["remdesivir", "TREATMENT", 234, 244], ["the Ebola virus", "PROBLEM", 253, 268]]], ["Interestingly, patients who received remdesivir had slower rates of viral clearance compared to patients who received single-dose antivirals (specifically, MAb114 and REGN-EB3), which the authors hypothesized may be related to the fact that the treatment plan for remdesivir involved multiple intravenous infusions.", [["intravenous", "ANATOMY", 293, 304], ["remdesivir", "CHEMICAL", 37, 47], ["remdesivir", "CHEMICAL", 264, 274], ["remdesivir", "CHEMICAL", 37, 47], ["remdesivir", "CHEMICAL", 264, 274], ["patients", "ORGANISM", 15, 23], ["patients", "ORGANISM", 96, 104], ["REGN-EB3", "GENE_OR_GENE_PRODUCT", 167, 175], ["remdesivir", "SIMPLE_CHEMICAL", 264, 274], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 293, 304], ["patients", "SPECIES", 15, 23], ["patients", "SPECIES", 96, 104], ["remdesivir", "TREATMENT", 37, 47], ["viral clearance", "PROBLEM", 68, 83], ["single-dose antivirals", "TREATMENT", 118, 140], ["MAb", "TEST", 156, 159], ["REGN", "TEST", 167, 171], ["remdesivir", "TREATMENT", 264, 274], ["multiple intravenous infusions", "TREATMENT", 284, 314]]], ["However, for now, information on the potential efficacy of remdesivir specifically against CoVs is largely limited to in vitro and animal studies, though COVID-19 related knowledge is evolving quickly.Human data ::: Summary of studies on remdesivir and coronavirusesOverall, past studies on other CoVs may have limited generalizability to the virus underlying the current pandemic because of the high genetic diversity of the Coronaviridae family, although broad-spectrum drugs tend to be directed at well-conserved targets [11,40].", [["remdesivir", "CHEMICAL", 59, 69], ["CoVs", "CHEMICAL", 91, 95], ["remdesivir", "CHEMICAL", 238, 248], ["remdesivir", "CHEMICAL", 59, 69], ["remdesivir", "SIMPLE_CHEMICAL", 59, 69], ["CoVs", "SIMPLE_CHEMICAL", 91, 95], ["Human", "ORGANISM", 201, 206], ["remdesivir", "SIMPLE_CHEMICAL", 238, 248], ["coronaviruses", "ORGANISM", 253, 266], ["CoVs", "GENE_OR_GENE_PRODUCT", 297, 301], ["Coronaviridae", "GENE_OR_GENE_PRODUCT", 426, 439], ["Human", "SPECIES", 201, 206], ["Human", "SPECIES", 201, 206], ["remdesivir", "TREATMENT", 59, 69], ["CoVs", "PROBLEM", 91, 95], ["animal studies", "TEST", 131, 145], ["COVID", "TEST", 154, 159], ["remdesivir", "TEST", 238, 248], ["coronaviruses", "PROBLEM", 253, 266], ["past studies", "TEST", 275, 287], ["other CoVs", "PROBLEM", 291, 301], ["the virus", "PROBLEM", 339, 348], ["broad-spectrum drugs", "TREATMENT", 457, 477]]], ["In addition to this issue, there are a number of factors that can impact how predictive findings from in vitro or in vivo models may be of clinical efficacy against SARS-CoV-2.", [["SARS", "DISEASE", 165, 169], ["SARS-CoV-2", "ORGANISM", 165, 175], ["SARS-CoV", "SPECIES", 165, 173], ["SARS", "PROBLEM", 165, 169], ["CoV", "TEST", 170, 173]]], ["For example, drugs that may be effective in vitro may not have clinical utility if the therapeutic dose induces severe adverse events in the patient.", [["patient", "ORGANISM", 141, 148], ["patient", "SPECIES", 141, 148], ["drugs", "TREATMENT", 13, 18], ["severe adverse events", "PROBLEM", 112, 133]]], ["Alternatively, if the treatment dose does not attain an effective serum concentration in patients, or if EC50 is greater than the achievable maximum serum concentration (Cmax), then the drug is less likely to have therapeutic utility.", [["serum", "ANATOMY", 66, 71], ["serum", "ANATOMY", 149, 154], ["serum", "ORGANISM_SUBSTANCE", 66, 71], ["patients", "ORGANISM", 89, 97], ["serum", "ORGANISM_SUBSTANCE", 149, 154], ["Cmax", "SIMPLE_CHEMICAL", 170, 174], ["patients", "SPECIES", 89, 97], ["the treatment dose", "TREATMENT", 18, 36], ["EC50", "TEST", 105, 109]]], ["With regard to animal models, how closely the model represents disease pathogenesis and drug metabolism in humans can be challenging to gauge.Clinical trials ::: Summary of studies on remdesivir and coronavirusesMultiple clinical trials are underway on the use of remdesivir for treatment of COVID-19 [41].", [["remdesivir", "CHEMICAL", 264, 274], ["remdesivir", "CHEMICAL", 264, 274], ["COVID-19", "CHEMICAL", 292, 300], ["humans", "ORGANISM", 107, 113], ["remdesivir", "SIMPLE_CHEMICAL", 184, 194], ["remdesivir", "SIMPLE_CHEMICAL", 264, 274], ["humans", "SPECIES", 107, 113], ["humans", "SPECIES", 107, 113], ["disease pathogenesis", "PROBLEM", 63, 83], ["drug metabolism in humans", "PROBLEM", 88, 113], ["studies", "TEST", 173, 180], ["remdesivir", "TREATMENT", 184, 194], ["coronaviruses", "TREATMENT", 199, 212], ["remdesivir", "TREATMENT", 264, 274], ["treatment", "TREATMENT", 279, 288], ["COVID", "TEST", 292, 297], ["disease", "OBSERVATION", 63, 70], ["drug metabolism", "OBSERVATION", 88, 103]]], ["The NIH-sponsored clinical trial, ongoing in the U.S. and the Republic of Korea, is a double-blinded, placebo-controlled trial in which patients are randomized to receive either placebo or an initial dose of 200 mg of intravenous remdesivir on the first day, followed by a maintenance dose of 100 mg per day, through discharge up to a maximum of 10 total treatment days [20].", [["intravenous", "ANATOMY", 218, 229], ["remdesivir", "CHEMICAL", 230, 240], ["patients", "ORGANISM", 136, 144], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 218, 229], ["remdesivir", "SIMPLE_CHEMICAL", 230, 240], ["patients", "SPECIES", 136, 144], ["placebo", "TREATMENT", 102, 109], ["placebo", "TREATMENT", 178, 185], ["intravenous remdesivir", "TREATMENT", 218, 240]]], ["The primary outcome of the trial, as described in the U.S. National Library of Medicine clinical trials registry, will be expressed as the proportion of patients in each category of a seven-category clinical severity scale on the fifteenth day post treatment initiation (Table 2) [42].", [["patients", "ORGANISM", 153, 161], ["patients", "SPECIES", 153, 161], ["treatment initiation", "TREATMENT", 249, 269]]], ["Additionally, Gilead Sciences is sponsoring a remdesivir study among patients with severe COVID-19 with a composite primary outcome measure of fever normalization and oxygen normalization [43].Clinical trials ::: Summary of studies on remdesivir and coronavirusesTwo double-blinded placebo-controlled trials are also recruiting in Hubei Province, China [44,45].", [["fever", "DISEASE", 143, 148], ["oxygen", "CHEMICAL", 167, 173], ["remdesivir", "CHEMICAL", 235, 245], ["oxygen", "CHEMICAL", 167, 173], ["patients", "ORGANISM", 69, 77], ["oxygen", "SIMPLE_CHEMICAL", 167, 173], ["remdesivir", "SIMPLE_CHEMICAL", 235, 245], ["coronaviruses", "ORGANISM", 250, 263], ["patients", "SPECIES", 69, 77], ["a remdesivir study", "TEST", 44, 62], ["severe COVID", "PROBLEM", 83, 95], ["fever normalization", "PROBLEM", 143, 162], ["oxygen normalization", "TEST", 167, 187], ["remdesivir", "TEST", 235, 245], ["coronaviruses", "PROBLEM", 250, 263], ["Two double-blinded placebo-controlled trials", "TREATMENT", 263, 307]]], ["One targets hospitalized patients with mild-to-moderate COVID-19 [44], while the other is focused on severe cases [45].", [["patients", "ORGANISM", 25, 33], ["patients", "SPECIES", 25, 33], ["mild-to-moderate COVID", "PROBLEM", 39, 61], ["mild", "OBSERVATION_MODIFIER", 39, 43]]], ["The primary outcome measure for the study on mild or moderate cases is time to clinical recovery, as defined by normalization of body temperature, respiratory rate, and oxygen saturation, and the resolution of cough for at least 72 h [44].", [["body", "ANATOMY", 129, 133], ["respiratory", "ANATOMY", 147, 158], ["oxygen", "CHEMICAL", 169, 175], ["cough", "DISEASE", 210, 215], ["oxygen", "CHEMICAL", 169, 175], ["body", "ORGANISM_SUBDIVISION", 129, 133], ["oxygen", "SIMPLE_CHEMICAL", 169, 175], ["the study", "TEST", 32, 41], ["body temperature", "TEST", 129, 145], ["respiratory rate", "TEST", 147, 163], ["oxygen saturation", "TEST", 169, 186], ["cough", "PROBLEM", 210, 215], ["respiratory rate", "OBSERVATION", 147, 163], ["oxygen saturation", "OBSERVATION", 169, 186], ["cough", "OBSERVATION", 210, 215]]], ["In the study on severe cases, time to clinical improvement is the primary outcome and is defined using a six-category scale, ranging from discharge to death [45].ConclusionsWhile previous studies on remdesivir are promising, formal clinical evaluation is strongly warranted.", [["death", "DISEASE", 151, 156], ["remdesivir", "CHEMICAL", 199, 209], ["remdesivir", "CHEMICAL", 199, 209], ["remdesivir", "SIMPLE_CHEMICAL", 199, 209], ["the study", "TEST", 3, 12], ["a six-category scale", "TREATMENT", 103, 123], ["previous studies", "TEST", 179, 195], ["remdesivir", "TREATMENT", 199, 209], ["formal clinical evaluation", "TEST", 225, 251]]], ["In general, there are many reasons why favorable preclinical data can fail to translate directly into human clinical trial results [46], such as inadvertent use of irrelevant models, inability to achieve effective serum drug concentrations in patients, or the occurrence of unanticipated severe adverse events among patients.", [["serum", "ANATOMY", 214, 219], ["human", "ORGANISM", 102, 107], ["serum", "ORGANISM_SUBSTANCE", 214, 219], ["patients", "ORGANISM", 243, 251], ["patients", "ORGANISM", 316, 324], ["human", "SPECIES", 102, 107], ["patients", "SPECIES", 243, 251], ["patients", "SPECIES", 316, 324], ["human", "SPECIES", 102, 107], ["irrelevant models", "PROBLEM", 164, 181], ["effective serum drug concentrations", "TREATMENT", 204, 239], ["unanticipated severe adverse events", "PROBLEM", 274, 309], ["severe", "OBSERVATION_MODIFIER", 288, 294]]], ["Therefore, postulating on expected results of the trials is extremely challenging.ConclusionsNonetheless, there are hundreds of clinical trials ongoing internationally on different drugs that utilize various mechanisms of action [41,51], including trials on other nucleosides inhibitors (e.g., ribavirin), protease inhibitors (e.g., lopinavir/ritonavir), and interleukin-6 receptor inhibitors (e.g., sarilumab) [41,47].", [["ribavirin", "CHEMICAL", 294, 303], ["lopinavir/ritonavir", "CHEMICAL", 333, 352], ["sarilumab", "CHEMICAL", 400, 409], ["nucleosides", "CHEMICAL", 264, 275], ["ribavirin", "CHEMICAL", 294, 303], ["lopinavir", "CHEMICAL", 333, 342], ["ritonavir", "CHEMICAL", 343, 352], ["sarilumab", "CHEMICAL", 400, 409], ["ribavirin", "SIMPLE_CHEMICAL", 294, 303], ["lopinavir", "SIMPLE_CHEMICAL", 333, 342], ["ritonavir", "SIMPLE_CHEMICAL", 343, 352], ["interleukin-6 receptor inhibitors", "SIMPLE_CHEMICAL", 359, 392], ["sarilumab", "SIMPLE_CHEMICAL", 400, 409], ["interleukin", "PROTEIN", 359, 370], ["clinical trials", "TREATMENT", 128, 143], ["different drugs", "TREATMENT", 171, 186], ["other nucleosides inhibitors", "TREATMENT", 258, 286], ["ribavirin", "TREATMENT", 294, 303], ["protease inhibitors", "TREATMENT", 306, 325], ["lopinavir", "TREATMENT", 333, 342], ["ritonavir", "TREATMENT", 343, 352], ["interleukin-6 receptor inhibitors", "TREATMENT", 359, 392]]], ["Another well-known candidate that is being evaluated in multiple trials against COVID-19 is chloroquine (or hydroxychloroquine), which is already approved as an antimalarial (and for extraintestinal amebiasis) [41,48].", [["COVID-19", "CHEMICAL", 80, 88], ["chloroquine", "CHEMICAL", 92, 103], ["hydroxychloroquine", "CHEMICAL", 108, 126], ["amebiasis", "DISEASE", 199, 208], ["COVID-19", "CHEMICAL", 80, 88], ["chloroquine", "CHEMICAL", 92, 103], ["hydroxychloroquine", "CHEMICAL", 108, 126], ["COVID-19", "SIMPLE_CHEMICAL", 80, 88], ["chloroquine", "SIMPLE_CHEMICAL", 92, 103], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 108, 126], ["COVID", "TREATMENT", 80, 85], ["chloroquine", "TREATMENT", 92, 103], ["hydroxychloroquine", "TREATMENT", 108, 126], ["extraintestinal amebiasis", "PROBLEM", 183, 208]]], ["Results of the clinical trials currently underway in the U.S. and China will provide crucial information about whether remdesivir represents a viable treatment option for COVID-19 [20,49].", [["remdesivir", "CHEMICAL", 119, 129], ["remdesivir", "CHEMICAL", 119, 129], ["COVID-19", "CHEMICAL", 171, 179], ["remdesivir", "SIMPLE_CHEMICAL", 119, 129], ["the clinical trials", "TEST", 11, 30], ["a viable treatment option", "TREATMENT", 141, 166], ["COVID", "TEST", 171, 176]]], ["Such a change in production may also allow for the added benefit of the drug becoming more available for agricultural and veterinary use for relevant indications.Funding statementThis work did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.Declaration of Competing InterestThe authors report no relevant conflicts of interest.", [["a change in production", "PROBLEM", 5, 27], ["the drug", "TREATMENT", 68, 76]]], ["However, none of these studies involved Gilead Sciences.", [["these studies", "TEST", 17, 30]]]], "PMC7486159": [["An event is serious (based on the ICH definition) when the patient outcome is:", [["ICH", "DISEASE", 34, 37], ["patient", "ORGANISM", 59, 66], ["patient", "SPECIES", 59, 66], ["the ICH definition", "TEST", 30, 48], ["serious", "OBSERVATION_MODIFIER", 12, 19]]]], "PMC7149941": [], "817e4dbb8bcf9f310c1e3220e3919c1b8fa132e5": [], "91f2b83e043674cce760a94483be618fcd91a901": [["The coronavirus infection which originated from Wuhan, China inDecember 2019 has turned in to a global catastrophe (1) .", [["coronavirus infection", "DISEASE", 4, 25], ["coronavirus", "ORGANISM", 4, 15], ["coronavirus", "SPECIES", 4, 15], ["The coronavirus infection", "PROBLEM", 0, 25], ["coronavirus", "OBSERVATION_MODIFIER", 4, 15], ["infection", "OBSERVATION", 16, 25]]], ["The virus has been designated as Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) and the disease caused by the agent as Coronavirus Disease 2019 (COVID- 19) (2).", [["Acute Respiratory Syndrome", "DISEASE", 40, 66], ["Severe Acute Respiratory Syndrome-Coronavirus-2", "ORGANISM", 33, 80], ["SARS-CoV-2", "ORGANISM", 82, 92], ["Severe Acute Respiratory Syndrome-Coronavirus-2", "SPECIES", 33, 80], ["SARS-CoV-2", "SPECIES", 82, 92], ["Coronavirus Disease 2019 (COVID- 19", "SPECIES", 133, 168], ["The virus", "PROBLEM", 0, 9], ["Severe Acute Respiratory Syndrome", "PROBLEM", 33, 66], ["Coronavirus", "TEST", 67, 78], ["SARS", "TEST", 82, 86], ["CoV", "TEST", 87, 90], ["the disease", "PROBLEM", 98, 109], ["Coronavirus Disease", "PROBLEM", 133, 152], ["COVID", "TEST", 159, 164], ["virus", "OBSERVATION", 4, 9], ["Severe", "OBSERVATION_MODIFIER", 33, 39], ["Acute", "OBSERVATION_MODIFIER", 40, 45], ["Respiratory Syndrome", "OBSERVATION", 46, 66], ["disease", "OBSERVATION", 102, 109]]], ["World Health Organization (WHO) pronounced the disease as a pandemic on March 11, 2020 (3) .", [["the disease", "PROBLEM", 43, 54], ["disease", "OBSERVATION", 47, 54]]], ["As of May 4 th, 2020, the infection has spread to 212 countries and territories around the World and 2 international conveyances, with over 3.5 million cases and around two hundred fifty-thousand deaths (4) .", [["infection", "DISEASE", 26, 35], ["deaths", "DISEASE", 196, 202], ["the infection", "PROBLEM", 22, 35], ["infection", "OBSERVATION", 26, 35]]], ["The disease on average affects over 33,000 individuals with over 1300 deaths daily.", [["deaths", "DISEASE", 70, 76], ["The disease", "PROBLEM", 0, 11], ["disease", "OBSERVATION", 4, 11]]], ["The world community has responded to the challenge of death and devastation with resilience and determination (5) .", [["death", "DISEASE", 54, 59], ["death", "PROBLEM", 54, 59]]], ["Governments have implemented lockdown measures, blocked international travel, and enforced other public containment measures to mitigate the virus morbidity and mortality (6) (7) (8) .", [["public containment measures", "TREATMENT", 97, 124], ["the virus morbidity", "PROBLEM", 137, 156]]], ["There has been a major understanding of the disease as well as the pathogen and these data have been generated and widely publicized in a matter of days and weeks rather than years and decades, an unprecedented occurrence in the history of medicine (9) (10) (11) (12) .Introduction.", [["the disease", "PROBLEM", 40, 51], ["disease", "OBSERVATION", 44, 51]]], ["The coronavirus infection which originated from Wuhan, China inCoronavirus Family.", [["coronavirus infection", "DISEASE", 4, 25], ["coronavirus", "ORGANISM", 4, 15], ["coronavirus", "SPECIES", 4, 15], ["The coronavirus infection", "PROBLEM", 0, 25], ["coronavirus", "OBSERVATION_MODIFIER", 4, 15], ["infection", "OBSERVATION", 16, 25]]], ["SARS-CoV-2 belongs to a family of zoonotic viruses known as Coronavirus, genus Betacononavirus and is closely related to two other viruses namely Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) and the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) (13) .", [["SARS", "DISEASE", 0, 4], ["zoonotic viruses", "DISEASE", 34, 50], ["Acute Respiratory Syndrome Coronavirus", "DISEASE", 153, 191], ["SARS-CoV)", "DISEASE", 193, 202], ["Middle East Respiratory Syndrome Coronavirus", "DISEASE", 211, 255], ["SARS-CoV-2", "ORGANISM", 0, 10], ["SARS-CoV", "ORGANISM", 193, 201], ["Middle East Respiratory Syndrome Coronavirus", "ORGANISM", 211, 255], ["MERS-CoV", "ORGANISM", 257, 265], ["SARS-CoV", "SPECIES", 0, 8], ["Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV", "SPECIES", 146, 201], ["Middle East Respiratory Syndrome Coronavirus (MERS-CoV", "SPECIES", 211, 265], ["zoonotic viruses", "PROBLEM", 34, 50], ["Coronavirus", "PROBLEM", 60, 71], ["genus Betacononavirus", "PROBLEM", 73, 94], ["two other viruses", "PROBLEM", 121, 138], ["Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)", "PROBLEM", 146, 202], ["the Middle East Respiratory Syndrome Coronavirus", "PROBLEM", 207, 255], ["Severe", "OBSERVATION_MODIFIER", 146, 152], ["Acute", "OBSERVATION_MODIFIER", 153, 158], ["Respiratory Syndrome Coronavirus", "OBSERVATION", 159, 191], ["Middle", "ANATOMY_MODIFIER", 211, 217], ["Respiratory Syndrome", "OBSERVATION", 223, 243]]], ["All three are bat viruses and cross over to cause human infection through an intermediate host (civets for SARS-CoV, camels for MERS-CoV, and possibly pangolins for SARS-CoV-2) (14) (15) (16) (17) (18) .", [["infection", "DISEASE", 56, 65], ["pangolins", "CHEMICAL", 151, 160], ["human", "ORGANISM", 50, 55], ["SARS-CoV", "ORGANISM", 107, 115], ["camels", "ORGANISM", 117, 123], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 128, 136], ["human", "SPECIES", 50, 55], ["human", "SPECIES", 50, 55], ["SARS-CoV", "SPECIES", 107, 115], ["MERS-CoV", "SPECIES", 128, 136], ["bat viruses", "PROBLEM", 14, 25], ["human infection", "PROBLEM", 50, 65], ["SARS", "PROBLEM", 107, 111], ["MERS", "PROBLEM", 128, 132], ["CoV", "TEST", 133, 136], ["SARS", "PROBLEM", 165, 169], ["CoV", "TEST", 170, 173], ["bat", "ANATOMY", 14, 17], ["viruses", "OBSERVATION", 18, 25], ["infection", "OBSERVATION", 56, 65]]], ["Coronaviruses are enveloped viruses, around 125 nm in diameter, with a positive-sense singlestranded RNA genome of around 30kb and a nucleocapsid of helical symmetry.", [["Coronaviruses", "GENE_OR_GENE_PRODUCT", 0, 13], ["singlestranded RNA genome", "DNA", 86, 111], ["Coronaviruses", "PROBLEM", 0, 13], ["enveloped viruses", "PROBLEM", 18, 35], ["a positive-sense singlestranded RNA genome", "PROBLEM", 69, 111], ["enveloped", "OBSERVATION_MODIFIER", 18, 27], ["viruses", "OBSERVATION", 28, 35], ["125 nm", "OBSERVATION_MODIFIER", 44, 50], ["diameter", "OBSERVATION_MODIFIER", 54, 62], ["positive", "OBSERVATION_MODIFIER", 71, 79], ["RNA genome", "OBSERVATION", 101, 111], ["nucleocapsid", "OBSERVATION", 133, 145], ["helical symmetry", "OBSERVATION", 149, 165]]], ["This is wrapped in an icosahedral protein shell.", [["an icosahedral protein shell", "TREATMENT", 19, 47], ["icosahedral protein shell", "OBSERVATION", 22, 47]]], ["The surface has multiple clubshaped spikes, which creates the appearance of solar corona on EM.", [["surface", "ANATOMY", 4, 11], ["surface", "CELLULAR_COMPONENT", 4, 11], ["multiple clubshaped spikes", "PROBLEM", 16, 42], ["surface", "OBSERVATION_MODIFIER", 4, 11], ["multiple", "OBSERVATION_MODIFIER", 16, 24], ["clubshaped spikes", "OBSERVATION", 25, 42], ["solar", "OBSERVATION_MODIFIER", 76, 81], ["corona", "OBSERVATION_MODIFIER", 82, 88]]], ["The viral envelope consists of a lipid bilayer, in which the membrane (M), envelope (E) and spike (S) structural proteins are anchored.", [["lipid bilayer", "ANATOMY", 33, 46], ["membrane", "ANATOMY", 61, 69], ["lipid bilayer", "CELLULAR_COMPONENT", 33, 46], ["membrane", "CELLULAR_COMPONENT", 61, 69], ["envelope (E) and spike (S) structural proteins", "PROTEIN", 75, 121], ["a lipid bilayer", "TEST", 31, 46], ["spike (S) structural proteins", "PROBLEM", 92, 121], ["viral envelope", "OBSERVATION", 4, 18]]], ["All the coronaviruses use Angiotensin-converting enzyme 2 (ACE2) receptors as a cellular entry receptor, however, the propensity of SARS-CoV-2 to attach to these receptors is much higher, giving it high infectivity (13) .Introduction.", [["cellular", "ANATOMY", 80, 88], ["Angiotensin", "CHEMICAL", 26, 37], ["coronaviruses", "ORGANISM", 8, 21], ["Angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 26, 57], ["ACE2", "GENE_OR_GENE_PRODUCT", 59, 63], ["cellular", "CELL", 80, 88], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 132, 142], ["Angiotensin-converting enzyme 2 (ACE2) receptors", "PROTEIN", 26, 74], ["cellular entry receptor", "PROTEIN", 80, 103], ["Angiotensin-converting enzyme", "TREATMENT", 26, 55], ["SARS", "PROBLEM", 132, 136], ["CoV", "TEST", 137, 140], ["coronaviruses", "OBSERVATION", 8, 21]]], ["The coronavirus infection which originated from Wuhan, China inNeed for Coronavirus Vaccine.", [["coronavirus infection", "DISEASE", 4, 25], ["coronavirus", "ORGANISM", 4, 15], ["Coronavirus Vaccine", "ORGANISM", 72, 91], ["coronavirus", "SPECIES", 4, 15], ["The coronavirus infection", "PROBLEM", 0, 25], ["Coronavirus Vaccine", "TREATMENT", 72, 91], ["coronavirus", "OBSERVATION_MODIFIER", 4, 15], ["infection", "OBSERVATION", 16, 25]]], ["There has been an intensive search for an effective drug against the virus or the resultant disease and has not led to any breakthrough agents.", [["the virus", "PROBLEM", 65, 74], ["the resultant disease", "PROBLEM", 78, 99], ["any breakthrough agents", "TREATMENT", 119, 142], ["resultant", "OBSERVATION_MODIFIER", 82, 91], ["disease", "OBSERVATION", 92, 99]]], ["Few drugs namely hydroxychloroquine and Remdesivir have been advocated as desperate measures to fight COVID-19 based on a few preliminary, contradictory, and inconclusive studies (19) (20) (21) (22) (23) .", [["hydroxychloroquine", "CHEMICAL", 17, 35], ["Remdesivir", "CHEMICAL", 40, 50], ["hydroxychloroquine", "CHEMICAL", 17, 35], ["Remdesivir", "CHEMICAL", 40, 50], ["COVID-19", "CHEMICAL", 102, 110], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 17, 35], ["Remdesivir", "SIMPLE_CHEMICAL", 40, 50], ["20) (21) (22)", "SIMPLE_CHEMICAL", 185, 198], ["Few drugs", "TREATMENT", 0, 9], ["hydroxychloroquine", "TREATMENT", 17, 35], ["Remdesivir", "TREATMENT", 40, 50], ["COVID", "TEST", 102, 107], ["inconclusive studies", "TEST", 158, 178]]], ["This leaves us with only one choice namely an effective and safe vaccine that shall be manufactured as soon as possible and available to all countries and populations affected by the pandemic at an affordable price (25, 26) .", [["safe vaccine", "TREATMENT", 60, 72]]], ["A vaccine has the power to generate herd immunity in the communities, which will reduce the incidence of disease, block transmission, and reduce the social and economic burden of the disease.", [["A vaccine", "TREATMENT", 0, 9], ["disease", "PROBLEM", 105, 112], ["block transmission", "TREATMENT", 114, 132], ["the disease", "PROBLEM", 179, 190], ["disease", "OBSERVATION", 183, 190]]], ["Very high immunization coverage can effectively fight the pandemic, prevent secondary waves of infection, and control the seasonal endemic infection outbursts.", [["infection", "DISEASE", 95, 104], ["infection", "DISEASE", 139, 148], ["Very high immunization coverage", "TREATMENT", 0, 31], ["secondary waves of infection", "PROBLEM", 76, 104], ["the seasonal endemic infection outbursts", "PROBLEM", 118, 158], ["infection", "OBSERVATION", 95, 104], ["seasonal", "OBSERVATION_MODIFIER", 122, 130], ["endemic", "OBSERVATION_MODIFIER", 131, 138], ["infection", "OBSERVATION", 139, 148]]], ["Eventually, the disease can be eradicated as has happened in many other diseases that have had even with higher potential than COVID-19 to cause pandemics namely smallpox, poliomyelitis, etc (27, 28).Vaccine Immunology.Adaptive Immune Response.", [["smallpox", "DISEASE", 162, 170], ["poliomyelitis", "DISEASE", 172, 185], ["the disease", "PROBLEM", 12, 23], ["many other diseases", "PROBLEM", 61, 80], ["COVID", "TEST", 127, 132], ["pandemics", "PROBLEM", 145, 154], ["smallpox", "PROBLEM", 162, 170], ["poliomyelitis", "PROBLEM", 172, 185], ["disease", "OBSERVATION", 16, 23], ["poliomyelitis", "OBSERVATION", 172, 185], ["Immune Response", "OBSERVATION", 228, 243]]], ["A vaccine is medical preparations ranging from intact organisms (attenuated live, or inactivated) to genetically engineered parts of the organisms (antigenic) that induce both arms of the adaptive immune system and stimulate a sufficient number of memory T cells and B lymphocytes (29) .", [["immune system", "ANATOMY", 197, 210], ["memory T cells", "ANATOMY", 248, 262], ["B lymphocytes", "ANATOMY", 267, 280], ["immune system", "ANATOMICAL_SYSTEM", 197, 210], ["memory T cells", "CELL", 248, 262], ["B lymphocytes", "CELL", 267, 280], ["memory T cells", "CELL_TYPE", 248, 262], ["B lymphocytes", "CELL_TYPE", 267, 280], ["A vaccine", "TREATMENT", 0, 9], ["medical preparations", "TREATMENT", 13, 33], ["intact organisms", "PROBLEM", 47, 63], ["B lymphocytes", "TEST", 267, 280]]], ["Vaccines should contain antigens necessary to mount the specific response without causing disease.", [["Vaccines", "TREATMENT", 0, 8], ["antigens", "TREATMENT", 24, 32], ["disease", "PROBLEM", 90, 97]]], ["Once challenged with the pathogen, memory cells yield effector T cells and antibody-producing B cells and fight the infection.", [["memory cells", "ANATOMY", 35, 47], ["effector T cells", "ANATOMY", 54, 70], ["B cells", "ANATOMY", 94, 101], ["infection", "DISEASE", 116, 125], ["memory cells", "CELL", 35, 47], ["effector T cells", "CELL", 54, 70], ["B cells", "CELL", 94, 101], ["memory cells", "CELL_TYPE", 35, 47], ["effector T cells", "CELL_TYPE", 54, 70], ["antibody-producing B cells", "CELL_TYPE", 75, 101], ["the pathogen", "PROBLEM", 21, 33], ["memory cells", "TEST", 35, 47], ["effector T cells", "TEST", 54, 70], ["antibody", "TEST", 75, 83], ["B cells", "PROBLEM", 94, 101], ["the infection", "PROBLEM", 112, 125], ["infection", "OBSERVATION", 116, 125]]], ["The antibodies have to be the neutralizing type which binds to the virus and block infection (30) .", [["infection", "DISEASE", 83, 92], ["antibodies", "PROTEIN", 4, 14], ["The antibodies", "PROBLEM", 0, 14], ["the neutralizing type", "PROBLEM", 26, 47], ["block infection", "PROBLEM", 77, 92]]], ["The virus coated with neutralizing antibodies either cannot interact with the receptor or may be unable to uncoat of the genome.", [["genome", "CELLULAR_COMPONENT", 121, 127], ["neutralizing antibodies", "PROTEIN", 22, 45], ["The virus coated with neutralizing antibodies", "TREATMENT", 0, 45], ["virus", "OBSERVATION", 4, 9], ["neutralizing antibodies", "OBSERVATION", 22, 45], ["genome", "OBSERVATION", 121, 127]]], ["Most currently licensed vaccines to induce neutralizing antibody responses capable of mediating long-term protection against lytic viruses such as influenza and smallpox (31) .", [["influenza and smallpox", "DISEASE", 147, 169], ["licensed vaccines", "TREATMENT", 15, 32], ["neutralizing antibody responses", "TEST", 43, 74], ["long-term protection", "TREATMENT", 96, 116], ["lytic viruses", "PROBLEM", 125, 138], ["influenza", "PROBLEM", 147, 156]]], ["The T cell-based responses that recognize and kill infected cells do also fight the infection (32) .", [["T cell", "ANATOMY", 4, 10], ["cells", "ANATOMY", 60, 65], ["infection", "DISEASE", 84, 93], ["T cell", "CELL", 4, 10], ["cells", "CELL", 60, 65], ["infected cells", "CELL_TYPE", 51, 65], ["kill infected cells", "PROBLEM", 46, 65], ["the infection", "PROBLEM", 80, 93], ["infection", "OBSERVATION", 84, 93]]], ["Following antigen processing in dendritic cells, the small peptides are displayed at the cell surface at the groove of major histocompatibility complex (MHC) class I and class II molecules.", [["dendritic cells", "ANATOMY", 32, 47], ["cell surface", "ANATOMY", 89, 101], ["dendritic cells", "CELL", 32, 47], ["cell surface", "CELLULAR_COMPONENT", 89, 101], ["dendritic cells", "CELL_TYPE", 32, 47], ["major histocompatibility complex (MHC) class I and class II molecules", "PROTEIN", 119, 188], ["the small peptides", "PROBLEM", 49, 67], ["dendritic cells", "OBSERVATION", 32, 47], ["small", "OBSERVATION_MODIFIER", 53, 58], ["groove", "ANATOMY_MODIFIER", 109, 115], ["major", "OBSERVATION_MODIFIER", 119, 124], ["histocompatibility", "OBSERVATION", 125, 143]]], ["Cytotoxic T cells (CD8 +) recognize MHC class I-peptide complexes and differentiate into cytotoxic effector cells capable of killing infected cells or pathogens.", [["Cytotoxic T cells", "ANATOMY", 0, 17], ["cells", "ANATOMY", 108, 113], ["cells", "ANATOMY", 142, 147], ["Cytotoxic T cells", "CELL", 0, 17], ["CD8", "GENE_OR_GENE_PRODUCT", 19, 22], ["cytotoxic effector cells", "CELL", 89, 113], ["cells", "CELL", 142, 147], ["Cytotoxic T cells", "CELL_TYPE", 0, 17], ["CD8", "PROTEIN", 19, 22], ["MHC class I-peptide complexes", "PROTEIN", 36, 65], ["cytotoxic effector cells", "CELL_TYPE", 89, 113], ["infected cells", "CELL_TYPE", 133, 147], ["Cytotoxic T cells", "TEST", 0, 17], ["CD8", "TEST", 19, 22], ["cytotoxic effector cells", "PROBLEM", 89, 113], ["killing infected cells", "PROBLEM", 125, 147], ["pathogens", "PROBLEM", 151, 160], ["cytotoxic effector cells", "OBSERVATION", 89, 113], ["killing", "OBSERVATION_MODIFIER", 125, 132], ["infected cells", "OBSERVATION", 133, 147]]], ["Helper T cells (CD4 +) recognize MHC class IIpeptide complexes and differentiate in effector cells that produce preferentially T helper Th1 or Th2 cytokines (Fig 1) .", [["Helper T cells", "ANATOMY", 0, 14], ["effector cells", "ANATOMY", 84, 98], ["Helper T cells", "CELL", 0, 14], ["CD4", "GENE_OR_GENE_PRODUCT", 16, 19], ["effector cells", "CELL", 84, 98], ["T helper Th1", "CELL", 127, 139], ["Th2", "GENE_OR_GENE_PRODUCT", 143, 146], ["Helper T cells", "CELL_TYPE", 0, 14], ["CD4", "PROTEIN", 16, 19], ["MHC class IIpeptide complexes", "PROTEIN", 33, 62], ["effector cells", "CELL_TYPE", 84, 98], ["T helper Th1 or Th2 cytokines", "PROTEIN", 127, 156], ["effector cells", "OBSERVATION", 84, 98]]], ["T helper cells 1 (Th1) support CD8 + T-cell differentiation, which is in contrast inhibited by T helper cells 2 (Th2) like cytokines.", [["T helper cells", "ANATOMY", 0, 14], ["CD8 + T-cell", "ANATOMY", 31, 43], ["T helper cells", "ANATOMY", 95, 109], ["T helper cells 1", "GENE_OR_GENE_PRODUCT", 0, 16], ["Th1", "GENE_OR_GENE_PRODUCT", 18, 21], ["CD8", "GENE_OR_GENE_PRODUCT", 31, 34], ["T helper cells 2", "CELL", 95, 111], ["Th2", "GENE_OR_GENE_PRODUCT", 113, 116], ["T helper cells 1", "CELL_TYPE", 0, 16], ["Th1", "CELL_TYPE", 18, 21], ["CD8", "PROTEIN", 31, 34], ["T helper cells 2", "CELL_TYPE", 95, 111], ["Th2", "CELL_TYPE", 113, 116], ["cytokines", "PROTEIN", 123, 132], ["T helper cells", "TEST", 0, 14], ["CD8", "TEST", 31, 34], ["cytokines", "PROBLEM", 123, 132]]], ["Vaccines against chronic pathogens namely Mycobacterium tuberculosis, malaria, HCV, HIV, etc more often require cell-mediated immune responses to control the infection (33) .Vaccine Immunology.Vaccine-Preventable Diseases.", [["cell", "ANATOMY", 112, 116], ["Mycobacterium tuberculosis", "DISEASE", 42, 68], ["malaria", "DISEASE", 70, 77], ["HCV, HIV", "DISEASE", 79, 87], ["infection", "DISEASE", 158, 167], ["Mycobacterium tuberculosis", "ORGANISM", 42, 68], ["HCV", "ORGANISM", 79, 82], ["HIV", "ORGANISM", 84, 87], ["cell", "CELL", 112, 116], ["Mycobacterium tuberculosis", "SPECIES", 42, 68], ["HIV", "SPECIES", 84, 87], ["Mycobacterium tuberculosis", "SPECIES", 42, 68], ["HCV", "SPECIES", 79, 82], ["HIV", "SPECIES", 84, 87], ["Vaccines", "TREATMENT", 0, 8], ["chronic pathogens", "PROBLEM", 17, 34], ["Mycobacterium tuberculosis", "PROBLEM", 42, 68], ["malaria", "PROBLEM", 70, 77], ["HCV", "PROBLEM", 79, 82], ["HIV", "PROBLEM", 84, 87], ["cell-mediated immune responses", "TREATMENT", 112, 142], ["the infection", "PROBLEM", 154, 167], ["Vaccine", "TREATMENT", 193, 200], ["Preventable Diseases", "PROBLEM", 201, 221], ["Mycobacterium tuberculosis", "OBSERVATION", 42, 68], ["infection", "OBSERVATION", 158, 167]]], ["The success of a vaccine against a pathogen is a complex issue and depends upon the biology of the virus and the type of immune response elicited by the body against the organism.", [["body", "ANATOMY", 153, 157], ["body", "ORGANISM_SUBDIVISION", 153, 157], ["a vaccine", "TREATMENT", 15, 24], ["a pathogen", "PROBLEM", 33, 43], ["the virus", "PROBLEM", 95, 104], ["immune response", "PROBLEM", 121, 136]]], ["While vaccines have been successful against several pathogens including 14 major infectious diseases (27, 28) , not all infectious diseases are vaccine-preventable (34, 35) .", [["infectious diseases", "DISEASE", 81, 100], ["infectious diseases", "DISEASE", 120, 139], ["vaccines", "TREATMENT", 6, 14], ["several pathogens", "PROBLEM", 44, 61], ["all infectious diseases", "PROBLEM", 116, 139], ["infectious", "OBSERVATION", 120, 130]]], ["The development of vaccines against HIV and HCV have proved challenging.", [["HIV and HCV", "DISEASE", 36, 47], ["HIV", "ORGANISM", 36, 39], ["HCV", "ORGANISM", 44, 47], ["HIV", "SPECIES", 36, 39], ["HIV", "SPECIES", 36, 39], ["HCV", "SPECIES", 44, 47], ["vaccines", "TREATMENT", 19, 27], ["HIV", "PROBLEM", 36, 39], ["HCV", "PROBLEM", 44, 47]]], ["These viruses have an extreme genetic heterogeneity including the hypervariable regions (target for neutralizing antibodies) and the mutation contribute to immune escape (36) .", [["hypervariable regions", "DNA", 66, 87], ["neutralizing antibodies", "PROTEIN", 100, 123], ["These viruses", "PROBLEM", 0, 13], ["an extreme genetic heterogeneity", "PROBLEM", 19, 51], ["the hypervariable regions", "PROBLEM", 62, 87], ["neutralizing antibodies", "TEST", 100, 123], ["the mutation", "PROBLEM", 129, 141], ["immune escape", "PROBLEM", 156, 169], ["viruses", "OBSERVATION", 6, 13], ["extreme", "OBSERVATION_MODIFIER", 22, 29], ["genetic", "OBSERVATION_MODIFIER", 30, 37], ["heterogeneity", "OBSERVATION", 38, 51], ["hypervariable", "OBSERVATION_MODIFIER", 66, 79], ["immune escape", "OBSERVATION", 156, 169]]], ["The mutations lead to a mixture of genomes in the patient over time and from patient to patient.", [["patient", "ORGANISM", 50, 57], ["patient", "ORGANISM", 77, 84], ["patient", "ORGANISM", 88, 95], ["patient", "SPECIES", 50, 57], ["patient", "SPECIES", 77, 84], ["patient", "SPECIES", 88, 95], ["The mutations", "PROBLEM", 0, 13]]], ["Also, antibodies mounted against such viral infections are predominantly non-neutralizing.", [["viral infections", "DISEASE", 38, 54], ["antibodies", "PROTEIN", 6, 16], ["antibodies", "TREATMENT", 6, 16], ["such viral infections", "PROBLEM", 33, 54], ["infections", "OBSERVATION", 44, 54], ["predominantly", "OBSERVATION_MODIFIER", 59, 72], ["non-neutralizing", "OBSERVATION_MODIFIER", 73, 89]]], ["Neutralizing antibodies are often either absent or weak to fight the pathogen or neutralize only a narrow range of circulating viral strains and only appear in a subgroup of patients who either recover or are 'elite controller' (37) .", [["patients", "ORGANISM", 174, 182], ["Neutralizing antibodies", "PROTEIN", 0, 23], ["patients", "SPECIES", 174, 182], ["Neutralizing antibodies", "TEST", 0, 23], ["weak", "PROBLEM", 51, 55], ["the pathogen", "PROBLEM", 65, 77], ["circulating viral strains", "PROBLEM", 115, 140], ["narrow range", "OBSERVATION_MODIFIER", 99, 111], ["viral strains", "OBSERVATION", 127, 140]]], ["Another aspect to be considered is whether the virus can be grown in cell culture and transmitted to small animals for experimentation.", [["cell culture", "ANATOMY", 69, 81], ["cell culture", "CELL", 69, 81], ["the virus", "PROBLEM", 43, 52], ["cell culture", "TEST", 69, 81], ["virus", "OBSERVATION", 47, 52]]], ["Since HCV has been discovered by molecular cloning in 1989, its propagation in cell culture has been difficult which hampers the ability of investigators to experiment with various antigenic components of the virus (38) .COVID-19 Vaccine immunology.To develop a safe and effective vaccine against COVID-19, we need to consider several things about the SARS-CoV-2 and the immune response against the natural infection and the vaccine.COVID-19 Vaccine immunology.Mutations.", [["cell culture", "ANATOMY", 79, 91], ["SARS", "DISEASE", 352, 356], ["infection", "DISEASE", 407, 416], ["HCV", "ORGANISM", 6, 9], ["cell culture", "CELL", 79, 91], ["COVID-19", "CELL", 297, 305], ["SARS-CoV-2", "ORGANISM", 352, 362], ["HCV", "SPECIES", 6, 9], ["HCV", "PROBLEM", 6, 9], ["cell culture", "TEST", 79, 91], ["the virus", "PROBLEM", 205, 214], ["a safe and effective vaccine", "TREATMENT", 260, 288], ["the SARS", "TEST", 348, 356], ["CoV", "TEST", 357, 360], ["the natural infection", "PROBLEM", 395, 416], ["the vaccine", "TREATMENT", 421, 432], ["infection", "OBSERVATION", 407, 416]]], ["Does SARS-CoV-2 mutate, how fast and will mutations cause a phenomenon of immune escape as is seen in HIV and HCV (34, 35) .", [["HIV and HCV", "DISEASE", 102, 113], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 5, 15], ["HIV", "SPECIES", 102, 105], ["HIV", "SPECIES", 102, 105], ["HCV", "SPECIES", 110, 113], ["immune escape", "PROBLEM", 74, 87], ["HIV and HCV", "PROBLEM", 102, 113], ["immune escape", "OBSERVATION", 74, 87]]], ["SARS-CoV-2 has shown mutations as is true to every RNA virus.", [["SARS", "DISEASE", 0, 4], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 0, 10], ["mutations", "PROBLEM", 21, 30], ["every RNA virus", "PROBLEM", 45, 60]]], ["However, the mutations are slow, mild and mutants show nearly similar sequences as in the parent strain.", [["the mutations", "PROBLEM", 9, 22], ["slow, mild and mutants", "PROBLEM", 27, 49], ["mild", "OBSERVATION_MODIFIER", 33, 37]]], ["Dorp et al (39) studied genomic diversity of SARS-CoV-2 and recorded 198 filtered recurrent mutations, however, most of the mutations were either neutral or even deleterious and of no clinical significance in vaccine immunity.", [["SARS-CoV-2", "ORGANISM", 45, 55], ["SARS-CoV", "SPECIES", 45, 53], ["SARS", "PROBLEM", 45, 49], ["CoV", "TEST", 50, 53], ["recurrent mutations", "PROBLEM", 82, 101], ["the mutations", "PROBLEM", 120, 133]]], ["Ahmad et al (40) found no mutations in 120 available SARS-CoV-2 sequences and identified a set of B cell and T cell epitopes derived from the spike (S) and nucleoprotein(N) proteins that map identically to SARS-CoV-2 proteins.", [["B cell", "ANATOMY", 98, 104], ["T cell", "ANATOMY", 109, 115], ["SARS", "DISEASE", 53, 57], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 53, 63], ["B cell", "CELL", 98, 104], ["T cell", "CELL", 109, 115], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 206, 216], ["SARS-CoV-2 sequences", "DNA", 53, 73], ["B cell and T cell epitopes", "PROTEIN", 98, 124], ["spike (S) and nucleoprotein(N) proteins", "PROTEIN", 142, 181], ["SARS-CoV-2 proteins", "PROTEIN", 206, 225], ["mutations", "PROBLEM", 26, 35], ["SARS-CoV-2 sequences", "TEST", 53, 73], ["B cell", "PROBLEM", 98, 104], ["T cell epitopes", "PROBLEM", 109, 124], ["the spike", "TEST", 138, 147], ["nucleoprotein(N) proteins", "TREATMENT", 156, 181], ["map", "TEST", 187, 190], ["SARS", "TEST", 206, 210], ["CoV", "TEST", 211, 214], ["no", "UNCERTAINTY", 23, 25]]], ["These findings provide a screened set of epitopes that can help guide experimental efforts towards the development of vaccines against SARS-CoV-2.COVID-19 Immune Response.What type of immune response occurs in natural COVID-19 and after vaccination and are antibodies neutralizing in nature?", [["SARS-CoV-2", "ORGANISM", 135, 145], ["COVID-19", "CELL", 218, 226], ["epitopes", "PROTEIN", 41, 49], ["antibodies", "PROTEIN", 257, 267], ["SARS-CoV-2", "SPECIES", 135, 145], ["epitopes", "TREATMENT", 41, 49], ["vaccines", "TREATMENT", 118, 126], ["SARS-CoV", "TEST", 135, 143], ["COVID", "TEST", 146, 151], ["immune response", "PROBLEM", 184, 199], ["natural COVID", "TEST", 210, 223], ["vaccination", "TREATMENT", 237, 248], ["antibodies neutralizing", "PROBLEM", 257, 280], ["19 Immune", "OBSERVATION_MODIFIER", 152, 161], ["immune response", "OBSERVATION", 184, 199]]], ["SARS-CoV-2 infection evokes a robust adaptive immune response of both T cell and B cell type arms (41, 42) .", [["T cell", "ANATOMY", 70, 76], ["B cell type arms", "ANATOMY", 81, 97], ["SARS", "DISEASE", 0, 4], ["infection", "DISEASE", 11, 20], ["SARS-CoV-2", "ORGANISM", 0, 10], ["T cell", "CELL", 70, 76], ["B cell type", "CELL", 81, 92], ["SARS", "PROBLEM", 0, 4], ["2 infection", "PROBLEM", 9, 20], ["both T cell", "OBSERVATION", 65, 76], ["B cell type", "OBSERVATION", 81, 92]]], ["Furthermore, both IgM and IgG antibodies appear around the 10 th day of infection and most patients seroconvert within 3 weeks.", [["infection", "DISEASE", 72, 81], ["IgM", "GENE_OR_GENE_PRODUCT", 18, 21], ["IgG antibodies", "GENE_OR_GENE_PRODUCT", 26, 40], ["patients", "ORGANISM", 91, 99], ["IgM", "PROTEIN", 18, 21], ["IgG antibodies", "PROTEIN", 26, 40], ["patients", "SPECIES", 91, 99], ["both IgM", "TEST", 13, 21], ["IgG antibodies", "TEST", 26, 40], ["infection", "PROBLEM", 72, 81], ["infection", "OBSERVATION", 72, 81]]], ["The antibodies are raised against internal nucleoprotein (N) and spike protein (S) of the virion and have neutralizing activity (43) .", [["spike protein (S)", "GENE_OR_GENE_PRODUCT", 65, 82], ["antibodies", "PROTEIN", 4, 14], ["internal nucleoprotein", "PROTEIN", 34, 56], ["N", "PROTEIN", 58, 59], ["spike protein", "PROTEIN", 65, 78], ["S", "PROTEIN", 80, 81], ["The antibodies", "TEST", 0, 14], ["internal nucleoprotein", "PROBLEM", 34, 56], ["spike protein", "TEST", 65, 78], ["the virion", "TREATMENT", 86, 96], ["neutralizing activity", "OBSERVATION", 106, 127]]], ["Now that several candidate vaccines are in the clinical trial, investigators shall study the strength and nature of immune response against the vaccine antigen (mostly spike protein).COVID-19 Re-infections.Are people who recover from COVID-19 infection protected from a second or a third infection?", [["infection", "DISEASE", 243, 252], ["infection", "DISEASE", 288, 297], ["people", "ORGANISM", 210, 216], ["COVID-19", "ORGANISM", 234, 242], ["vaccine antigen", "PROTEIN", 144, 159], ["spike protein", "PROTEIN", 168, 181], ["people", "SPECIES", 210, 216], ["several candidate vaccines", "TREATMENT", 9, 35], ["shall study", "TEST", 77, 88], ["immune response", "PROBLEM", 116, 131], ["the vaccine antigen", "TEST", 140, 159], ["COVID", "TEST", 183, 188], ["COVID", "TEST", 234, 239], ["infection", "PROBLEM", 243, 252], ["a third infection", "PROBLEM", 280, 297], ["infection", "OBSERVATION", 243, 252], ["infection", "OBSERVATION", 288, 297]]], ["Should reinfections occur it would imply that immune response against SARS-CoV-2 is not protective, making possibilities of a successful vaccine difficult.", [["SARS", "DISEASE", 70, 74], ["SARS-CoV-2", "ORGANISM", 70, 80], ["SARS-CoV", "SPECIES", 70, 78], ["SARS", "PROBLEM", 70, 74], ["a successful vaccine", "TREATMENT", 124, 144]]], ["There were scary reports from South Korea about patients thought to have recovered from COVID-19 had tested positive again (44) .", [["patients", "ORGANISM", 48, 56], ["patients", "SPECIES", 48, 56], ["COVID", "TEST", 88, 93]]], ["An intense debate started about re-activation or re-infections of the virus.", [["the virus", "PROBLEM", 66, 75]]], ["Soon these reports were put to rest and the positive sample were found to be residual dead fragments of the virus, not the virus, which had reactivated or re-infected (45) .", [["fragments", "ANATOMY", 91, 100], ["the positive sample", "PROBLEM", 40, 59], ["residual dead fragments", "PROBLEM", 77, 100], ["the virus", "PROBLEM", 104, 113], ["the virus", "PROBLEM", 119, 128], ["residual", "OBSERVATION_MODIFIER", 77, 85], ["dead fragments", "OBSERVATION", 86, 100]]], ["After these reports, two groups of investigators have shown that SARS-CoV-2 antibodies are protective.", [["SARS", "DISEASE", 65, 69], ["SARS-CoV-2 antibodies", "GENE_OR_GENE_PRODUCT", 65, 86], ["SARS-CoV-2 antibodies", "PROTEIN", 65, 86], ["SARS", "TEST", 65, 69], ["CoV", "TEST", 70, 73]]], ["Bao et al showed that 2 monkeys who recovered from SARS-CoV-2 infection were protected from re-infection on the challenge during convalescence (46).", [["SARS-CoV-2 infection", "DISEASE", 51, 71], ["monkeys", "ORGANISM", 24, 31], ["SARS-CoV-2", "ORGANISM", 51, 61], ["CoV-", "SPECIES", 56, 60], ["SARS-CoV", "SPECIES", 51, 59], ["SARS", "PROBLEM", 51, 55], ["CoV", "PROBLEM", 56, 59], ["2 infection", "PROBLEM", 60, 71], ["re-infection", "PROBLEM", 92, 104], ["infection", "OBSERVATION", 62, 71]]], ["Gao et al administered candidate vaccine PiCoVacc Sinovac Biotech to mice, rats, and non-human primates.", [["mice", "ORGANISM", 69, 73], ["rats", "ORGANISM", 75, 79], ["non-human", "ORGANISM", 85, 94], ["primates", "ORGANISM", 95, 103], ["mice", "SPECIES", 69, 73], ["rats", "SPECIES", 75, 79], ["non-human", "SPECIES", 85, 94], ["mice", "SPECIES", 69, 73], ["Gao et al administered candidate vaccine", "TREATMENT", 0, 40]]], ["The antibodies raised against the vaccine in animals showed neutralizing ability against SARS-CoV-2 strains.", [["animals", "ORGANISM", 45, 52], ["SARS-CoV-2 strains", "ORGANISM", 89, 107], ["antibodies", "PROTEIN", 4, 14], ["SARS-CoV-2", "SPECIES", 89, 99], ["The antibodies", "TEST", 0, 14], ["the vaccine", "TREATMENT", 30, 41], ["neutralizing ability", "PROBLEM", 60, 80], ["SARS", "PROBLEM", 89, 93], ["CoV", "TEST", 94, 97], ["2 strains", "PROBLEM", 98, 107]]], ["Three immunizations of two doses (3\u00b5g or 6\u00b5g per dose) gave partial or complete protection in macaques against SARS-CoV-2 (47).", [["macaques", "ORGANISM", 94, 102], ["SARS-CoV-2", "ORGANISM", 111, 121], ["macaques", "SPECIES", 94, 102], ["SARS-CoV-2", "SPECIES", 111, 121], ["Three immunizations", "TREATMENT", 0, 19], ["CoV", "TEST", 116, 119]]], ["These data are exciting and if reproducible in humans confirm that vaccines against COVID-19 shall be protective.Duration of immunity.For the COVID-19 vaccination program to succeed, the antibody response mounted against the virus/vaccine must be long-lasting.", [["humans", "ORGANISM", 47, 53], ["humans", "SPECIES", 47, 53], ["humans", "SPECIES", 47, 53], ["vaccines", "TREATMENT", 67, 75], ["COVID", "TEST", 84, 89], ["the COVID-19 vaccination program", "TREATMENT", 138, 170], ["the antibody response", "TEST", 183, 204], ["the virus/vaccine", "TREATMENT", 221, 238]]], ["As of today, it is not possible to address this question as the virus has been in the community only for the last few months.", [["the virus", "PROBLEM", 60, 69]]], ["However, we can take leads from data generated about the duration of immunity against 2 other coronaviruses namely SARS-CoV and MERS-CoV (14, 17) .", [["coronaviruses", "ORGANISM", 94, 107], ["SARS-CoV", "ORGANISM", 115, 123], ["MERS-CoV", "ORGANISM", 128, 136], ["SARS-CoV", "SPECIES", 115, 123], ["MERS-CoV", "SPECIES", 128, 136]]], ["Both these viruses, which are closely related to SARS-CoV-2 induce a robust T cell and B cell immune response which is long-lasting.", [["T cell", "ANATOMY", 76, 82], ["B cell", "ANATOMY", 87, 93], ["SARS", "DISEASE", 49, 53], ["SARS-CoV-2", "ORGANISM", 49, 59], ["T cell", "CELL", 76, 82], ["B cell", "CELL", 87, 93], ["SARS-CoV", "SPECIES", 49, 57], ["Both these viruses", "PROBLEM", 0, 18], ["SARS", "PROBLEM", 49, 53], ["CoV", "TEST", 54, 57], ["a robust T cell", "PROBLEM", 67, 82], ["B cell immune response", "PROBLEM", 87, 109], ["viruses", "OBSERVATION", 11, 18], ["cell immune response", "OBSERVATION", 89, 109]]], ["Many candidate vaccines against both these viruses had gone through successful clinical trials and are safe and immunogenic (48) .Antibody-Dependent Enhancement (ADE).The greatest fear among vaccine developers is to create a vaccine that does not protect from infection but causes disease exacerbation, increased morbidity, and mortality (48) (49) (50) (51) .", [["infection", "DISEASE", 260, 269], ["Many candidate vaccines", "TREATMENT", 0, 23], ["these viruses", "PROBLEM", 37, 50], ["Antibody", "TEST", 130, 138], ["a vaccine", "TREATMENT", 223, 232], ["infection", "PROBLEM", 260, 269], ["disease exacerbation", "PROBLEM", 281, 301], ["increased morbidity", "PROBLEM", 303, 322], ["mortality", "TEST", 328, 337], ["viruses", "OBSERVATION", 43, 50], ["Dependent Enhancement", "OBSERVATION_MODIFIER", 139, 160], ["greatest", "OBSERVATION_MODIFIER", 171, 179], ["infection", "OBSERVATION", 260, 269], ["increased", "OBSERVATION_MODIFIER", 303, 312], ["morbidity", "OBSERVATION_MODIFIER", 313, 322]]], ["Some vaccines can mount Antibody-Dependent Enhancement (ADE), which negates the basic purpose of vaccination (52).", [["Some vaccines", "TREATMENT", 0, 13], ["Antibody", "TEST", 24, 32], ["Dependent Enhancement", "PROBLEM", 33, 54], ["Dependent Enhancement", "OBSERVATION_MODIFIER", 33, 54]]], ["This response is mediated by the type of non-neutralizing antibodies mounted against infection or vaccination.", [["infection", "DISEASE", 85, 94], ["non-neutralizing antibodies", "PROTEIN", 41, 68], ["non-neutralizing antibodies", "TREATMENT", 41, 68], ["infection", "PROBLEM", 85, 94], ["vaccination", "PROBLEM", 98, 109]]], ["The immune response to such vaccines is subverted, leading to exacerbated illness.", [["such vaccines", "TREATMENT", 23, 36], ["exacerbated illness", "PROBLEM", 62, 81], ["exacerbated", "OBSERVATION_MODIFIER", 62, 73], ["illness", "OBSERVATION", 74, 81]]], ["This could be due to Fc receptor-or complement bearing cells-mediated mechanisms.", [["cells", "ANATOMY", 55, 60], ["Fc receptor", "GENE_OR_GENE_PRODUCT", 21, 32], ["cells", "CELL", 55, 60], ["Fc receptor", "PROTEIN", 21, 32], ["Fc receptor", "TEST", 21, 32], ["complement bearing cells", "PROBLEM", 36, 60], ["could be due to", "UNCERTAINTY", 5, 20]]], ["The Fc-region of the antibody binds to FC\u03b3R on the immune cells, which subverts the immune response by reducing T H 1 cytokines (IL2, TNF-a, and IFN-g) and skews T H 2 cytokines (IL-10, IL-6, PGE-2, and INF-a) and inhibits STAT pathway leading to increased viral replication (Fig 2) .", [["immune cells", "ANATOMY", 51, 63], ["R", "GENE_OR_GENE_PRODUCT", 42, 43], ["immune cells", "CELL", 51, 63], ["T H 1", "GENE_OR_GENE_PRODUCT", 112, 117], ["IL2", "GENE_OR_GENE_PRODUCT", 129, 132], ["TNF-a", "GENE_OR_GENE_PRODUCT", 134, 139], ["IFN-g", "GENE_OR_GENE_PRODUCT", 145, 150], ["T H 2", "GENE_OR_GENE_PRODUCT", 162, 167], ["IL-10", "GENE_OR_GENE_PRODUCT", 179, 184], ["IL-6", "GENE_OR_GENE_PRODUCT", 186, 190], ["PGE-2", "GENE_OR_GENE_PRODUCT", 192, 197], ["INF-a", "GENE_OR_GENE_PRODUCT", 203, 208], ["STAT", "GENE_OR_GENE_PRODUCT", 223, 227], ["FC", "PROTEIN", 39, 41], ["immune cells", "CELL_TYPE", 51, 63], ["T H 1 cytokines", "PROTEIN", 112, 127], ["IL2", "PROTEIN", 129, 132], ["TNF", "PROTEIN", 134, 137], ["IFN", "PROTEIN", 145, 148], ["cytokines", "PROTEIN", 168, 177], ["PGE", "PROTEIN", 192, 195], ["INF", "PROTEIN", 203, 206], ["STAT", "PROTEIN", 223, 227], ["cytokines", "TEST", 118, 127], ["IL2", "TEST", 129, 132], ["TNF", "TEST", 134, 137], ["IFN", "TEST", 145, 148], ["skews T H", "TEST", 156, 165], ["cytokines", "TEST", 168, 177], ["IL", "TEST", 179, 181], ["IL", "TEST", 186, 188], ["PGE", "TEST", 192, 195], ["inhibits STAT pathway", "PROBLEM", 214, 235], ["increased viral replication", "PROBLEM", 247, 274], ["immune cells", "OBSERVATION", 51, 63], ["increased", "OBSERVATION_MODIFIER", 247, 256], ["viral replication", "OBSERVATION", 257, 274]]], ["ADE is of clinical significance in several viral infections including influenza, RSV, SARS-CoV, MERS-CoV, Dengue virus, Zika virus, and West Nile virus.", [["ADE", "DISEASE", 0, 3], ["viral infections", "DISEASE", 43, 59], ["influenza", "DISEASE", 70, 79], ["SARS", "DISEASE", 86, 90], ["Dengue virus", "DISEASE", 106, 118], ["RSV", "ORGANISM", 81, 84], ["SARS-CoV", "ORGANISM", 86, 94], ["MERS-CoV", "ORGANISM", 96, 104], ["Dengue virus", "ORGANISM", 106, 118], ["Zika virus", "ORGANISM", 120, 130], ["West Nile virus", "ORGANISM", 136, 151], ["MERS-CoV", "SPECIES", 96, 104], ["Dengue virus", "SPECIES", 106, 118], ["Zika virus", "SPECIES", 120, 130], ["West Nile virus", "SPECIES", 136, 151], ["RSV", "SPECIES", 81, 84], ["SARS-CoV", "SPECIES", 86, 94], ["MERS-CoV", "SPECIES", 96, 104], ["Dengue virus", "SPECIES", 106, 118], ["Zika virus", "SPECIES", 120, 130], ["West Nile virus", "SPECIES", 136, 151], ["several viral infections", "PROBLEM", 35, 59], ["influenza", "PROBLEM", 70, 79], ["RSV", "PROBLEM", 81, 84], ["SARS", "PROBLEM", 86, 90], ["CoV", "PROBLEM", 91, 94], ["MERS", "PROBLEM", 96, 100], ["CoV", "PROBLEM", 101, 104], ["Dengue virus", "PROBLEM", 106, 118], ["Zika virus", "PROBLEM", 120, 130], ["West Nile virus", "PROBLEM", 136, 151], ["viral", "OBSERVATION_MODIFIER", 43, 48], ["infections", "OBSERVATION", 49, 59]]], ["Considering ADE is a major impediment to vaccine development, efforts to identify highly selected epitopes have been done to avoid the production of antibodies responsible for disease enhancement.Antibody-Dependent Enhancement (ADE).ADE has been reported in animals during vaccination trials with SARS-CoV and MERS-CoV (14, 17, 35) .", [["ADE", "DISEASE", 12, 15], ["ADE", "DISEASE", 233, 236], ["SARS-CoV", "ORGANISM", 297, 305], ["MERS-CoV", "ORGANISM", 310, 318], ["epitopes", "PROTEIN", 98, 106], ["antibodies", "PROTEIN", 149, 159], ["SARS-CoV", "SPECIES", 297, 305], ["MERS-CoV", "SPECIES", 310, 318], ["the production of antibodies", "PROBLEM", 131, 159], ["disease enhancement", "PROBLEM", 176, 195], ["Antibody", "TEST", 196, 204], ["vaccination trials", "TREATMENT", 273, 291], ["SARS", "PROBLEM", 297, 301], ["Dependent Enhancement", "OBSERVATION_MODIFIER", 205, 226]]], ["Vaccine candidates against coronaviruses based on full-length Spike protein induce non-neutralizing antibodies, lack of protection of animals against a viral challenge, and severe disease enhancement presenting as enhanced hepatitis, increased morbidity, and stronger inflammatory response (17) .", [["hepatitis", "DISEASE", 223, 232], ["coronaviruses", "ORGANISM", 27, 40], ["Spike", "GENE_OR_GENE_PRODUCT", 62, 67], ["full-length Spike protein", "PROTEIN", 50, 75], ["non-neutralizing antibodies", "PROTEIN", 83, 110], ["Vaccine candidates", "TREATMENT", 0, 18], ["coronaviruses", "PROBLEM", 27, 40], ["non-neutralizing antibodies", "PROBLEM", 83, 110], ["a viral challenge", "PROBLEM", 150, 167], ["severe disease enhancement", "PROBLEM", 173, 199], ["enhanced hepatitis", "PROBLEM", 214, 232], ["increased morbidity", "PROBLEM", 234, 253], ["stronger inflammatory response", "PROBLEM", 259, 289], ["severe", "OBSERVATION_MODIFIER", 173, 179], ["disease", "OBSERVATION", 180, 187], ["enhanced", "OBSERVATION_MODIFIER", 214, 222], ["hepatitis", "OBSERVATION", 223, 232], ["increased", "OBSERVATION_MODIFIER", 234, 243], ["morbidity", "OBSERVATION", 244, 253], ["stronger", "OBSERVATION_MODIFIER", 259, 267], ["inflammatory", "OBSERVATION_MODIFIER", 268, 280]]], ["As of today, there are no reports of ADE with the use of COVID-19 candidate vaccines in non-human primates and humans (51) .", [["ADE", "DISEASE", 37, 40], ["COVID-19", "CHEMICAL", 57, 65], ["non-human primates", "ORGANISM", 88, 106], ["humans", "ORGANISM", 111, 117], ["humans", "SPECIES", 111, 117], ["humans", "SPECIES", 111, 117], ["COVID-19 candidate vaccines", "TREATMENT", 57, 84]]], ["However, it is an early period in the development of these vaccines and as the matter is of major importance in the success of such a vaccine, we need to be vigilant.", [["these vaccines", "TREATMENT", 53, 67], ["a vaccine", "TREATMENT", 132, 141], ["early", "OBSERVATION_MODIFIER", 18, 23], ["period", "OBSERVATION_MODIFIER", 24, 30]]], ["ADE following COVID-19 vaccination if reported can be prevented by shielding non-neutralizing epitopes of S protein by glycosylation or selecting critical neutralizing epitopes of the S antigen to elicit a more robust protective immunity.Developing a Covid-19 Vaccine.Stages of Vaccine Development.", [["ADE", "DISEASE", 0, 3], ["COVID-19", "CHEMICAL", 14, 22], ["S protein", "GENE_OR_GENE_PRODUCT", 106, 115], ["S antigen", "GENE_OR_GENE_PRODUCT", 184, 193], ["non-neutralizing epitopes", "PROTEIN", 77, 102], ["S protein", "PROTEIN", 106, 115], ["neutralizing epitopes", "PROTEIN", 155, 176], ["S antigen", "PROTEIN", 184, 193], ["COVID-19 vaccination", "TREATMENT", 14, 34], ["non-neutralizing epitopes of S protein", "TREATMENT", 77, 115], ["glycosylation", "TREATMENT", 119, 132], ["a Covid-19 Vaccine", "TREATMENT", 249, 267]]], ["Every new Vaccine follows a stringent protocol in R&D which has to be meticulously followed and completed before it is licensed to be marketed (Fig 3) .", [["a stringent protocol", "TREATMENT", 26, 46]]], ["It has also to be considered that vaccine development is a high cost and high-risk involvement (59) .", [["vaccine development", "PROBLEM", 34, 53], ["a high cost", "PROBLEM", 57, 68]]], ["Apart from competition between other major vaccine manufacturers, the cost of developing a single new vaccine against an infectious disease exceeds US 1 Billion.", [["infectious disease", "DISEASE", 121, 139], ["other major vaccine manufacturers", "TREATMENT", 31, 64], ["a single new vaccine", "TREATMENT", 89, 109], ["an infectious disease", "PROBLEM", 118, 139], ["infectious", "OBSERVATION", 121, 131]]], ["This figure includes vaccines that are abandoned during the development process. \u03b4=The overall success rate for vaccine development is around 15%.", [["vaccines", "TREATMENT", 21, 29], ["vaccine development", "TREATMENT", 112, 131]]]], "PMC7194999": [["Experience in China and the rest of AsiaWithin the space of a few months, COVID-19 has escalated from a little known respiratory infectious disease concentrated in a hotspot in China to a devastating pandemic threatening the heath and disrupting the daily life of everyone around the world.", [["COVID-19", "CHEMICAL", 74, 82], ["respiratory infectious disease", "DISEASE", 117, 147], ["COVID", "TEST", 74, 79], ["a little known respiratory infectious disease", "PROBLEM", 102, 147], ["respiratory", "ANATOMY", 117, 128], ["infectious", "OBSERVATION", 129, 139], ["devastating", "OBSERVATION_MODIFIER", 188, 199], ["pandemic", "OBSERVATION", 200, 208]]], ["The Severe Acute Respiratory Syndrome (SARS) arrived out of the blue in 2003 as a highly lethal epidemic, devastating several communities.", [["Acute Respiratory Syndrome", "DISEASE", 11, 37], ["SARS", "DISEASE", 39, 43], ["The Severe Acute Respiratory Syndrome", "PROBLEM", 0, 37], ["SARS", "PROBLEM", 39, 43], ["Severe", "OBSERVATION_MODIFIER", 4, 10], ["Acute", "OBSERVATION_MODIFIER", 11, 16], ["Respiratory Syndrome", "OBSERVATION", 17, 37]]], ["Pediatric surgery might have been a footnote during SARS, but was hardly a bystander: in Hong Kong, a pediatric surgeon-scientist characterized genetic susceptibility to SARS in a high-impact study [2].", [["SARS", "DISEASE", 52, 56], ["SARS", "DISEASE", 170, 174], ["Pediatric surgery", "TREATMENT", 0, 17], ["SARS", "PROBLEM", 170, 174]]], ["In contrast, sadly, a pediatric surgeon (Dr. James TK Lau) contracted SARS during work and died.", [["SARS", "DISEASE", 70, 74]]], ["While SARS did not develop into a pandemic, lessons learned stayed with the affected populations.", [["SARS", "DISEASE", 6, 10], ["the affected populations", "PROBLEM", 72, 96]]], ["As the first cluster of patients from Wuhan was being reported to the WHO on December 31st pediatric surgeons (including several editorial board members in their professional capacities) were gathering in Wuhan on January 3rd for a symposium on Hirschsprung Disease and a conference on robotic surgery, oblivious to what would lie ahead.", [["Hirschsprung Disease", "DISEASE", 245, 265], ["patients", "ORGANISM", 24, 32], ["patients", "SPECIES", 24, 32], ["Hirschsprung Disease", "PROBLEM", 245, 265], ["robotic surgery", "TREATMENT", 286, 301]]], ["Those of us scarred by the bitter experience of SARS17 years earlier were nervous and took extra precautions.", [["nervous", "ANATOMY", 74, 81], ["nervous", "ANATOMICAL_SYSTEM", 74, 81], ["extra precautions", "TREATMENT", 91, 108], ["scarred", "OBSERVATION", 12, 19]]], ["But the public alarm of the serious health threat did not start until the identification of the novel coronavirus as the cause of the disease on January 7th, and the observation of the exponential increase in the number of cases in Wuhan and neighboring regions, soon spreading to other parts of China, Asia (Thailand reported the first case on January 13th) and the rest of the world (the U.S. reported the first case on January 20th).", [["coronavirus", "DISEASE", 102, 113], ["coronavirus", "ORGANISM", 102, 113], ["the novel coronavirus", "PROBLEM", 92, 113], ["the disease", "PROBLEM", 130, 141], ["exponential", "OBSERVATION_MODIFIER", 185, 196], ["increase", "OBSERVATION_MODIFIER", 197, 205]]], ["During the first month, while few cases were encountered outside of the country, the disease threatened to spiral out of control within China.", [["the disease", "PROBLEM", 81, 92], ["disease", "OBSERVATION", 85, 92]]], ["Drastic measures were implemented, starting with Wuhan being locked down on January 23th, followed by the entire Hubei Province and other parts of China.", [["Drastic measures", "TREATMENT", 0, 16]]], ["Unlike SARS, which shattered several parts of Asia but disappeared after three months, the new COVID-19 proved to be much more contagious, with the number of confirmed cases skyrocketing worldwide.", [["SARS", "DISEASE", 7, 11], ["skyrocketing", "DISEASE", 174, 186], ["Unlike SARS", "PROBLEM", 0, 11], ["the new COVID", "TEST", 87, 100], ["SARS", "OBSERVATION", 7, 11]]], ["While the extreme quarantine measures in China seem to have brought the spread of disease under control at this time (early April), other countries are facing the full forces of this \u201cinfectious hurricane\u201d.Experience in China and the rest of AsiaThe experiences in China, Hong Kong, Japan and other parts of Asia suggest that children are less frequently and less severely affected by COVID-19 than adults, and surgical patients constitute a small proportion of COVID-19 pediatric patients.", [["children", "ORGANISM", 326, 334], ["adults", "ORGANISM", 399, 405], ["patients", "ORGANISM", 420, 428], ["patients", "ORGANISM", 481, 489], ["children", "SPECIES", 326, 334], ["patients", "SPECIES", 420, 428], ["patients", "SPECIES", 481, 489], ["disease", "PROBLEM", 82, 89], ["extreme", "OBSERVATION_MODIFIER", 10, 17], ["quarantine", "OBSERVATION", 18, 28], ["disease", "OBSERVATION", 82, 89]]], ["However, they are not exempt from the infection.", [["infection", "DISEASE", 38, 47], ["the infection", "PROBLEM", 34, 47], ["infection", "OBSERVATION", 38, 47]]], ["A series of 6 children with COVID-19 from Wuhan was first reported in early January, although no surgical patients were involved [3].", [["children", "ORGANISM", 14, 22], ["patients", "ORGANISM", 106, 114], ["children", "SPECIES", 14, 22], ["patients", "SPECIES", 106, 114], ["COVID", "TEST", 28, 33]]], ["The first pediatric surgical mortality was recorded in February (a 10-month old child with intussusception who died from multiorgan failure after a 4-week hospitalization) [4].", [["multiorgan", "ANATOMY", 121, 131], ["intussusception", "DISEASE", 91, 106], ["multiorgan failure", "DISEASE", 121, 139], ["multiorgan", "ORGAN", 121, 131], ["intussusception", "PROBLEM", 91, 106], ["multiorgan failure", "PROBLEM", 121, 139], ["multiorgan failure", "OBSERVATION", 121, 139]]], ["On a somber note that mirrored events during SARS in Hong Kong, the Philippines mourned the loss of a senior surgeon (Dr. Leandro L. Resureccion III) in the battle against COVID-19.", [["SARS", "DISEASE", 45, 49], ["COVID-19", "DNA", 172, 180], ["mirrored events", "PROBLEM", 22, 37], ["COVID", "TEST", 172, 177]]], ["These anecdotes illustrate that in the ongoing war against COVID-19, while pediatric surgery remains a small player in the \u201cbig picture\u201d, we cannot afford to ignore any pediatric surgery-specific issues.", [["COVID", "TEST", 59, 64], ["pediatric surgery", "TREATMENT", 75, 92], ["any pediatric surgery", "TREATMENT", 165, 186]]], ["Good science, sound clinical judgment, and data were primarily responsible for the successful fight against SARS in Asia.", [["SARS", "DISEASE", 108, 112], ["sound clinical judgment", "TEST", 14, 37], ["SARS", "PROBLEM", 108, 112]]], ["In the war against COVID-19, basic, translational and clinical research is likely to play a key role again.Experience in China and the rest of AsiaWe know from the SARS experiences, and now from the COVID-19 pandemic, that the most effective preventive measures revolve around population-wide testing for the virus, contact tracing, quarantine/isolation, social distancing, travel restrictions, hand hygiene, and mask-wearing (an already widely accepted behavior in SARS-affected communities).", [["hand", "ANATOMY", 395, 399], ["SARS", "DISEASE", 164, 168], ["SARS", "DISEASE", 466, 470], ["hand", "ORGANISM_SUBDIVISION", 395, 399], ["COVID", "TEST", 19, 24], ["wide testing", "TEST", 288, 300], ["the virus", "PROBLEM", 305, 314], ["contact tracing", "TEST", 316, 331], ["quarantine/isolation", "TREATMENT", 333, 353], ["hand hygiene", "TREATMENT", 395, 407], ["mask", "TREATMENT", 413, 417]]], ["Disease treatment is mostly supportive at this time, but efforts are being made towards the identification of drugs that could hasten recovery and reduce mortality (e.g. hydrochloroquine).", [["hydrochloroquine", "CHEMICAL", 170, 186], ["hydrochloroquine", "CHEMICAL", 170, 186], ["hydrochloroquine", "SIMPLE_CHEMICAL", 170, 186], ["Disease treatment", "TREATMENT", 0, 17], ["drugs", "TREATMENT", 110, 115], ["hydrochloroquine", "TREATMENT", 170, 186]]], ["Mass vaccination is widely acknowledged to be the ultimate solution, but while early human trials have started, it is likely that it will be many months before a safe and effective vaccine will be ready.", [["human", "ORGANISM", 85, 90], ["human", "SPECIES", 85, 90], ["human", "SPECIES", 85, 90], ["Mass vaccination", "PROBLEM", 0, 16], ["a safe and effective vaccine", "TREATMENT", 160, 188]]], ["In Hong Kong, a weekly/biweekly interactive staff forum (with teleconferencing access) was conducted by the hospital leadership and relevant experts as the crisis escalated.", [["the crisis", "PROBLEM", 152, 162]]], ["Protecting health care workers is a top priority as any health care system will collapse if a large number of practitioners become patients.Experience in the European Union and the UKFrance reported three confirmed cases on January 24th, the first occurrences within the European Union with connection to China.", [["patients", "ORGANISM", 131, 139], ["patients", "SPECIES", 131, 139], ["collapse", "OBSERVATION", 80, 88], ["large", "OBSERVATION_MODIFIER", 94, 99]]], ["Isolated cases, typically in tourists or repatriated nationals, swiftly followed throughout the rest of February, but towards the end of March, a full-blown outbreak had been confirmed in and around Milan in Lombardy, Northern Italy [7].", [["cases", "OBSERVATION", 9, 14]]], ["Cases and deaths increased across the continent exponentially with major outbreaks being found in Spain and France.Experience in the European Union and the UKInterestingly, the effects of the disease appear to be varied across Europe with some countries' health systems being overwhelmed with high numbers of deaths (e.g. Italy and Spain) and others where the overall numbers have appeared high but deaths proportionately small (e.g. Germany) [8].", [["deaths", "DISEASE", 10, 16], ["deaths", "DISEASE", 309, 315], ["deaths", "DISEASE", 399, 405], ["the disease", "PROBLEM", 188, 199], ["disease", "OBSERVATION", 192, 199]]], ["This can be numerated by considering the CFR for COVID-19 which, based on the early Chinese data, has been calculated to be around 4%.", [["the CFR", "TEST", 37, 44], ["COVID", "TEST", 49, 54]]], ["On that basis, Germany is at this time much lower at about 2% compared to around 10\u201312% for Italy and Spain, both of whom top the current European mortality statistics [9] (Table 1).Experience in the European Union and the UKSince person-to-person spread appears to be largely by aerosolized droplet transmission and surface contact from sufferers during their symptom peak, surgeons and anesthesiologists are at particular risk given their intimate contact with patients on the ward and in the operating room.", [["surface", "ANATOMY", 317, 324], ["patients", "ORGANISM", 463, 471], ["person", "SPECIES", 231, 237], ["person", "SPECIES", 241, 247], ["patients", "SPECIES", 463, 471]]], ["FFP-2 (Filtering Face-Piece) (the equivalent to the N95) masks made of a conforming synthetic polymer weave have been approved by WHO though FFP-3 masks (typically with an expiration valve) appear more protective and are the standard in the UK.Experience in Finland and the other Nordic countriesThe numbers of symptomatic COVID-19 patients and virus-related deaths in the Nordic countries are still much less when compared to most parts of the world and Europe.", [["deaths", "DISEASE", 359, 365], ["UK", "GENE_OR_GENE_PRODUCT", 241, 243], ["patients", "ORGANISM", 332, 340], ["patients", "SPECIES", 332, 340], ["FFP", "TREATMENT", 0, 3], ["Filtering Face-Piece", "TREATMENT", 7, 27], ["the N95) masks", "TREATMENT", 48, 62], ["a conforming synthetic polymer weave", "TREATMENT", 71, 107], ["FFP-3 masks", "TREATMENT", 141, 152], ["an expiration valve", "TREATMENT", 169, 188], ["symptomatic COVID", "TEST", 311, 328], ["virus", "PROBLEM", 345, 350], ["more protective", "OBSERVATION_MODIFIER", 197, 212], ["symptomatic", "OBSERVATION_MODIFIER", 311, 322]]], ["This might simply reflect the natural timespan for geographical spreading of the virus, and most likely, the situation will level at least to some degree in the near future.", [["the virus", "PROBLEM", 77, 86], ["most likely", "UNCERTAINTY", 92, 103]]], ["At this time, none of the infected children in Finland has required hospitalization, and no child has died in the Nordic countries.", [["children", "ORGANISM", 35, 43], ["children", "SPECIES", 35, 43], ["infected", "OBSERVATION", 26, 34]]], ["However, the national approach to the pandemic threat has been very different in individual Nordic countries, which may also affect how much and for how long the pandemic will disturb pediatric surgery.", [["pediatric surgery", "TREATMENT", 184, 201], ["very", "OBSERVATION_MODIFIER", 63, 67], ["different", "OBSERVATION_MODIFIER", 68, 77]]], ["For example, Sweden has adopted a relatively liberal approach without really restricting free-time activities or movement of people.", [["people", "ORGANISM", 125, 131], ["people", "SPECIES", 125, 131], ["a relatively liberal approach", "TREATMENT", 32, 61]]], ["Finland, by contrast, issued prompt actions very early in the course of the epidemic to try to constrain and slow down COVID-19 spread, with the hope of thus increasing the number of intensive care beds.", [["slow down COVID", "PROBLEM", 109, 124], ["intensive care beds", "TREATMENT", 183, 202]]], ["These restrictions have included temporary lock-down of the Helsinki-Uusimaa region with 1.7 million inhabitants (representing 30% of the population and with the largest children's hospital and national pediatric surgery referral center in the country), cessation of schools and universities, closure of restaurants, and prohibition of all public events.Experience in Finland and the other Nordic countriesMost pediatric surgical patients thus far are suffering mostly from \u201ccollateral damage\u201d since the national health care system is being primed to manage the increasing number of severely affected adult patients.", [["collateral damage", "DISEASE", 475, 492], ["patients", "ORGANISM", 430, 438], ["patients", "ORGANISM", 607, 615], ["children", "SPECIES", 170, 178], ["patients", "SPECIES", 430, 438], ["patients", "SPECIES", 607, 615], ["temporary lock", "TREATMENT", 33, 47], ["closure of restaurants", "TREATMENT", 293, 315], ["collateral damage", "PROBLEM", 475, 492], ["collateral damage", "OBSERVATION", 475, 492]]], ["Already, a number of anesthesiologists and nurses in the Helsinki Children's Hospital have been relocated to adult intensive care units or have training for providing critical adult care, reducing pediatric surgical resources.", [["critical adult care", "TREATMENT", 167, 186], ["pediatric surgical resources", "TREATMENT", 197, 225]]], ["Elective and day surgical procedures have been reduced, although emergent and most semiemergent operations, including most organ transplantation, are performed according to usual practice.Experience in Finland and the other Nordic countriesAlthough movement of pediatric patients is not officially restricted from other parts of Finland to Helsinki, many parents, also local ones, are postponing their child's operation for fear of infection, contributing to the significantly decreased activity in pediatric surgery.", [["organ", "ANATOMY", 123, 128], ["infection", "DISEASE", 432, 441], ["organ", "ORGAN", 123, 128], ["patients", "ORGANISM", 271, 279], ["patients", "SPECIES", 271, 279], ["Elective and day surgical procedures", "TREATMENT", 0, 36], ["most semiemergent operations", "TREATMENT", 78, 106], ["most organ transplantation", "TREATMENT", 118, 144], ["'s operation", "TREATMENT", 407, 419], ["infection", "PROBLEM", 432, 441], ["pediatric surgery", "TREATMENT", 499, 516], ["infection", "OBSERVATION", 432, 441], ["decreased", "OBSERVATION_MODIFIER", 477, 486], ["activity", "OBSERVATION_MODIFIER", 487, 495]]], ["In some patients, this unplanned delay may have a significant negative effect on surgical outcomes, but the consequences of the infection are potentially much more significant for the parents than their child.", [["infection", "DISEASE", 128, 137], ["patients", "ORGANISM", 8, 16], ["patients", "SPECIES", 8, 16], ["surgical outcomes", "TREATMENT", 81, 98], ["the infection", "PROBLEM", 124, 137], ["significant", "OBSERVATION_MODIFIER", 50, 61], ["negative", "OBSERVATION", 62, 70], ["infection", "OBSERVATION", 128, 137]]], ["Most strikingly, the number of emergency department visits has crashed, and the true consequences remain yet to be seen, as some of these patients have underlying conditions requiring urgent intervention.", [["patients", "ORGANISM", 138, 146], ["patients", "SPECIES", 138, 146], ["underlying conditions", "PROBLEM", 152, 173], ["urgent intervention", "TREATMENT", 184, 203]]], ["Limited supply of ECMO equipment owing to the widespread infection situation in the concentrated production areas of the Europe, the Nordic countries, and the world has obligated prioritization of care to those patients with the greatest need.Experience in Latin AmericaSouth American countries witnessed the early development and rapid expansion of the disease from a distance.", [["infection", "DISEASE", 57, 66], ["patients", "ORGANISM", 211, 219], ["patients", "SPECIES", 211, 219], ["ECMO equipment", "TREATMENT", 18, 32], ["the widespread infection situation", "PROBLEM", 42, 76], ["the disease", "PROBLEM", 350, 361], ["ECMO", "OBSERVATION", 18, 22], ["widespread", "OBSERVATION_MODIFIER", 46, 56], ["infection", "OBSERVATION", 57, 66], ["concentrated", "OBSERVATION_MODIFIER", 84, 96], ["production", "OBSERVATION_MODIFIER", 97, 107], ["areas", "OBSERVATION_MODIFIER", 108, 113], ["rapid", "OBSERVATION_MODIFIER", 331, 336], ["expansion", "OBSERVATION_MODIFIER", 337, 346], ["disease", "OBSERVATION", 354, 361]]], ["Some countries, such as Argentina, Bolivia, Uruguay and Chile, were aggressive in implementing measures to limit the influx of COVID-19 early in the pandemic.", [["COVID-19", "CHEMICAL", 127, 135], ["COVID", "TEST", 127, 132]]], ["The generalized closing of national borders, harbors and airports; the mandatory commercial lock-down; and the social distance rules have resulted in a remarkably low number of deaths in these countries.", [["deaths", "DISEASE", 177, 183], ["generalized", "OBSERVATION_MODIFIER", 4, 15], ["closing", "OBSERVATION", 16, 23]]], ["As of April 14th, the total death count is slightly above 215 in these countries.", [["death", "DISEASE", 28, 33], ["the total death count", "TEST", 18, 39]]], ["Fortunately, and mirroring what has occurred in other regions of the world, the number of pediatric cases has been minimal so far.", [["minimal", "OBSERVATION_MODIFIER", 115, 122]]], ["For instance, at the National Pediatric Hospital in Buenos Aires (the largest pediatric hospital in Argentina), there have been no COVID-19 cases yet.", [["COVID", "TEST", 131, 136], ["no", "UNCERTAINTY", 128, 130]]], ["However, the entire region is bracing for the upcoming weeks, since the peak is expected to occur 3\u20134 weeks after the peak in Europe and 2\u20133 weeks after the peak in North America.Experience in Latin AmericaIn the Central America region, the approach to the pandemic has been quite variable.", [["entire", "OBSERVATION_MODIFIER", 13, 19], ["bracing", "OBSERVATION", 30, 37], ["Central", "ANATOMY_MODIFIER", 213, 220], ["America", "ANATOMY_MODIFIER", 221, 228], ["variable", "OBSERVATION_MODIFIER", 281, 289]]], ["COVID-19 cases have been increasing exponentially, and the number of deaths has tripled in the last week (about 90 on April 6th to about 270 on April 11th).", [["deaths", "DISEASE", 69, 75], ["COVID", "TEST", 0, 5], ["increasing", "OBSERVATION_MODIFIER", 25, 35], ["exponentially", "OBSERVATION_MODIFIER", 36, 49]]], ["The health system is vastly overwhelmed in some regions, and some cities (e.g. Tijuana) have started closing its hospital's doors.", [["vastly", "OBSERVATION_MODIFIER", 21, 27], ["overwhelmed", "OBSERVATION", 28, 39]]], ["While the exact demographics of the COVID-19 patients are not known, there have been at least 3 COVID-19 cases in children younger than 1 year.", [["patients", "ORGANISM", 45, 53], ["children", "ORGANISM", 114, 122], ["patients", "SPECIES", 45, 53], ["children", "SPECIES", 114, 122]]], ["In Colombia, on the other hand, the lock-down started in early March.", [["the lock", "TREATMENT", 32, 40], ["Colombia", "OBSERVATION", 3, 11]]], ["As of today, the number of fatalities has been relatively low (about 100), but there have been at least 9 children who have tested positive, one of which required hospital admission.Experience in North AmericaThe incidence of pediatric COVID-19 cases requiring hospitalization in the U.S. has been low this far, but the peak is approaching.", [["fatalities", "DISEASE", 27, 37], ["COVID", "DISEASE", 236, 241], ["children", "ORGANISM", 106, 114], ["children", "SPECIES", 106, 114], ["pediatric COVID", "TREATMENT", 226, 241], ["relatively", "OBSERVATION_MODIFIER", 47, 57], ["low", "OBSERVATION_MODIFIER", 58, 61], ["low", "OBSERVATION", 298, 301]]], ["Children's hospitals across the U.S. are preparing twofold: on one side, to receive the potential surge of cases in the upcoming weeks, and on the other side, to provide the best possible protection to their workforce.", [["Children", "ORGANISM", 0, 8], ["Children", "SPECIES", 0, 8]]], ["Most children's hospitals across the U.S. have postponed all elective operations at this time.", [["children", "ORGANISM", 5, 13], ["children", "SPECIES", 5, 13], ["all elective operations", "TREATMENT", 57, 80]]], ["The only operations allowed are those that can speed up the hospital discharge of patients already admitted, and obviously all emergencies.", [["patients", "ORGANISM", 82, 90], ["patients", "SPECIES", 82, 90]]], ["Most U.S. children's hospitals now require all patients to be tested for COVID-19 prior to going to the operating room.", [["children", "ORGANISM", 10, 18], ["patients", "ORGANISM", 47, 55], ["children", "SPECIES", 10, 18], ["patients", "SPECIES", 47, 55], ["COVID", "TEST", 73, 78]]], ["Rapid RT-PCR tests with a turnaround time of less than 2 h from nasopharyngeal swabs have already been developed, but are not available everywhere, and still have an unknown false negative rate.", [["nasopharyngeal swabs", "ANATOMY", 64, 84], ["nasopharyngeal swabs", "CANCER", 64, 84], ["Rapid RT-PCR tests", "TEST", 0, 18], ["nasopharyngeal swabs", "TEST", 64, 84], ["nasopharyngeal", "ANATOMY", 64, 78], ["negative rate", "OBSERVATION", 180, 193]]], ["In the event of a life-threatening or limb/organ-threatening situation, patients are assumed COVID-19 positive and, at many hospitals, are treated in a dedicated negative-pressure operating room, with appropriate PPE.", [["limb", "ANATOMY", 38, 42], ["organ", "ANATOMY", 43, 48], ["limb", "ORGANISM_SUBDIVISION", 38, 42], ["organ", "ORGAN", 43, 48], ["patients", "ORGANISM", 72, 80], ["patients", "SPECIES", 72, 80], ["limb/organ-threatening situation", "PROBLEM", 38, 70], ["COVID", "TEST", 93, 98], ["limb", "ANATOMY", 38, 42], ["organ", "ANATOMY", 43, 48]]], ["All Level-I and Level-II trauma resuscitations are treated as COVID-19 positive or at least as \u201cperson under investigation\u201d (PUI), with only essential personnel inside the trauma bay.", [["trauma", "DISEASE", 25, 31], ["trauma", "DISEASE", 172, 178], ["person", "SPECIES", 96, 102], ["All Level", "TEST", 0, 9], ["Level-II trauma resuscitations", "TREATMENT", 16, 46], ["COVID", "TEST", 62, 67]]], ["For all operations, nonessential team members must remain outside of the operating room at the time of anesthesia induction and airway intubation.", [["airway", "ANATOMY", 128, 134], ["airway", "MULTI-TISSUE_STRUCTURE", 128, 134], ["anesthesia induction", "TREATMENT", 103, 123], ["airway intubation", "TREATMENT", 128, 145], ["airway", "ANATOMY", 128, 134], ["intubation", "OBSERVATION", 135, 145]]], ["Many pediatric surgery groups across the U.S. have divided and the teams are staggered in order to have a team on service and a team on back up, or even just a weekend-like crew on-site every day.", [["Many pediatric surgery", "TREATMENT", 0, 22]]], ["One reason for separating the surgical group into different teams is to make sure the entire team of surgeons does not contract the disease at the same time.", [["the disease", "PROBLEM", 128, 139], ["disease", "OBSERVATION", 132, 139]]], ["Some pediatric surgery groups have excluded from clinical duties surgeons older than 60 years of age or those who are vulnerable in any other way.", [["Some pediatric surgery", "TREATMENT", 0, 22]]], ["Several pediatric surgery groups are seeing their rotating residents being pulled back to their own general surgery programs, and even though the overall surgical volumes have dropped remarkably, this move decreases the number of bodies available for on-service/off-service schedules.", [["Several pediatric surgery groups", "TREATMENT", 0, 32], ["general surgery programs", "TREATMENT", 100, 124], ["surgical", "OBSERVATION", 154, 162]]], ["In some hospitals, residents and fellows are kept off all clinical duties related to COVID-19 positive patients, leaving that role for the attending surgeons.", [["patients", "ORGANISM", 103, 111], ["patients", "SPECIES", 103, 111]]], ["Several children's hospitals have even modified their scope of practice to adapt to the crisis.", [["children", "ORGANISM", 8, 16], ["children", "SPECIES", 8, 16]]], ["Some have opened units for the care of adult patients (COVID-19 positive or negative), and most have extended the age of the patients that can be admitted to pediatric units to 25 years.", [["patients", "ORGANISM", 45, 53], ["patients", "ORGANISM", 125, 133], ["patients", "SPECIES", 45, 53], ["patients", "SPECIES", 125, 133], ["COVID", "TEST", 55, 60]]], ["Lastly, some pediatric surgeons around the country are taking shifts in adult COVID-19 intensive care units, or in adult trauma services.Experience in North AmericaPediatric surgical care practices have been modified in some hospitals, but not in all.", [["trauma", "DISEASE", 121, 127]]], ["In the case of acute appendicitis, some institutions have adopted nonoperative treatment when appropriate, whereas other places continue to operate on all cases.", [["appendicitis", "DISEASE", 21, 33], ["acute appendicitis", "PROBLEM", 15, 33], ["nonoperative treatment", "TREATMENT", 66, 88], ["acute", "OBSERVATION_MODIFIER", 15, 20], ["appendicitis", "OBSERVATION", 21, 33]]], ["The reason for the latter is that most patients with simple appendicitis can be discharged home from the postanesthesia care unit shortly after the operation, whereas patients treated nonoperatively require at least 24 h in the hospital for intravenous antibiotics, which represents a longer time for patients and their family members being potentially exposed to COVID-19, and an unnecessary use of hospital beds and personnel.", [["intravenous", "ANATOMY", 241, 252], ["appendicitis", "DISEASE", 60, 72], ["patients", "ORGANISM", 39, 47], ["patients", "ORGANISM", 167, 175], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 241, 252], ["patients", "ORGANISM", 301, 309], ["patients", "SPECIES", 39, 47], ["patients", "SPECIES", 167, 175], ["patients", "SPECIES", 301, 309], ["simple appendicitis", "PROBLEM", 53, 72], ["the operation", "TREATMENT", 144, 157], ["intravenous antibiotics", "TREATMENT", 241, 264], ["appendicitis", "OBSERVATION", 60, 72]]], ["There is no right or wrong management choice, and each institution is adopting the strategy believed to be the most appropriate according to their manpower, hospital resources, and limitations.", [["right or wrong management choice", "PROBLEM", 12, 44], ["no", "UNCERTAINTY", 9, 11], ["right", "ANATOMY_MODIFIER", 12, 17]]], ["In the particular case of ECMO cannulations, some institutions have determined that patients with baseline diseases who develop COVID-19-related ARDS will not be candidates for ECMO/ECPR.", [["ARDS", "DISEASE", 145, 149], ["COVID-19", "CHEMICAL", 128, 136], ["patients", "ORGANISM", 84, 92], ["patients", "SPECIES", 84, 92], ["ECMO cannulations", "TREATMENT", 26, 43], ["baseline diseases", "PROBLEM", 98, 115], ["COVID", "TEST", 128, 133], ["ARDS", "PROBLEM", 145, 149], ["ECMO", "TREATMENT", 177, 181], ["ECPR", "TREATMENT", 182, 186], ["ECMO", "OBSERVATION", 26, 30]]], ["However, since the need for ECMO in COVID-19 positive children/teenagers has been minimal so far (not zero), the eligibility is being evaluated on a case-by-case basis.", [["COVID-19", "GENE_OR_GENE_PRODUCT", 36, 44], ["children", "ORGANISM", 54, 62], ["children", "SPECIES", 54, 62], ["ECMO", "TREATMENT", 28, 32], ["COVID", "TEST", 36, 41]]], ["As regards the use of laparoscopy and thoracoscopy, there is growing concern worldwide related to the potential aerosolization of viral particles through the pressurized CO2.", [["CO2", "CHEMICAL", 170, 173], ["CO2", "CHEMICAL", 170, 173], ["CO2", "SIMPLE_CHEMICAL", 170, 173], ["laparoscopy", "TEST", 22, 33], ["thoracoscopy", "TREATMENT", 38, 50], ["viral particles", "PROBLEM", 130, 145], ["the pressurized CO2", "TREATMENT", 154, 173], ["laparoscopy", "OBSERVATION", 22, 33], ["thoracoscopy", "OBSERVATION", 38, 50], ["aerosolization", "OBSERVATION", 112, 126], ["viral particles", "OBSERVATION", 130, 145], ["pressurized", "OBSERVATION_MODIFIER", 158, 169], ["CO2", "OBSERVATION_MODIFIER", 170, 173]]], ["Evidence is lacking, but many institutions are turning towards open procedures (for example for pyloromyotomies) and are implementing the use of filters for insufflation/desufflation, and the use of smoke evacuators throughout the entire operation.", [["open procedures", "TREATMENT", 63, 78], ["pyloromyotomies", "TREATMENT", 96, 111], ["filters", "TREATMENT", 145, 152], ["insufflation", "TREATMENT", 157, 169], ["desufflation", "TREATMENT", 170, 182], ["smoke evacuators", "TREATMENT", 199, 215], ["the entire operation", "TREATMENT", 227, 247]]], ["These devices, however, are not available everywhere.Experience in North AmericaAt the time of this writing, almost every major children's hospital across the U.S. has had COVID-19 patients.", [["children", "ORGANISM", 128, 136], ["patients", "ORGANISM", 181, 189], ["children", "SPECIES", 128, 136], ["patients", "SPECIES", 181, 189], ["These devices", "TREATMENT", 0, 13]]], ["However, the minority have presented to the hospital with respiratory symptoms, only a few required a transfer to the intensive care unit, and only one (to our knowledge) has required ECMO.", [["respiratory", "ANATOMY", 58, 69], ["respiratory symptoms", "DISEASE", 58, 78], ["respiratory symptoms", "PROBLEM", 58, 78], ["ECMO", "TREATMENT", 184, 188]]], ["Most of the COVID-19 pediatric surgical patients have actually presented to the hospital with a variety of surgical needs, and then were found to be COVID-19 positive on the preoperative screening or testing of patients who have had close contacts with confirmed cases.", [["patients", "ORGANISM", 40, 48], ["patients", "ORGANISM", 211, 219], ["patients", "SPECIES", 40, 48], ["patients", "SPECIES", 211, 219], ["COVID", "TEST", 149, 154], ["the preoperative screening", "TEST", 170, 196], ["testing", "TEST", 200, 207]]], ["Lastly, as of April 14, there have been 2 neonatal deaths, and at least one more newborn requiring admission, all infected through vertical transmission.Experience in North AmericaPediatric surgeons and children's hospitals in the U.S. are adapting to this pandemic in ways never seen before.", [["deaths", "DISEASE", 51, 57], ["children", "ORGANISM", 203, 211], ["children", "SPECIES", 203, 211], ["2 neonatal deaths", "PROBLEM", 40, 57], ["infected", "OBSERVATION", 114, 122]]], ["Each institution, as well as each national surgical society, is setting guidelines for optimal patient care and for the protection of healthcare workers.", [["patient", "ORGANISM", 95, 102], ["patient", "SPECIES", 95, 102], ["optimal patient care", "TREATMENT", 87, 107]]], ["As the crisis approaches its predicted peak in the U.S. in the upcoming days/weeks, pediatric surgeons must remain in close (virtual) contact with each other and take advantage of the experiences of our colleagues around the world.Effects on pediatric surgery traineesThere are no areas of healthcare that have not been impacted by the COVID-19 pandemic, and the education of our pediatric surgery trainees is no exception.", [["the crisis", "PROBLEM", 3, 13], ["pediatric surgery trainees", "TREATMENT", 242, 268], ["our pediatric surgery", "TREATMENT", 376, 397], ["no", "UNCERTAINTY", 278, 280], ["areas", "OBSERVATION_MODIFIER", 281, 286], ["no exception", "UNCERTAINTY", 410, 422]]], ["Since the beginning of the crisis, training programs (at least in the U.S.) have been forced to adjust the workflow of their trainees in order to minimize exposure to COVID-19, not just for the sake of their health (a blunt truth), but to have a backup person if one falls ill.", [["falls ill", "DISEASE", 267, 276], ["person", "SPECIES", 253, 259], ["training programs", "TREATMENT", 35, 52], ["their trainees", "TREATMENT", 119, 133], ["COVID", "TREATMENT", 167, 172]]], ["In some programs the pediatric surgery fellows are being pulled into the medical care of adult patients, as is also happening to many general surgery residents across the U.S. who are being pulled to work as medical interns, or even to fill nursing roles.", [["patients", "ORGANISM", 95, 103], ["patients", "SPECIES", 95, 103]]], ["Most elective pediatric surgery cases, appropriately, were canceled for a minimum of 6 weeks starting in mid-March.", [["Most elective pediatric surgery", "TREATMENT", 0, 31]]], ["This time frame will likely be extended, since the peak of COVID-19 cases in the U.S is anticipated to occur in mid- to late April.", [["COVID", "TEST", 59, 64]]], ["Morning and afternoon patient rounds are limited to the essential personnel, with didactic discussions reduced to near zero.", [["patient", "ORGANISM", 22, 29], ["patient", "SPECIES", 22, 29]]], ["Surgical units have been shut down to reduce traffic of personnel, which brought the number of inpatients with typical pediatric surgical conditions to almost zero (except for patients treated for emergencies).", [["patients", "ORGANISM", 176, 184], ["patients", "SPECIES", 176, 184], ["Surgical units", "TREATMENT", 0, 14], ["typical pediatric surgical conditions", "TREATMENT", 111, 148]]], ["Pediatric surgery fellowships in the U.S. are only two years long, and within those two years the trainees take several weeks off for vacation, holidays, surgical meetings, and job interviews.", [["Pediatric surgery", "TREATMENT", 0, 17]]], ["With all the changes described above, it is easy to see that if the COVID-19 crisis extends even a mere two to three months, it will cause a significant negative impact to the overall surgical experience of our trainees.", [["the COVID-19 crisis", "PROBLEM", 64, 83]]], ["When the psychological toll that this pandemic is putting on our trainees is added to the natural fear for the well-being of their loved ones with whom they live (as all healthcare workers who are exposed daily to COVID-19 do), suddenly \u201ctraining\u201d does not feel as a priority anymore.Effects on pediatric surgery traineesThere are strict requirements established by the regulatory bodies (e.g. American Board of Surgery) that trainees must fulfill in order to graduate.", [["pediatric surgery trainees", "TREATMENT", 295, 321], ["Surgery", "TREATMENT", 412, 419], ["strict requirements", "OBSERVATION_MODIFIER", 331, 350]]], ["One of them is the number of operations that surgical trainees need to perform before the end of their training.", [["surgical trainees", "TREATMENT", 45, 62], ["their training", "TREATMENT", 97, 111]]], ["These required numbers have already been lowered (as have the required number of weeks of clinical time) because it is very likely that trainees in many programs won't be able to fulfill them.", [["very likely", "UNCERTAINTY", 119, 130]]], ["The real challenge will be for all pediatric surgery training programs to find effective ways to fill the educational gap that this unpredicted crisis is causing.", [["all pediatric surgery training programs", "TREATMENT", 31, 70], ["this unpredicted crisis", "PROBLEM", 127, 150]]], ["This may come in the form of extended training times, relaxed working hour restrictions, reduced administrative obligations, individualized mentorships, and collaborations between training programs, among others.", [["reduced administrative obligations", "TREATMENT", 89, 123], ["training programs", "TREATMENT", 180, 197]]], ["We, as a community of pediatric surgical educators, owe our pediatric surgery trainees every bit of the training that we promised them.ConclusionsPediatric surgery around the world has been profoundly impacted by the COVID-19 pandemic.", [["the training", "TREATMENT", 100, 112], ["ConclusionsPediatric surgery", "TREATMENT", 135, 163], ["the COVID", "TEST", 213, 222], ["pandemic", "PROBLEM", 226, 234]]], ["From the ways in which we practice, to the ways in which we teach and learn, to what we can and cannot do for our patients, every aspect of our profession has been changed on an unprecedented scale.", [["patients", "ORGANISM", 114, 122], ["patients", "SPECIES", 114, 122], ["an unprecedented scale", "TREATMENT", 175, 197]]], ["These are challenging times, for us and for our patients.", [["patients", "ORGANISM", 48, 56], ["patients", "SPECIES", 48, 56]]], ["The Journal of Pediatric Surgery is committed to provide a valuable platform to disseminate relevant new knowledge, and to contribute meaningfully to the health and well-being of all children and their families around the world.", [["children", "ORGANISM", 183, 191], ["children", "SPECIES", 183, 191], ["Pediatric Surgery", "TREATMENT", 15, 32]]]], "bca9a53758cc15d59cbae278f6a1f38bd64518fd": [["Introduction 1Parkinson's disease (PD) is a common progressive neurodegenerative disorder characterized 2 clinically by motor symptoms attributed to a loss of dopaminergic neurons in the substantia nigra 3 (SN).", [["dopaminergic neurons", "ANATOMY", 159, 179], ["substantia nigra", "ANATOMY", 187, 203], ["1Parkinson's disease", "DISEASE", 13, 33], ["PD", "DISEASE", 35, 37], ["neurodegenerative disorder", "DISEASE", 63, 89], ["loss of dopaminergic neurons", "DISEASE", 151, 179], ["dopaminergic neurons", "CELL", 159, 179], ["substantia nigra 3", "GENE_OR_GENE_PRODUCT", 187, 205], ["SN", "MULTI-TISSUE_STRUCTURE", 207, 209], ["dopaminergic neurons", "CELL_TYPE", 159, 179], ["1Parkinson's disease", "PROBLEM", 13, 33], ["a common progressive neurodegenerative disorder", "PROBLEM", 42, 89], ["motor symptoms", "PROBLEM", 120, 134], ["a loss of dopaminergic neurons", "PROBLEM", 149, 179], ["progressive", "OBSERVATION_MODIFIER", 51, 62], ["neurodegenerative", "OBSERVATION", 63, 80], ["substantia nigra", "ANATOMY", 187, 203]]], ["At post-mortem examination neurons in various brain regions of PD patients present with 4 cytosolic inclusions named Lewy bodies that contain amyloid-like fibrils of the presynaptic 5 protein \u03b1-synuclein (aSyn) (1) .", [["neurons", "ANATOMY", 27, 34], ["brain", "ANATOMY", 46, 51], ["cytosolic", "ANATOMY", 90, 99], ["PD", "DISEASE", 63, 65], ["neurons", "CELL", 27, 34], ["brain", "ORGAN", 46, 51], ["patients", "ORGANISM", 66, 74], ["Lewy bodies", "CELLULAR_COMPONENT", 117, 128], ["amyloid-like fibrils", "GENE_OR_GENE_PRODUCT", 142, 162], ["\u03b1-synuclein", "GENE_OR_GENE_PRODUCT", 192, 203], ["aSyn) (1)", "GENE_OR_GENE_PRODUCT", 205, 214], ["amyloid-like fibrils", "PROTEIN", 142, 162], ["presynaptic 5 protein \u03b1-synuclein", "PROTEIN", 170, 203], ["aSyn", "PROTEIN", 205, 209], ["patients", "SPECIES", 66, 74], ["post-mortem examination", "TEST", 3, 26], ["4 cytosolic inclusions named Lewy bodies", "PROBLEM", 88, 128], ["amyloid", "TEST", 142, 149], ["brain", "ANATOMY", 46, 51], ["Lewy bodies", "OBSERVATION", 117, 128], ["amyloid", "OBSERVATION", 142, 149]]], ["A number of patients with familial forms of PD have been found 6 to harbor mutations in the SNCA gene, including point mutations encoding the substitutions 7 A30P, E46K, H50Q, G51D, A53E, and A53T and gene multiplications (2).", [["PD", "DISEASE", 44, 46], ["patients", "ORGANISM", 12, 20], ["SNCA", "GENE_OR_GENE_PRODUCT", 92, 96], ["A30P", "GENE_OR_GENE_PRODUCT", 158, 162], ["E46K", "GENE_OR_GENE_PRODUCT", 164, 168], ["SNCA gene", "DNA", 92, 101], ["patients", "SPECIES", 12, 20], ["familial forms of PD", "PROBLEM", 26, 46], ["harbor mutations", "PROBLEM", 68, 84], ["point mutations", "PROBLEM", 113, 128]]], ["Genetic and 8 neuropathological findings in humans and data from animal model studies suggest that aSyn 9Introduction 1self-assembly plays a central role in the pathogenesis of PD and other neurodegenerative 10 disorders involving an accumulation of aSyn aggregates in the brain, collectively referred to as 11 synucleinopathies (3).", [["brain", "ANATOMY", 273, 278], ["PD", "DISEASE", 177, 179], ["neurodegenerative 10 disorders", "DISEASE", 190, 220], ["humans", "ORGANISM", 44, 50], ["aSyn 9Introduction 1self", "GENE_OR_GENE_PRODUCT", 99, 123], ["aSyn", "GENE_OR_GENE_PRODUCT", 250, 254], ["brain", "ORGAN", 273, 278], ["humans", "SPECIES", 44, 50], ["humans", "SPECIES", 44, 50], ["Genetic and 8 neuropathological findings", "PROBLEM", 0, 40], ["animal model studies", "TEST", 65, 85], ["PD", "PROBLEM", 177, 179], ["other neurodegenerative 10 disorders", "PROBLEM", 184, 220], ["an accumulation of aSyn aggregates in the brain", "PROBLEM", 231, 278], ["aSyn aggregates", "OBSERVATION", 250, 265], ["brain", "ANATOMY", 273, 278]]], ["A detailed understanding of molecular mechanisms by which aSyn forms 12 neurotoxic aggregates is critical for developing therapies aimed at slowing neurodegeneration in 13 the brains of patients with PD and other synucleinopathy disorders.", [["brains", "ANATOMY", 176, 182], ["neurotoxic", "DISEASE", 72, 82], ["neurodegeneration", "DISEASE", 148, 165], ["PD", "DISEASE", 200, 202], ["synucleinopathy disorders", "DISEASE", 213, 238], ["aSyn", "GENE_OR_GENE_PRODUCT", 58, 62], ["patients", "ORGANISM", 186, 194], ["patients", "SPECIES", 186, 194], ["developing therapies", "TREATMENT", 110, 130], ["slowing neurodegeneration", "PROBLEM", 140, 165], ["PD", "PROBLEM", 200, 202], ["other synucleinopathy disorders", "PROBLEM", 207, 238]]], ["14 aSyn has been reported to adopt a natively unfolded, monomeric structure in solution (4) 15 and to exist as a compact disordered monomer in mammalian cells (5), although additional 16 evidence suggests that it can also exist as an oligomer in the cytosol (6).", [["cells", "ANATOMY", 153, 158], ["cytosol", "ANATOMY", 250, 257], ["aSyn", "CHEMICAL", 3, 7], ["mammalian cells", "CELL", 143, 158], ["cytosol", "CELLULAR_COMPONENT", 250, 257], ["aSyn", "PROTEIN", 3, 7], ["monomeric structure", "PROTEIN", 56, 75], ["mammalian cells", "CELL_TYPE", 143, 158], ["a compact disordered monomer in mammalian cells", "PROBLEM", 111, 158], ["unfolded", "OBSERVATION_MODIFIER", 46, 54], ["monomeric structure", "OBSERVATION", 56, 75], ["mammalian cells", "OBSERVATION", 143, 158]]], ["The protein is typically 17 expressed as a 14.4 kDa polypeptide and consists of 3 domains.", [["14.4 kDa polypeptide", "PROTEIN", 43, 63], ["The protein", "TEST", 0, 11], ["a 14.4 kDa polypeptide", "TEST", 41, 63]]], ["The N-terminal domain 18 spanning residues 1-67 contains five conserved, lysine-rich repeats.", [["lysine", "CHEMICAL", 73, 79], ["N-terminal domain 18", "PROTEIN", 4, 24], ["residues 1-67", "PROTEIN", 34, 47], ["lysine-rich repeats", "PROTEIN", 73, 92], ["The N-terminal domain", "TEST", 0, 21]]], ["The central region 19Introduction 1spanning residues 61-95 contains a sixth lysine-rich repeat and is highly hydrophobic.", [["19Introduction 1spanning residues 61-95", "CHEMICAL", 19, 58], ["lysine", "CHEMICAL", 76, 82], ["sixth lysine-rich repeat", "PROTEIN", 70, 94], ["a sixth lysine", "TREATMENT", 68, 82], ["central", "ANATOMY_MODIFIER", 4, 11], ["highly", "OBSERVATION_MODIFIER", 102, 108], ["hydrophobic", "OBSERVATION_MODIFIER", 109, 120]]], ["A key 20 feature of this region is the presence of a segment spanning residues 71-82 that is required for 21 aSyn aggregation (7).", [["a segment spanning residues", "PROBLEM", 51, 78], ["20 feature", "OBSERVATION_MODIFIER", 6, 16], ["segment", "OBSERVATION_MODIFIER", 53, 60], ["spanning", "OBSERVATION_MODIFIER", 61, 69], ["residues", "OBSERVATION_MODIFIER", 70, 78]]], ["The C-terminal region spanning residues 96-140 is enriched with proline 22Introduction 1and acidic residues and is thought to regulate aSyn aggregation through auto-inhibitory long-23 range interactions (8, 9) , with electrostatic interactions mediated by the acidic residues playing a 24 major role in increasing the fibrillization lag time (10). aSyn binds to anionic phospholipid 25 vesicles by forming an amphipathic \u03b1-helix with varying lengths, including a short N-terminal 26 helix spanning residues ~1-25 and a longer helix spanning residues ~1-97 encompassing both 27 the N-terminal and central hydrophobic domains (11, 12) .", [["anionic phospholipid 25 vesicles", "ANATOMY", 362, 394], ["residues 96-140", "CHEMICAL", 31, 46], ["proline", "CHEMICAL", 64, 71], ["aSyn", "CHEMICAL", 348, 352], ["proline", "CHEMICAL", 64, 71], ["N", "CHEMICAL", 469, 470], ["N", "CHEMICAL", 581, 582], ["proline", "AMINO_ACID", 64, 71], ["aSyn", "GENE_OR_GENE_PRODUCT", 135, 139], ["aSyn", "SIMPLE_CHEMICAL", 348, 352], ["C-terminal region", "PROTEIN", 4, 21], ["proline 22Introduction 1and acidic residues", "PROTEIN", 64, 107], ["aSyn", "PROTEIN", 348, 352], ["amphipathic \u03b1-helix", "PROTEIN", 409, 428], ["N-terminal 26 helix", "PROTEIN", 469, 488], ["N-terminal", "PROTEIN", 581, 591], ["central hydrophobic domains", "PROTEIN", 596, 623], ["The C-terminal region spanning residues", "PROBLEM", 0, 39], ["proline 22Introduction", "TREATMENT", 64, 86], ["acidic residues", "PROBLEM", 92, 107], ["aSyn aggregation", "PROBLEM", 135, 151], ["the acidic residues", "PROBLEM", 256, 275], ["anionic phospholipid", "TEST", 362, 382], ["a short N-terminal 26 helix spanning residues", "PROBLEM", 461, 506], ["a longer helix spanning residues", "PROBLEM", 517, 549], ["-terminal", "ANATOMY_MODIFIER", 5, 14], ["region", "ANATOMY_MODIFIER", 15, 21], ["amphipathic \u03b1-helix", "OBSERVATION", 409, 428], ["terminal", "ANATOMY_MODIFIER", 583, 591], ["central", "ANATOMY_MODIFIER", 596, 603], ["hydrophobic domains", "OBSERVATION", 604, 623]]], ["Although membrane binding 28 apparently plays an important role in the normal function of aSyn related to regulation of 29 synaptic vesicle trafficking (12, 13), the protein has also been shown to undergo accelerated 30 aggregation when incubated in the presence of phospholipid vesicles at high protein:lipid ratios 31 (14-16). aSyn aggregation at the membrane surface is likely stimulated by the exposure of 32 hydrophobic residues as the membrane-bound protein shifts from the long-helix form to the 33 short-helix form (11, 16) , and by the fact that molecular interactions needed for aSyn self-34 assembly likely occur with a higher probability on the two dimensional surface of the lipid bilayer 35 than in solution (17, 18).", [["membrane", "ANATOMY", 9, 17], ["synaptic vesicle", "ANATOMY", 123, 139], ["phospholipid vesicles", "ANATOMY", 266, 287], ["membrane surface", "ANATOMY", 353, 369], ["membrane", "ANATOMY", 441, 449], ["lipid bilayer", "ANATOMY", 688, 701], ["membrane", "CELLULAR_COMPONENT", 9, 17], ["aSyn", "GENE_OR_GENE_PRODUCT", 90, 94], ["synaptic vesicle", "CELLULAR_COMPONENT", 123, 139], ["phospholipid vesicles", "CELLULAR_COMPONENT", 266, 287], ["lipid", "SIMPLE_CHEMICAL", 304, 309], ["aSyn", "GENE_OR_GENE_PRODUCT", 329, 333], ["membrane surface", "CELLULAR_COMPONENT", 353, 369], ["membrane", "CELLULAR_COMPONENT", 441, 449], ["membrane binding 28", "PROTEIN", 9, 28], ["aSyn", "PROTEIN", 90, 94], ["membrane-bound protein", "PROTEIN", 441, 463], ["long-helix form", "PROTEIN", 480, 495], ["33 short-helix form", "PROTEIN", 503, 522], ["membrane binding", "PROBLEM", 9, 25], ["accelerated 30 aggregation", "PROBLEM", 205, 231], ["phospholipid vesicles", "PROBLEM", 266, 287], ["lipid ratios", "TEST", 304, 316], ["aSyn aggregation", "PROBLEM", 329, 345], ["32 hydrophobic residues", "PROBLEM", 410, 433], ["the membrane-bound protein shifts", "PROBLEM", 437, 470], ["aSyn self", "TEST", 589, 598], ["the lipid bilayer", "TREATMENT", 684, 701], ["aggregation", "OBSERVATION", 334, 345], ["likely", "UNCERTAINTY", 373, 379], ["protein shifts", "OBSERVATION", 456, 470]]], ["Evidence from our laboratory suggests that membrane-induced aSyn 36 aggregation plays a key role in neurotoxicity (16), potentially via a mechanism involving 37 membrane permeabilization (19) (20) (21) (22) . toxic oligomers (26, 35, 36) .", [["membrane", "ANATOMY", 43, 51], ["membrane", "ANATOMY", 161, 169], ["neurotoxicity", "DISEASE", 100, 113], ["toxic oligomers", "DISEASE", 209, 224], ["membrane", "CELLULAR_COMPONENT", 43, 51], ["aSyn 36", "GENE_OR_GENE_PRODUCT", 60, 67], ["our laboratory", "TEST", 14, 28], ["aSyn 36 aggregation", "PROBLEM", 60, 79], ["neurotoxicity", "PROBLEM", 100, 113], ["toxic oligomers", "PROBLEM", 209, 224], ["oligomers", "OBSERVATION", 215, 224]]], ["As a corollary, we reasoned that the human-to-mouse substitutions 180 could stimulate aSyn fibrillization, which in turn could account for the reduced neurotoxicity of m-181 aSyn and h-aSyn Chimera compared to h-aSyn A53T.", [["neurotoxicity", "DISEASE", 151, 164], ["human", "ORGANISM", 37, 42], ["mouse", "ORGANISM", 46, 51], ["aSyn", "GENE_OR_GENE_PRODUCT", 86, 90], ["m-181 aSyn", "SIMPLE_CHEMICAL", 168, 178], ["h-aSyn Chimera", "GENE_OR_GENE_PRODUCT", 183, 197], ["h-aSyn A53T", "GENE_OR_GENE_PRODUCT", 210, 221], ["h-aSyn A53T", "PROTEIN", 210, 221], ["human", "SPECIES", 37, 42], ["mouse", "SPECIES", 46, 51], ["human", "SPECIES", 37, 42], ["the human-to-mouse substitutions", "TREATMENT", 33, 65], ["aSyn fibrillization", "PROBLEM", 86, 105], ["the reduced neurotoxicity", "PROBLEM", 139, 164], ["aSyn fibrillization", "OBSERVATION", 86, 105]]], ["To address this hypothesis, we 182 monitored the fibrillization of human, mouse, and chimeric aSyn variants using a thioflavin T 183 fluorescence assay.", [["thioflavin T", "CHEMICAL", 116, 128], ["thioflavin T 183", "CHEMICAL", 116, 132], ["human", "ORGANISM", 67, 72], ["mouse", "ORGANISM", 74, 79], ["aSyn", "GENE_OR_GENE_PRODUCT", 94, 98], ["human, mouse, and chimeric aSyn variants", "CELL_LINE", 67, 107], ["human", "SPECIES", 67, 72], ["mouse", "SPECIES", 74, 79], ["human", "SPECIES", 67, 72], ["mouse", "SPECIES", 74, 79], ["fluorescence assay", "TEST", 133, 151]]], ["Consistent with previous results, we found that m-aSyn and h-aSyn A53T 184 formed fibrils with a markedly reduced lag time compared to h-aSyn WT, although the decrease 185 in lag time was more pronounced for the mouse protein ( Figure 5A ).", [["fibrils", "ANATOMY", 82, 89], ["m-aSyn", "GENE_OR_GENE_PRODUCT", 48, 54], ["mouse", "ORGANISM", 212, 217], ["m-aSyn", "PROTEIN", 48, 54], ["h-aSyn WT", "CELL_LINE", 135, 144], ["mouse protein", "PROTEIN", 212, 225], ["Figure 5A", "PROTEIN", 228, 237], ["mouse", "SPECIES", 212, 217], ["mouse", "SPECIES", 212, 217], ["m-aSyn", "TEST", 48, 54], ["formed fibrils", "PROBLEM", 75, 89], ["a markedly reduced lag time", "PROBLEM", 95, 122], ["h-aSyn WT", "TEST", 135, 144], ["markedly", "OBSERVATION_MODIFIER", 97, 105], ["reduced", "OBSERVATION_MODIFIER", 106, 113], ["decrease", "OBSERVATION_MODIFIER", 159, 167]]], ["Analysis of the chimeric 186 aSyn variants revealed that h-aSyn Chimera formed fibrils with a longer lag time compared to h-187 aSyn A53T, whereas the rate of fibrillization was only slightly decreased for m-aSyn Chimera 188 compared to m-aSyn ( Figure 5B ).Effects of human/mouse aSyn mismatches on fibril morphology and dimensions 203Next, we examined the impact of human/mouse aSyn mismatches on fibril morphology 204 and dimensions based on evidence that different types of aSyn fibrils (e.g. cylindrical fibrils 205 versus flatter ribbons) can trigger different levels of neurotoxicity in cellular and animal models 206 (37).", [["fibrils", "ANATOMY", 79, 86], ["fibril", "ANATOMY", 300, 306], ["fibril", "ANATOMY", 399, 405], ["cellular", "ANATOMY", 594, 602], ["neurotoxicity", "DISEASE", 577, 590], ["aSyn", "GENE_OR_GENE_PRODUCT", 29, 33], ["human", "ORGANISM", 269, 274], ["mouse", "ORGANISM", 275, 280], ["aSyn", "GENE_OR_GENE_PRODUCT", 281, 285], ["human", "ORGANISM", 368, 373], ["mouse", "ORGANISM", 374, 379], ["aSyn", "GENE_OR_GENE_PRODUCT", 380, 384], ["aSyn fibrils", "GENE_OR_GENE_PRODUCT", 478, 490], ["cellular", "CELL", 594, 602], ["chimeric 186 aSyn variants", "DNA", 16, 42], ["h-aSyn Chimera", "PROTEIN", 57, 71], ["m-aSyn", "PROTEIN", 237, 243], ["aSyn fibrils", "PROTEIN", 478, 490], ["human", "SPECIES", 269, 274], ["mouse", "SPECIES", 275, 280], ["human", "SPECIES", 368, 373], ["mouse", "SPECIES", 374, 379], ["human", "SPECIES", 269, 274], ["mouse", "SPECIES", 275, 280], ["human", "SPECIES", 368, 373], ["mouse", "SPECIES", 374, 379], ["Analysis", "TEST", 0, 8], ["the chimeric 186 aSyn variants", "TEST", 12, 42], ["h-aSyn Chimera formed fibrils", "PROBLEM", 57, 86], ["aSyn A53T", "TEST", 128, 137], ["the rate of fibrillization", "PROBLEM", 147, 173], ["m-aSyn Chimera", "TEST", 206, 220], ["human/mouse aSyn mismatches", "TREATMENT", 269, 296], ["human/mouse aSyn mismatches", "TREATMENT", 368, 395], ["fibril morphology", "TEST", 399, 416], ["aSyn fibrils", "PROBLEM", 478, 490], ["cylindrical fibrils", "PROBLEM", 497, 516], ["flatter ribbons)", "PROBLEM", 528, 544], ["neurotoxicity", "PROBLEM", 577, 590], ["aSyn mismatches", "OBSERVATION", 380, 395], ["aSyn fibrils", "OBSERVATION", 478, 490]]], ["Examination of incubated samples of human, mouse, and chimeric aSyn by atomic force 207 microscopy (AFM) revealed that all of the variants formed straight, rigid, unbranched fibrils, 208 organized either as individual fibrils or in fibril bundles ( Figure 6A-D) .", [["samples", "ANATOMY", 25, 32], ["fibrils", "ANATOMY", 174, 181], ["fibrils", "ANATOMY", 218, 225], ["human", "ORGANISM", 36, 41], ["mouse", "ORGANISM", 43, 48], ["aSyn", "CELL", 63, 67], ["chimeric aSyn", "PROTEIN", 54, 67], ["human", "SPECIES", 36, 41], ["mouse", "SPECIES", 43, 48], ["human", "SPECIES", 36, 41], ["mouse", "SPECIES", 43, 48], ["Examination of incubated samples", "TEST", 0, 32], ["microscopy (AFM)", "TEST", 88, 104], ["rigid, unbranched fibrils", "PROBLEM", 156, 181], ["individual fibrils", "PROBLEM", 207, 225]]], ["Two types of fibrils 209 ('twisted' and 'non-twisted') were detected in samples of m-aSyn and h-aSyn-Chimera, whereas 210 only non-twisted fibrils were observed in samples of h-aSyn-A53T and m-aSyn-Chimera under 211 our experimental conditions.", [["samples", "ANATOMY", 72, 79], ["fibrils", "ANATOMY", 139, 146], ["samples", "ANATOMY", 164, 171], ["m-aSyn", "SIMPLE_CHEMICAL", 83, 89], ["fibrils", "GENE_OR_GENE_PRODUCT", 139, 146], ["h-aSyn-A53T", "GENE_OR_GENE_PRODUCT", 175, 186], ["m-aSyn", "PROTEIN", 83, 89], ["h-aSyn", "PROTEIN", 94, 100], ["Chimera", "PROTEIN", 101, 108], ["h-aSyn", "PROTEIN", 175, 181], ["fibrils", "TEST", 13, 20], ["m-aSyn", "TEST", 83, 89], ["h-aSyn", "TEST", 94, 100], ["non-twisted fibrils", "PROBLEM", 127, 146], ["h-aSyn", "TEST", 175, 181], ["m-aSyn", "TREATMENT", 191, 197]]], ["The heights of the non-twisted fibrils ranged from ~8 to ~11 nm, 212Effects of human/mouse aSyn mismatches on fibril morphology and dimensions 203whereas the heights of the 'valley' and 'peak' regions of the twisted fibrils ranged from ~7 to ~9 213 nm and ~11 to ~12 nm, respectively.", [["fibrils", "ANATOMY", 31, 38], ["fibril", "ANATOMY", 110, 116], ["fibrils", "ANATOMY", 216, 223], ["human", "ORGANISM", 79, 84], ["mouse", "ORGANISM", 85, 90], ["aSyn", "GENE_OR_GENE_PRODUCT", 91, 95], ["human", "SPECIES", 79, 84], ["mouse", "SPECIES", 85, 90], ["human", "SPECIES", 79, 84], ["mouse", "SPECIES", 85, 90], ["the non-twisted fibrils", "TEST", 15, 38], ["human/mouse aSyn mismatches", "TREATMENT", 79, 106], ["fibril morphology", "TEST", 110, 127], ["the twisted fibrils", "TEST", 204, 223], ["heights", "OBSERVATION_MODIFIER", 4, 11], ["aSyn mismatches", "OBSERVATION", 91, 106], ["fibril morphology", "OBSERVATION_MODIFIER", 110, 127], ["twisted fibrils", "OBSERVATION", 208, 223]]], ["The average pitch of twisted fibrils formed by m-aSyn and 214 h-aSyn Chimera was 123 \u00b1 5 nm and 91 \u00b1 8 nm, respectively ( Figure 6E ,F).", [["fibrils", "ANATOMY", 29, 36], ["m-aSyn", "PROTEIN", 47, 53], ["Syn Chimera", "PROTEIN", 65, 76], ["Syn Chimera", "TEST", 65, 76], ["average", "OBSERVATION_MODIFIER", 4, 11], ["pitch", "OBSERVATION_MODIFIER", 12, 17]]], ["215Effects of human/mouse aSyn mismatches on fibril morphology and dimensions 203Further analysis of the fibrils by TEM also revealed the presence of straight, rigid, 216Effects of human/mouse aSyn mismatches on fibril morphology and dimensions 203unbranched fibrils for all of the variants ( Figure 6G -L).", [["fibril", "ANATOMY", 45, 51], ["fibrils", "ANATOMY", 105, 112], ["fibril", "ANATOMY", 212, 218], ["fibrils", "ANATOMY", 259, 266], ["human", "ORGANISM", 14, 19], ["mouse", "ORGANISM", 20, 25], ["aSyn", "GENE_OR_GENE_PRODUCT", 26, 30], ["human", "ORGANISM", 181, 186], ["mouse", "ORGANISM", 187, 192], ["aSyn", "GENE_OR_GENE_PRODUCT", 193, 197], ["human/mouse aSyn mismatches", "DNA", 14, 41], ["human", "SPECIES", 14, 19], ["mouse", "SPECIES", 20, 25], ["human", "SPECIES", 181, 186], ["mouse", "SPECIES", 187, 192], ["human", "SPECIES", 14, 19], ["mouse", "SPECIES", 20, 25], ["human", "SPECIES", 181, 186], ["mouse", "SPECIES", 187, 192], ["human/mouse aSyn mismatches", "TREATMENT", 14, 41], ["fibril morphology", "TEST", 45, 62], ["the fibrils", "TEST", 101, 112], ["human/mouse aSyn mismatches", "TREATMENT", 181, 208], ["fibril morphology", "TEST", 212, 229], ["unbranched fibrils", "PROBLEM", 248, 266], ["aSyn mismatches", "OBSERVATION", 193, 208], ["fibril morphology", "OBSERVATION_MODIFIER", 212, 229], ["unbranched", "OBSERVATION_MODIFIER", 248, 258], ["fibrils", "OBSERVATION_MODIFIER", 259, 266]]], ["The fibrils had similar properties as those 217 described for previously reported aSyn amyloid-like fibrils (e.g. diameter of ~10-15 nm; apparent 218 winding of two fibrils around each other via a helical twist) (26).", [["fibrils", "ANATOMY", 4, 11], ["aSyn amyloid-like fibrils", "PROTEIN", 82, 107], ["fibrils", "PROTEIN", 165, 172], ["aSyn amyloid", "PROBLEM", 82, 94], ["fibrils", "PROBLEM", 100, 107], ["diameter", "TEST", 114, 122], ["two fibrils", "PROBLEM", 161, 172], ["a helical twist", "TREATMENT", 195, 210], ["amyloid", "OBSERVATION", 87, 94]]], ["Similar features were also 219 observed for fibrils formed by aSyn variants with the S87N or N87S substitution.", [["fibrils", "ANATOMY", 44, 51], ["aSyn", "GENE_OR_GENE_PRODUCT", 62, 66], ["S87N", "GENE_OR_GENE_PRODUCT", 85, 89], ["fibrils", "PROBLEM", 44, 51], ["N87S substitution", "TREATMENT", 93, 110], ["aSyn variants", "OBSERVATION", 62, 75]]], ["There were no 220 striking differences in fibril morphology among the different aSyn variants, except that individual 221 fibrils formed by h-aSyn-Chimera had a twisted appearance similar to that observed for this 222 variant by AFM (in contrast, twisted fibrils of m-aSyn were not observed by TEM).", [["fibril", "ANATOMY", 42, 48], ["fibrils", "ANATOMY", 122, 129], ["aSyn", "GENE_OR_GENE_PRODUCT", 80, 84], ["aSyn variants", "CELL_LINE", 80, 93], ["h-aSyn", "PROTEIN", 140, 146], ["Chimera", "PROTEIN", 147, 154], ["222 variant", "PROTEIN", 214, 225], ["m-aSyn", "PROTEIN", 266, 272], ["fibril morphology", "TEST", 42, 59], ["the different aSyn variants", "PROBLEM", 66, 93], ["a twisted appearance", "PROBLEM", 159, 179], ["no", "UNCERTAINTY", 11, 13], ["220 striking", "OBSERVATION_MODIFIER", 14, 26], ["fibril morphology", "OBSERVATION_MODIFIER", 42, 59], ["aSyn variants", "OBSERVATION", 80, 93]]], ["It is unclear 223 why different results were obtained for m-aSyn and h-aSyn Chimera via AFM versus TEM, 224 although this discrepancy can potentially be explained by the fact that (i) the variants formed 225 two different types of twisted fibrils, as implied by their different pitch values ( Figure 6E ,F), and 226 (ii) different types of fibrils adsorb with different efficiencies to substrates with different 227 properties such as the hydrophilic mica and hydrophobic carbon-coated grids used here for 228 AFM and TEM, respectively (38) .", [["fibrils", "ANATOMY", 239, 246], ["carbon", "CHEMICAL", 472, 478], ["m-aSyn", "TREATMENT", 58, 64], ["twisted fibrils", "PROBLEM", 231, 246], ["fibrils adsorb", "PROBLEM", 340, 354], ["different efficiencies", "PROBLEM", 360, 382], ["the hydrophilic mica and hydrophobic carbon-coated grids", "TREATMENT", 435, 491]]], ["229Effects of human/mouse aSyn mismatches on fibril morphology and dimensions 203Overall, these data suggest that differences in the morphologies of aSyn fibrils formed 230 under the self-assembly conditions used in this study could potentially contribute to differences 231 in neurotoxicity among the human, mouse, and chimeric aSyn variants (Figures 2-4) .", [["fibril", "ANATOMY", 45, 51], ["neurotoxicity", "DISEASE", 278, 291], ["human", "ORGANISM", 14, 19], ["mouse", "ORGANISM", 20, 25], ["aSyn", "GENE_OR_GENE_PRODUCT", 26, 30], ["aSyn fibrils", "GENE_OR_GENE_PRODUCT", 149, 161], ["human", "ORGANISM", 302, 307], ["mouse", "ORGANISM", 309, 314], ["aSyn", "GENE_OR_GENE_PRODUCT", 329, 333], ["aSyn fibrils", "PROTEIN", 149, 161], ["chimeric aSyn variants", "CELL_LINE", 320, 342], ["human", "SPECIES", 14, 19], ["mouse", "SPECIES", 20, 25], ["human", "SPECIES", 302, 307], ["mouse", "SPECIES", 309, 314], ["human", "SPECIES", 14, 19], ["mouse", "SPECIES", 20, 25], ["human", "SPECIES", 302, 307], ["mouse", "SPECIES", 309, 314], ["human/mouse aSyn mismatches", "TREATMENT", 14, 41], ["these data", "TEST", 90, 100], ["aSyn fibrils", "PROBLEM", 149, 161], ["this study", "TEST", 216, 226], ["neurotoxicity", "PROBLEM", 278, 291]]], ["232 233 Effects of human/mouse aSyn mismatches on membrane-induced aSyn aggregation.", [["membrane", "ANATOMY", 50, 58], ["human", "ORGANISM", 19, 24], ["mouse", "ORGANISM", 25, 30], ["aSyn", "GENE_OR_GENE_PRODUCT", 31, 35], ["membrane", "CELLULAR_COMPONENT", 50, 58], ["aSyn", "SIMPLE_CHEMICAL", 67, 71], ["human/mouse aSyn mismatches", "DNA", 19, 46], ["human", "SPECIES", 19, 24], ["mouse", "SPECIES", 25, 30], ["human", "SPECIES", 19, 24], ["mouse", "SPECIES", 25, 30], ["human/mouse aSyn mismatches on membrane", "TREATMENT", 19, 58], ["aSyn aggregation", "PROBLEM", 67, 83], ["aSyn aggregation", "OBSERVATION", 67, 83]]], ["234Effects of human/mouse aSyn mismatches on fibril morphology and dimensions 203Based on our earlier finding that lipid-induced self-assembly plays a key role in aSyn 235 neurotoxicity (16), we hypothesized that human-to-mouse substitutions should lead to a 236 decrease in aSyn aggregation propensity at membrane surfaces.", [["fibril", "ANATOMY", 45, 51], ["membrane surfaces", "ANATOMY", 306, 323], ["neurotoxicity", "DISEASE", 172, 185], ["aSyn 235", "CHEMICAL", 163, 171], ["human", "ORGANISM", 14, 19], ["mouse", "ORGANISM", 20, 25], ["aSyn", "GENE_OR_GENE_PRODUCT", 26, 30], ["lipid", "SIMPLE_CHEMICAL", 115, 120], ["aSyn 235", "SIMPLE_CHEMICAL", 163, 171], ["human", "ORGANISM", 213, 218], ["mouse", "ORGANISM", 222, 227], ["aSyn", "SIMPLE_CHEMICAL", 275, 279], ["membrane surfaces", "CELLULAR_COMPONENT", 306, 323], ["human", "SPECIES", 14, 19], ["mouse", "SPECIES", 20, 25], ["human", "SPECIES", 213, 218], ["mouse", "SPECIES", 222, 227], ["human", "SPECIES", 14, 19], ["mouse", "SPECIES", 20, 25], ["human", "SPECIES", 213, 218], ["human/mouse aSyn mismatches", "TREATMENT", 14, 41], ["mouse substitutions", "PROBLEM", 222, 241], ["a 236 decrease in aSyn aggregation propensity at membrane surfaces", "PROBLEM", 257, 323], ["fibril morphology", "OBSERVATION_MODIFIER", 45, 62]]], ["Our rationale was that 237 although aSyn aggregation is primarily driven by the central hydrophobic region (7, 11, 16) , 238Effects of human/mouse aSyn mismatches on fibril morphology and dimensions 203modifications to the C-terminal domain have been shown to modulate aSyn self-assembly (39) 239 and aSyn-membrane interactions (40) through effects on long-range interactions.", [["fibril", "ANATOMY", 166, 172], ["membrane", "ANATOMY", 306, 314], ["aggregation", "DISEASE", 41, 52], ["C", "CHEMICAL", 223, 224], ["aSyn", "GENE_OR_GENE_PRODUCT", 36, 40], ["human", "ORGANISM", 135, 140], ["mouse", "ORGANISM", 141, 146], ["aSyn", "GENE_OR_GENE_PRODUCT", 147, 151], ["human/mouse aSyn mismatches", "DNA", 135, 162], ["C-terminal domain", "PROTEIN", 223, 240], ["human", "SPECIES", 135, 140], ["mouse", "SPECIES", 141, 146], ["human", "SPECIES", 135, 140], ["mouse", "SPECIES", 141, 146], ["aSyn aggregation", "PROBLEM", 36, 52], ["human/mouse aSyn mismatches", "TREATMENT", 135, 162], ["fibril morphology", "TEST", 166, 183], ["the C-terminal domain", "PROBLEM", 219, 240], ["aSyn-membrane interactions", "PROBLEM", 301, 327], ["central", "ANATOMY_MODIFIER", 80, 87], ["hydrophobic", "ANATOMY_MODIFIER", 88, 99], ["aSyn mismatches", "OBSERVATION", 147, 162], ["fibril morphology", "OBSERVATION_MODIFIER", 166, 183]]], ["240Effects of human/mouse aSyn mismatches on fibril morphology and dimensions 203As a first step, we characterized the human, mouse, and chimeric variants in terms of 241 membrane affinities, based on the premise that differences in affinity could lead to differences in 242 the variants' propensity to undergo membrane-induced aggregation (16).", [["fibril", "ANATOMY", 45, 51], ["membrane", "ANATOMY", 171, 179], ["membrane", "ANATOMY", 311, 319], ["aggregation", "DISEASE", 328, 339], ["human", "ORGANISM", 14, 19], ["mouse", "ORGANISM", 20, 25], ["aSyn", "GENE_OR_GENE_PRODUCT", 26, 30], ["human", "ORGANISM", 119, 124], ["mouse", "ORGANISM", 126, 131], ["membrane", "CELLULAR_COMPONENT", 311, 319], ["human/mouse aSyn mismatches", "DNA", 14, 41], ["human, mouse, and chimeric variants", "PROTEIN", 119, 154], ["human", "SPECIES", 14, 19], ["mouse", "SPECIES", 20, 25], ["human", "SPECIES", 119, 124], ["mouse", "SPECIES", 126, 131], ["human", "SPECIES", 14, 19], ["mouse", "SPECIES", 20, 25], ["human", "SPECIES", 119, 124], ["mouse", "SPECIES", 126, 131], ["human/mouse aSyn mismatches", "TREATMENT", 14, 41], ["chimeric variants", "PROBLEM", 137, 154], ["membrane-induced aggregation", "PROBLEM", 311, 339]]], ["Recombinant h-aSyn 243 WT, h-aSyn A53T, h-aSyn Chimera, m-aSyn, and m-aSyn Chimera in a monomeric state were 244 titrated with small unilamellar vesicles (SUVs) composed of egg phosphatidylglycerol (PG) and 245 egg phosphatidylcholine (PC) (1:1 mol/mol).", [["unilamellar vesicles", "ANATOMY", 133, 153], ["SUVs", "ANATOMY", 155, 159], ["phosphatidylglycerol", "CHEMICAL", 177, 197], ["PG", "CHEMICAL", 199, 201], ["phosphatidylcholine", "CHEMICAL", 215, 234], ["phosphatidylglycerol", "CHEMICAL", 177, 197], ["phosphatidylcholine", "CHEMICAL", 215, 234], ["h-aSyn 243 WT", "ORGANISM", 12, 25], ["h-aSyn A53T", "ORGANISM", 27, 38], ["h-aSyn", "GENE_OR_GENE_PRODUCT", 40, 46], ["m-aSyn", "GENE_OR_GENE_PRODUCT", 56, 62], ["unilamellar vesicles", "MULTI-TISSUE_STRUCTURE", 133, 153], ["egg phosphatidylglycerol", "SIMPLE_CHEMICAL", 173, 197], ["PG", "SIMPLE_CHEMICAL", 199, 201], ["245 egg phosphatidylcholine", "SIMPLE_CHEMICAL", 207, 234], ["PC", "SIMPLE_CHEMICAL", 236, 238], ["Recombinant h-aSyn 243 WT", "PROTEIN", 0, 25], ["h-aSyn A53T", "PROTEIN", 27, 38], ["h-aSyn Chimera", "PROTEIN", 40, 54], ["m-aSyn", "PROTEIN", 56, 62], ["m-aSyn Chimera", "PROTEIN", 68, 82], ["m-aSyn", "TREATMENT", 56, 62], ["small unilamellar vesicles", "TREATMENT", 127, 153], ["egg phosphatidylglycerol", "TREATMENT", 173, 197], ["egg phosphatidylcholine (PC)", "TREATMENT", 211, 239]]], ["Analysis of the samples via far-UV CD, a method 246 used to monitor the increase in aSyn \u03b1-helical structure that results from binding of the protein 247 to phospholipids, yielded similar lipid titration curves, K d values, and maximum \u03b1-helical 248 contents for all of the aSyn variants ( Figure 7A ; Table S1 ).", [["samples", "ANATOMY", 16, 23], ["phospholipids", "SIMPLE_CHEMICAL", 157, 170], ["lipid", "SIMPLE_CHEMICAL", 188, 193], ["aSyn \u03b1-helical structure", "PROTEIN", 84, 108], ["protein 247", "PROTEIN", 142, 153], ["aSyn variants", "PROTEIN", 274, 287], ["the samples", "TEST", 12, 23], ["a method", "TEST", 39, 47], ["the increase in aSyn \u03b1-helical structure", "PROBLEM", 68, 108], ["the protein", "TEST", 138, 149], ["phospholipids", "TEST", 157, 170], ["similar lipid titration curves", "TEST", 180, 210], ["K d values", "TEST", 212, 222], ["the aSyn variants", "PROBLEM", 270, 287]]], ["These results suggested that the C-249 terminal human/mouse mismatches have little effect on the affinity of aSyn for phospholipid 250 membranes, or on the degree of \u03b1-helical structure adopted by the protein in the presence of 251 saturating lipid.", [["phospholipid 250 membranes", "ANATOMY", 118, 144], ["human", "ORGANISM", 48, 53], ["mouse", "ORGANISM", 54, 59], ["aSyn", "SIMPLE_CHEMICAL", 109, 113], ["phospholipid 250", "GENE_OR_GENE_PRODUCT", 118, 134], ["membranes", "CELLULAR_COMPONENT", 135, 144], ["lipid", "SIMPLE_CHEMICAL", 243, 248], ["C-249 terminal human/mouse mismatches", "DNA", 33, 70], ["aSyn", "PROTEIN", 109, 113], ["\u03b1-helical structure", "PROTEIN", 166, 185], ["human", "SPECIES", 48, 53], ["mouse", "SPECIES", 54, 59], ["human", "SPECIES", 48, 53], ["mouse", "SPECIES", 54, 59], ["the C-249 terminal human/mouse mismatches", "PROBLEM", 29, 70], ["phospholipid 250 membranes", "TREATMENT", 118, 144], ["mouse mismatches", "OBSERVATION", 54, 70]]], ["252Effects of human/mouse aSyn mismatches on fibril morphology and dimensions 203Next, we compared the human, mouse, and chimeric aSyn variants in terms of their 253 ability to undergo membrane-induced aggregation using a lipid-flotation assay.", [["fibril", "ANATOMY", 45, 51], ["membrane", "ANATOMY", 185, 193], ["human", "ORGANISM", 14, 19], ["mouse", "ORGANISM", 20, 25], ["aSyn", "GENE_OR_GENE_PRODUCT", 26, 30], ["human", "ORGANISM", 103, 108], ["mouse", "ORGANISM", 110, 115], ["aSyn", "GENE_OR_GENE_PRODUCT", 130, 134], ["membrane", "CELLULAR_COMPONENT", 185, 193], ["lipid", "SIMPLE_CHEMICAL", 222, 227], ["human/mouse aSyn mismatches", "DNA", 14, 41], ["chimeric aSyn variants", "CELL_LINE", 121, 143], ["human", "SPECIES", 14, 19], ["mouse", "SPECIES", 20, 25], ["human", "SPECIES", 103, 108], ["mouse", "SPECIES", 110, 115], ["human", "SPECIES", 14, 19], ["mouse", "SPECIES", 20, 25], ["human", "SPECIES", 103, 108], ["mouse", "SPECIES", 110, 115], ["human/mouse aSyn mismatches", "TREATMENT", 14, 41], ["chimeric aSyn variants", "PROBLEM", 121, 143], ["induced aggregation", "PROBLEM", 194, 213], ["a lipid-flotation assay", "TREATMENT", 220, 243], ["fibril morphology", "OBSERVATION_MODIFIER", 45, 62]]], ["The proteins 254Effects of human/mouse aSyn mismatches on fibril morphology and dimensions 203were incubated with PG:PC SUVs under conditions that promote aSyn self-assembly, and the 255 membrane fraction was isolated by gradient centrifugation and analyzed via Western blotting.", [["fibril", "ANATOMY", 58, 64], ["membrane", "ANATOMY", 187, 195], ["PG", "CHEMICAL", 114, 116], ["254Effects", "GENE_OR_GENE_PRODUCT", 13, 23], ["human", "ORGANISM", 27, 32], ["mouse", "ORGANISM", 33, 38], ["aSyn", "GENE_OR_GENE_PRODUCT", 39, 43], ["PG:PC SUVs", "SIMPLE_CHEMICAL", 114, 124], ["aSyn", "SIMPLE_CHEMICAL", 155, 159], ["human/mouse aSyn mismatches", "DNA", 27, 54], ["human", "SPECIES", 27, 32], ["mouse", "SPECIES", 33, 38], ["human", "SPECIES", 27, 32], ["mouse", "SPECIES", 33, 38], ["The proteins", "TEST", 0, 12], ["human/mouse aSyn mismatches", "TREATMENT", 27, 54], ["PC SUVs under conditions", "TREATMENT", 117, 141], ["the 255 membrane fraction", "TREATMENT", 179, 204], ["gradient centrifugation", "TREATMENT", 221, 244], ["gradient centrifugation", "OBSERVATION", 221, 244]]], ["256Effects of human/mouse aSyn mismatches on fibril morphology and dimensions 203The lane loaded with h-aSyn WT contained immunoreactive bands at ~45 and 60 kDa, whereas 257 the lane containing h-aSyn A53T or m-aSyn Chimera displayed more extensive laddering, 258 including bands at 75 and 100 kDa, and an intense smear of aSyn immunoreactivity in the 259 region of the gel above 245 kDa ( Figure 7B ).", [["fibril", "ANATOMY", 45, 51], ["human", "ORGANISM", 14, 19], ["mouse", "ORGANISM", 20, 25], ["aSyn", "GENE_OR_GENE_PRODUCT", 26, 30], ["h-aSyn A53T", "GENE_OR_GENE_PRODUCT", 194, 205], ["aSyn", "GENE_OR_GENE_PRODUCT", 323, 327], ["h-aSyn WT", "PROTEIN", 102, 111], ["h-aSyn A53T", "PROTEIN", 194, 205], ["m-aSyn Chimera", "PROTEIN", 209, 223], ["aSyn", "PROTEIN", 323, 327], ["259 region", "PROTEIN", 352, 362], ["human", "SPECIES", 14, 19], ["mouse", "SPECIES", 20, 25], ["human", "SPECIES", 14, 19], ["mouse", "SPECIES", 20, 25], ["human/mouse aSyn mismatches", "TREATMENT", 14, 41], ["immunoreactive bands", "PROBLEM", 122, 142], ["m-aSyn Chimera", "TEST", 209, 223], ["bands", "TEST", 274, 279], ["an intense smear of aSyn immunoreactivity", "PROBLEM", 303, 344], ["fibril morphology", "OBSERVATION_MODIFIER", 45, 62], ["immunoreactive bands", "OBSERVATION", 122, 142], ["intense", "OBSERVATION_MODIFIER", 306, 313], ["aSyn immunoreactivity", "OBSERVATION", 323, 344]]], ["In contrast, high molecular-weight species were cultured neurons and in mouse brain.", [["neurons", "ANATOMY", 57, 64], ["brain", "ANATOMY", 78, 83], ["neurons", "CELL", 57, 64], ["mouse", "ORGANISM", 72, 77], ["brain", "ORGAN", 78, 83], ["cultured neurons", "CELL_LINE", 48, 64], ["mouse", "SPECIES", 72, 77], ["mouse", "SPECIES", 72, 77], ["high molecular-weight species", "PROBLEM", 13, 42], ["brain", "ANATOMY", 78, 83]]], ["Here we report that m-aSyn has a reduced propensity to 305 elicit dopaminergic cell death compared to h-aSyn A53T in primary midbrain cultures and 306 exhibits a similar effect when expressed from an AAV vector in rat SN.", [["cell", "ANATOMY", 79, 83], ["midbrain cultures", "ANATOMY", 125, 142], ["SN", "ANATOMY", 218, 220], ["m-aSyn", "CHEMICAL", 20, 26], ["death", "DISEASE", 84, 89], ["h-aSyn", "CHEMICAL", 102, 108], ["m-aSyn", "CHEMICAL", 20, 26], ["m-aSyn", "SIMPLE_CHEMICAL", 20, 26], ["dopaminergic cell", "CELL", 66, 83], ["h-aSyn A53T", "GENE_OR_GENE_PRODUCT", 102, 113], ["midbrain cultures", "CELL", 125, 142], ["AAV", "ORGANISM", 200, 203], ["rat", "ORGANISM", 214, 217], ["SN", "CELL", 218, 220], ["m-aSyn", "PROTEIN", 20, 26], ["h-aSyn A53T", "CELL_LINE", 102, 113], ["primary midbrain cultures", "CELL_LINE", 117, 142], ["rat", "SPECIES", 214, 217], ["rat", "SPECIES", 214, 217], ["a reduced propensity", "PROBLEM", 31, 51], ["dopaminergic cell death", "PROBLEM", 66, 89], ["h-aSyn A53T", "TEST", 102, 113], ["primary midbrain cultures", "TEST", 117, 142], ["dopaminergic cell death", "OBSERVATION", 66, 89], ["midbrain", "ANATOMY", 125, 133], ["AAV", "OBSERVATION", 200, 203]]], ["Furthermore, we show 307 for the first time that this differential toxicity is associated with differences in aSyn-mediated 308 vesicle disruption and aggregation at the membrane surface, rather than differences in aSyn 309 fibrillization previously suggested to be important for modulating its toxicity (43).", [["vesicle", "ANATOMY", 128, 135], ["membrane surface", "ANATOMY", 170, 186], ["toxicity", "DISEASE", 67, 75], ["toxicity", "DISEASE", 295, 303], ["aSyn 309", "CHEMICAL", 215, 223], ["vesicle", "CELLULAR_COMPONENT", 128, 135], ["membrane surface", "CELLULAR_COMPONENT", 170, 186], ["aSyn 309", "SIMPLE_CHEMICAL", 215, 223], ["this differential toxicity", "PROBLEM", 49, 75], ["aSyn-mediated 308 vesicle disruption", "PROBLEM", 110, 146], ["aggregation at the membrane surface", "PROBLEM", 151, 186], ["modulating its toxicity", "PROBLEM", 280, 303], ["associated with", "UNCERTAINTY", 79, 94], ["vesicle disruption", "OBSERVATION", 128, 146], ["aggregation", "OBSERVATION_MODIFIER", 151, 162], ["membrane surface", "OBSERVATION_MODIFIER", 170, 186]]], ["Most 310 importantly, we provide evidence that these characteristics of the overtly toxic h-aSyn A53T Importantly, our data reveal a strong correlation between aggregation propensity at 460 membrane surfaces and neurotoxicity among the human, mouse, and chimeric aSyn variants, 461 and thus they further support the hypothesis that lipid-induced self-assembly plays a key role in 462 aSyn-mediated neurodegeneration (11, 16, 18, 22) .", [["membrane surfaces", "ANATOMY", 190, 207], ["aggregation", "DISEASE", 160, 171], ["neurotoxicity", "DISEASE", 212, 225], ["neurodegeneration", "DISEASE", 398, 415], ["human", "ORGANISM", 236, 241], ["mouse", "ORGANISM", 243, 248], ["aSyn", "GENE_OR_GENE_PRODUCT", 263, 267], ["lipid", "SIMPLE_CHEMICAL", 332, 337], ["aSyn", "GENE_OR_GENE_PRODUCT", 384, 388], ["human", "SPECIES", 236, 241], ["mouse", "SPECIES", 243, 248], ["human", "SPECIES", 236, 241], ["mouse", "SPECIES", 243, 248], ["our data", "TEST", 115, 123], ["aggregation propensity", "PROBLEM", 160, 182], ["neurotoxicity", "PROBLEM", 212, 225], ["aSyn-mediated neurodegeneration", "PROBLEM", 384, 415], ["neurodegeneration", "OBSERVATION", 398, 415]]], ["The importance of membrane-induced aSyn 463 aggregation to the pathogenesis of synucleinopathy disorders is further underscored by 464 evidence that non-membrane-associated aSyn adopts a compact, aggregation-resistant 465 conformation, with little exposure of the central hydrophobic region, in mammalian cells (5).", [["membrane", "ANATOMY", 18, 26], ["cells", "ANATOMY", 305, 310], ["synucleinopathy disorders", "DISEASE", 79, 104], ["aggregation", "DISEASE", 196, 207], ["membrane", "CELLULAR_COMPONENT", 18, 26], ["aSyn 463", "GENE_OR_GENE_PRODUCT", 35, 43], ["aSyn", "SIMPLE_CHEMICAL", 173, 177], ["mammalian cells", "CELL", 295, 310], ["aSyn 463", "PROTEIN", 35, 43], ["non-membrane-associated aSyn", "PROTEIN", 149, 177], ["central hydrophobic region", "PROTEIN", 264, 290], ["mammalian cells", "CELL_TYPE", 295, 310], ["synucleinopathy disorders", "PROBLEM", 79, 104], ["a compact, aggregation-resistant 465 conformation", "PROBLEM", 185, 234], ["central", "ANATOMY_MODIFIER", 264, 271], ["hydrophobic", "ANATOMY_MODIFIER", 272, 283], ["mammalian cells", "OBSERVATION", 295, 310]]], ["Unexpectedly, we found that h-aSyn WT triggered vesicle disruption to a similar extent as h-488 aSyn A53T and m-aSyn Chimera.", [["vesicle", "ANATOMY", 48, 55], ["h-aSyn", "CHEMICAL", 28, 34], ["h-aSyn WT", "ORGANISM", 28, 37], ["vesicle", "CELLULAR_COMPONENT", 48, 55], ["h-aSyn WT", "PROTEIN", 28, 37], ["m-aSyn Chimera", "PROTEIN", 110, 124], ["vesicle disruption", "PROBLEM", 48, 66], ["vesicle disruption", "OBSERVATION", 48, 66]]], ["This observation was inconsistent with the fact that h-aSyn 489Effects of human/mouse aSyn mismatches on fibril morphology and dimensions 203WT exhibited a non-significant trend towards less extensive membrane-induced self-assembly, 490 or with evidence from our earlier studies that h-aSyn WT is considerably less toxic than h-aSyn 491 A53T in primary midbrain cultures (16) and causes neurodegeneration less rapidly than h-aSyn 492 A53T in rat midbrain (67).", [["fibril", "ANATOMY", 105, 111], ["membrane", "ANATOMY", 201, 209], ["midbrain cultures", "ANATOMY", 353, 370], ["midbrain", "ANATOMY", 446, 454], ["h-aSyn", "CHEMICAL", 284, 290], ["neurodegeneration", "DISEASE", 387, 404], ["h-aSyn", "GENE_OR_GENE_PRODUCT", 53, 59], ["human", "ORGANISM", 74, 79], ["mouse", "ORGANISM", 80, 85], ["aSyn", "GENE_OR_GENE_PRODUCT", 86, 90], ["membrane", "CELLULAR_COMPONENT", 201, 209], ["h-aSyn WT", "ORGANISM", 284, 293], ["midbrain cultures", "CELL", 353, 370], ["rat", "ORGANISM", 442, 445], ["midbrain", "ORGAN", 446, 454], ["h-aSyn 489Effects", "PROTEIN", 53, 70], ["human/mouse aSyn mismatches", "DNA", 74, 101], ["primary midbrain cultures", "CELL_LINE", 345, 370], ["human", "SPECIES", 74, 79], ["mouse", "SPECIES", 80, 85], ["rat", "SPECIES", 442, 445], ["human", "SPECIES", 74, 79], ["mouse", "SPECIES", 80, 85], ["human/mouse aSyn mismatches", "TREATMENT", 74, 101], ["fibril morphology", "TEST", 105, 122], ["a non-significant trend", "PROBLEM", 154, 177], ["our earlier studies", "TEST", 259, 278], ["h-aSyn WT", "TEST", 284, 293], ["primary midbrain cultures", "TEST", 345, 370], ["neurodegeneration", "PROBLEM", 387, 404], ["neurodegeneration", "OBSERVATION_MODIFIER", 387, 404], ["less", "OBSERVATION_MODIFIER", 405, 409], ["midbrain", "ANATOMY", 446, 454]]], ["HEK293 cells were co-transfected at a confluency of 70-80% using the calcium-616 phosphate precipitation method.", [["HEK293 cells", "ANATOMY", 0, 12], ["calcium-616 phosphate", "CHEMICAL", 69, 90], ["calcium-616 phosphate", "CHEMICAL", 69, 90], ["HEK293 cells", "CELL", 0, 12], ["calcium-616 phosphate", "SIMPLE_CHEMICAL", 69, 90], ["HEK293 cells", "CELL_LINE", 0, 12], ["HEK293 cells", "TEST", 0, 12], ["a confluency", "TEST", 36, 48], ["the calcium", "TEST", 65, 76], ["phosphate precipitation method", "TREATMENT", 81, 111]]], ["Plasmids used here encode essential adenoviral packaging 617 and AAV5 capsid genes as previously described (76).", [["adenoviral", "ORGANISM", 36, 46], ["AAV5 capsid", "GENE_OR_GENE_PRODUCT", 65, 76], ["adenoviral packaging 617 and AAV5 capsid genes", "DNA", 36, 82], ["Plasmids", "TREATMENT", 0, 8], ["essential adenoviral packaging", "TREATMENT", 26, 56], ["AAV5 capsid genes", "PROBLEM", 65, 82], ["capsid genes", "OBSERVATION", 70, 82]]], ["Three days after transfection, cells were 618 harvested in PBS and lysed by performing three freeze-thaw cycles in a dry ice/ethanol bath.", [["cells", "ANATOMY", 31, 36], ["ethanol", "CHEMICAL", 125, 132], ["ethanol", "CHEMICAL", 125, 132], ["cells", "CELL", 31, 36], ["ethanol", "SIMPLE_CHEMICAL", 125, 132], ["cells", "TEST", 31, 36], ["a dry ice/ethanol bath", "TREATMENT", 115, 137]]], ["619Effects of human/mouse aSyn mismatches on fibril morphology and dimensions 203The lysate was then treated with benzonase and purified using a discontinuous iodixanol 620 gradient followed by Sepharose Q column chromatography (77).", [["fibril", "ANATOMY", 45, 51], ["lysate", "ANATOMY", 85, 91], ["benzonase", "CHEMICAL", 114, 123], ["iodixanol", "CHEMICAL", 159, 168], ["benzonase", "CHEMICAL", 114, 123], ["human", "ORGANISM", 14, 19], ["mouse", "ORGANISM", 20, 25], ["aSyn", "GENE_OR_GENE_PRODUCT", 26, 30], ["lysate", "ORGANISM_SUBSTANCE", 85, 91], ["benzonase", "SIMPLE_CHEMICAL", 114, 123], ["iodixanol", "SIMPLE_CHEMICAL", 159, 168], ["human", "SPECIES", 14, 19], ["mouse", "SPECIES", 20, 25], ["human", "SPECIES", 14, 19], ["mouse", "SPECIES", 20, 25], ["human/mouse aSyn mismatches", "TREATMENT", 14, 41], ["The lysate", "TREATMENT", 81, 91], ["benzonase", "TREATMENT", 114, 123], ["a discontinuous iodixanol", "TREATMENT", 143, 168], ["Sepharose Q column chromatography", "TREATMENT", 194, 227], ["fibril morphology", "OBSERVATION_MODIFIER", 45, 62]]], ["Vectors were concentrated 621 using a 100 kDa molecular weight cut-off column, and titers of the stock solution were 622 determined by qPCR using primers and probes targeting the ITR sequence.", [["ITR sequence", "DNA", 179, 191], ["the stock solution", "TREATMENT", 93, 111], ["the ITR sequence", "TEST", 175, 191]]], ["Before being used 623 in an experiment, vectors were diluted in PBS, pH 7.4 and re-titered, yielding the values 624 reported in the Results and in Figure 3 . delivery of the vector, the capillary was left in place for 5 min, retracted 0.1 mm, and after 1 min it was slowly removed from the brain.", [["capillary", "ANATOMY", 186, 195], ["brain", "ANATOMY", 290, 295], ["capillary", "TISSUE", 186, 195], ["brain", "ORGAN", 290, 295], ["pH", "TEST", 69, 71], ["delivery of the vector", "TREATMENT", 158, 180], ["capillary", "ANATOMY", 186, 195], ["left", "ANATOMY_MODIFIER", 200, 204], ["brain", "ANATOMY", 290, 295]]], ["After closing the wound with clips, Antisedan and 666Effects of human/mouse aSyn mismatches on fibril morphology and dimensions 203Temgesic were administered s.c. as an analgesic treatment and to reverse the anesthesia.", [["wound", "ANATOMY", 18, 23], ["fibril", "ANATOMY", 95, 101], ["wound", "PATHOLOGICAL_FORMATION", 18, 23], ["human", "ORGANISM", 64, 69], ["mouse", "ORGANISM", 70, 75], ["aSyn", "GENE_OR_GENE_PRODUCT", 76, 80], ["human", "SPECIES", 64, 69], ["mouse", "SPECIES", 70, 75], ["human", "SPECIES", 64, 69], ["mouse", "SPECIES", 70, 75], ["closing the wound", "PROBLEM", 6, 23], ["clips", "TREATMENT", 29, 34], ["Antisedan", "TREATMENT", 36, 45], ["human/mouse aSyn mismatches", "TREATMENT", 64, 91], ["an analgesic treatment", "TREATMENT", 166, 188], ["the anesthesia", "TREATMENT", 204, 218], ["wound", "ANATOMY", 18, 23], ["clips", "OBSERVATION", 29, 34]]], ["667 668Effects of human/mouse aSyn mismatches on fibril morphology and dimensions 203Histology.", [["fibril", "ANATOMY", 49, 55], ["human", "ORGANISM", 18, 23], ["mouse", "ORGANISM", 24, 29], ["aSyn", "GENE_OR_GENE_PRODUCT", 30, 34], ["human", "SPECIES", 18, 23], ["mouse", "SPECIES", 24, 29], ["human", "SPECIES", 18, 23], ["mouse", "SPECIES", 24, 29], ["human/mouse aSyn mismatches", "TREATMENT", 18, 45]]], ["An overdose of sodium pentobarbital was used to kill rats 8 weeks after vector 669 delivery.", [["overdose", "DISEASE", 3, 11], ["sodium pentobarbital", "CHEMICAL", 15, 35], ["sodium pentobarbital", "CHEMICAL", 15, 35], ["sodium pentobarbital", "SIMPLE_CHEMICAL", 15, 35], ["rats", "ORGANISM", 53, 57], ["rats", "SPECIES", 53, 57], ["sodium pentobarbital", "TREATMENT", 15, 35]]], ["Animals were perfused via the ascending aorta first with 50 mL of 0.9% (w/v) NaCl 670 followed by 250 mL of ice-cold 4% (w/v) PFA in 0.1 M phosphate buffer, pH 7.4, for 5 min. collected from the 5% iodixanol fraction at the top of the gradient, concentrated using a 10 kDa 806 spin filter, and analyzed via Western blotting using a primary antibody specific for aSyn (Syn-1) 807 For membrane disruption experiments, monomeric aSyn variants were isolated as 820 fibrils (10 \u00b5L, prepared as described above under 'aSyn fibrillization' with an incubation time of 839 ~100 h and diluted 1/20 in deionized water) was deposited onto the APS-mica surface, and the 840 sample was incubated for 2 min, rinsed with deionized water, and dried under an argon stream.", [["ascending aorta", "ANATOMY", 30, 45], ["membrane", "ANATOMY", 383, 391], ["sample", "ANATOMY", 661, 667], ["NaCl", "CHEMICAL", 77, 81], ["phosphate", "CHEMICAL", 139, 148], ["iodixanol", "CHEMICAL", 198, 207], ["NaCl", "CHEMICAL", 77, 81], ["PFA", "CHEMICAL", 126, 129], ["phosphate", "CHEMICAL", 139, 148], ["iodixanol", "CHEMICAL", 198, 207], ["Animals", "ORGANISM", 0, 7], ["aorta", "ORGAN", 40, 45], ["/v) PFA", "SIMPLE_CHEMICAL", 122, 129], ["iodixanol", "SIMPLE_CHEMICAL", 198, 207], ["Syn-1", "GENE_OR_GENE_PRODUCT", 368, 373], ["membrane", "CELLULAR_COMPONENT", 383, 391], ["aSyn", "GENE_OR_GENE_PRODUCT", 426, 430], ["aSyn (Syn-1) 807", "PROTEIN", 362, 378], ["monomeric aSyn variants", "PROTEIN", 416, 439], ["APS", "PROTEIN", 631, 634], ["NaCl", "TREATMENT", 77, 81], ["PFA in 0.1 M phosphate buffer", "TREATMENT", 126, 155], ["pH", "TEST", 157, 159], ["the 5% iodixanol fraction", "TREATMENT", 191, 216], ["a 10 kDa 806 spin filter", "TREATMENT", 264, 288], ["a primary antibody", "TEST", 330, 348], ["aSyn", "TEST", 362, 366], ["membrane disruption experiments", "PROBLEM", 383, 414], ["monomeric aSyn variants", "PROBLEM", 416, 439], ["deionized water", "TREATMENT", 705, 720], ["an argon stream", "TREATMENT", 738, 753], ["ascending aorta", "ANATOMY", 30, 45], ["gradient", "OBSERVATION_MODIFIER", 235, 243], ["aSyn variants", "OBSERVATION", 426, 439], ["argon stream", "OBSERVATION", 741, 753]]], ["841Effects of human/mouse aSyn mismatches on fibril morphology and dimensions 203The sample was imaged with an AFM Nanoscope VIII system (Bruker, Santa Barbara, CA) 842 using MSNL probes (Cantilever F with spring constant 0.6 N/m), operating in air in peak force 843 mode.", [["fibril", "ANATOMY", 45, 51], ["sample", "ANATOMY", 85, 91], ["human", "ORGANISM", 14, 19], ["mouse", "ORGANISM", 20, 25], ["aSyn", "CELL", 26, 30], ["human", "SPECIES", 14, 19], ["mouse", "SPECIES", 20, 25], ["human", "SPECIES", 14, 19], ["mouse", "SPECIES", 20, 25], ["human/mouse aSyn mismatches", "TREATMENT", 14, 41], ["The sample", "TEST", 81, 91], ["MSNL probes (Cantilever F with spring constant", "TREATMENT", 175, 221], ["air", "ANATOMY", 245, 248]]], ["Images were acquired over a few randomly selected locations.", [["Images", "TEST", 0, 6]]], ["Images were analyzed 844 using Gwyddion and FemtoScan online software (Advanced Technologies Center, Moscow, 845 Russia) (88, 89) .", [["Images", "TEST", 0, 6]]], ["867 Statistical analysis.", [["Statistical analysis", "TEST", 4, 24]]], ["Statistical analyses were carried out using GraphPad Prism 6.0 (La Jolla, 868 CA).", [["Statistical analyses", "TEST", 0, 20], ["GraphPad Prism", "TEST", 44, 58]]], ["Primary neuron viability data, in vivo stereology and densitometry data, densitometry data 869 from Western blots, and calcein dye release data were analyzed via ANOVA followed by 870Effects of human/mouse aSyn mismatches on fibril morphology and dimensions 203Tukey's multiple comparisons post hoc test for normally distributed measurements.", [["Primary neuron", "ANATOMY", 0, 14], ["fibril", "ANATOMY", 225, 231], ["calcein", "CHEMICAL", 119, 126], ["calcein", "CHEMICAL", 119, 126], ["Primary neuron", "CELL", 0, 14], ["calcein dye", "SIMPLE_CHEMICAL", 119, 130], ["human", "ORGANISM", 194, 199], ["mouse", "ORGANISM", 200, 205], ["aSyn", "CELL", 206, 210], ["human", "SPECIES", 194, 199], ["mouse", "SPECIES", 200, 205], ["human", "SPECIES", 194, 199], ["mouse", "SPECIES", 200, 205], ["Primary neuron viability data", "TEST", 0, 29], ["densitometry data", "TEST", 54, 71], ["densitometry data", "TEST", 73, 90], ["Western blots", "TEST", 100, 113], ["calcein dye release data", "TEST", 119, 143], ["human/mouse aSyn mismatches", "TREATMENT", 194, 221], ["fibril morphology", "TEST", 225, 242], ["hoc test", "TEST", 295, 303]]], ["In analyzing 871 percentage dye release data and percentage cell viability data by ANOVA, square root 872 transformations were carried out to conform to ANOVA assumptions.", [["cell", "ANATOMY", 60, 64], ["cell", "CELL", 60, 64], ["percentage cell viability data", "TEST", 49, 79]]], ["Normalized FFN-102 873 fluorescence data were subjected to a log transformation to account for skewness in the data.", [["FFN", "PROTEIN", 11, 14], ["FFN", "TEST", 11, 14], ["fluorescence data", "TEST", 23, 40], ["a log transformation", "PROBLEM", 59, 79], ["skewness in the data", "PROBLEM", 95, 115]]], ["874Effects of human/mouse aSyn mismatches on fibril morphology and dimensions 203The log-transformed data were analyzed using an approach that accounts for comparison Table S2 ).", [["fibril", "ANATOMY", 45, 51], ["human", "ORGANISM", 14, 19], ["mouse", "ORGANISM", 20, 25], ["aSyn", "CELL", 26, 30], ["human", "SPECIES", 14, 19], ["mouse", "SPECIES", 20, 25], ["human", "SPECIES", 14, 19], ["mouse", "SPECIES", 20, 25], ["human/mouse aSyn mismatches", "TREATMENT", 14, 41], ["an approach", "TREATMENT", 126, 137]]], ["The data in (B) and (C) are presented as the mean \u00b1 SEM, n = 4 (B) or 1223 n = 3 (C). p<0.001, ****p<0.0001, one-way ANOVA followed by Tukey's 1224 multiple comparisons post hoc test (a square root transformation was carried out on the data in 1225 panel C).", [["The data", "TEST", 0, 8], ["hoc test", "TEST", 174, 182], ["a square root transformation", "PROBLEM", 184, 212]]]], "PMC7451978": [["In April 2016, a resolution by all members of the 68th World Health Assembly* in coordination with the Global Polio Eradication Initiative (GPEI) resulted in the removal of the Sabin-strain type 2 oral poliovirus vaccine (OPV) component from all immunization activities to avert outbreaks of type 2 circulating vaccine-derived poliovirus (cVDPV2).", [["Sabin-strain type 2", "ORGANISM", 177, 196], ["oral poliovirus", "ORGANISM", 197, 212], ["type 2 circulating vaccine-derived poliovirus", "ORGANISM", 292, 337], ["cVDPV2", "ORGANISM", 339, 345], ["oral poliovirus vaccine", "SPECIES", 197, 220], ["Sabin-strain type 2 oral poliovirus", "SPECIES", 177, 212], ["OPV", "SPECIES", 222, 225], ["cVDPV2", "SPECIES", 339, 345], ["the removal", "TREATMENT", 158, 169], ["the Sabin-strain type 2 oral poliovirus vaccine (OPV) component", "TREATMENT", 173, 236], ["all immunization activities", "TREATMENT", 242, 269], ["type 2 circulating vaccine", "TREATMENT", 292, 318]]], ["In the first quarter of 2016, house-to-house supplementary immunization activities (SIAs) with trivalent OPV (containing Sabin-strain types 1, 2 and 3) were conducted in 42 at-risk countries\u2020 in an effort to close type 2 immunity gaps in countries with chronically weak routine childhood immunization systems.", [["trivalent OPV", "CHEMICAL", 95, 108], ["Sabin-strain", "ORGANISM", 121, 133], ["supplementary immunization activities", "TREATMENT", 45, 82], ["trivalent OPV", "TREATMENT", 95, 108], ["Sabin-strain types", "TREATMENT", 121, 139], ["routine childhood immunization systems", "TREATMENT", 270, 308]]], ["However, the quality of SIAs in some countries was inadequate, and pockets of unimmunized and underimmunized children remained.", [["children", "ORGANISM", 109, 117], ["children", "SPECIES", 109, 117], ["pockets", "OBSERVATION_MODIFIER", 67, 74]]], ["Sabin-strain monovalent OPV type 2 (mOPV2) was then successfully used in response to many cVDPV2 outbreaks; however, some outbreaks in sub-Saharan Africa were not promptly controlled and spread to other countries.", [["Sabin-strain", "ORGANISM", 0, 12], ["monovalent OPV type 2", "GENE_OR_GENE_PRODUCT", 13, 34], ["mOPV2", "ORGANISM", 36, 41], ["many cVDPV2 outbreaks", "PROBLEM", 85, 106]]], ["Where mOPV2 SIA quality was low, prolonged Sabin-strain type 2 circulation allowed new cVDPV2 outbreaks to emerge (1).", [["mOPV2", "GENE_OR_GENE_PRODUCT", 6, 11], ["prolonged Sabin-strain type 2 circulation", "PROBLEM", 33, 74]]], ["In 2019, 358 cVDPV2 cases were reported, representing a fourfold increase over the 71 cases reported in 2018 and more than tripling the number of countries with outbreaks, from five (2) to 16.", [["fourfold", "OBSERVATION_MODIFIER", 56, 64], ["increase", "OBSERVATION_MODIFIER", 65, 73]]], ["As of August 2, a total of 236 cVDPV2 cases in 17 countries have been reported in 2020.", [["cVDPV2 cases", "TEST", 31, 43]]]], "PMC7543883": [["COVID-19 and older people\u2014an introductionThe impact of coronavirus disease 2019 (COVID-19) has been particularly severe amongst older people.", [["coronavirus disease", "DISEASE", 55, 74], ["COVID-19", "CHEMICAL", 81, 89], ["coronavirus", "ORGANISM", 55, 66], ["people", "ORGANISM", 134, 140], ["people", "SPECIES", 134, 140], ["COVID", "TEST", 0, 5], ["older people\u2014an introduction", "TREATMENT", 13, 41], ["coronavirus disease", "PROBLEM", 55, 74], ["COVID", "TEST", 81, 86], ["coronavirus disease", "OBSERVATION", 55, 74], ["severe", "OBSERVATION_MODIFIER", 113, 119]]], ["In total, 80% of deaths amongst confirmed COVID-19 cases in the United States have been in adults aged over 65.", [["deaths", "DISEASE", 17, 23], ["COVID", "DISEASE", 42, 47], ["COVID", "TEST", 42, 47]]], ["Data from April 2020 reported a mortality rate of 4\u201311% for those aged 65\u201384 and 10\u201325% in those over 85 [1].", [["a mortality rate", "TEST", 30, 46]]], ["In Italy, one of the reasons proposed for the high death rate has been the proportion of older people in the population.", [["death", "DISEASE", 51, 56], ["people", "ORGANISM", 95, 101], ["people", "SPECIES", 95, 101], ["the high death rate", "PROBLEM", 42, 61]]], ["Data from China, South Korea and Spain [2\u20134] all confirm that older people are disproportionately affected.", [["people", "ORGANISM", 68, 74], ["people", "SPECIES", 68, 74], ["disproportionately", "OBSERVATION_MODIFIER", 79, 97], ["affected", "OBSERVATION", 98, 106]]], ["The impact of COVID-19 has been particularly apparent in care homes and similar institutions.", [["COVID-19", "CHEMICAL", 14, 22], ["COVID", "TREATMENT", 14, 19]]], ["In this commentary, we discuss the vulnerability of older people to epidemics in general.", [["people", "ORGANISM", 58, 64], ["people", "SPECIES", 58, 64]]], ["We provide recommendations on how the needs and views of older people need to be systematically factored into the current and future epidemic responses.Impact of past epidemics on older peopleIn the last century, influenza viruses were primarily responsible for global respiratory epidemics.", [["respiratory", "ANATOMY", 269, 280], ["influenza viruses", "DISEASE", 213, 230], ["respiratory epidemics", "DISEASE", 269, 290], ["people", "ORGANISM", 63, 69], ["people", "ORGANISM", 186, 192], ["influenza viruses", "ORGANISM", 213, 230], ["people", "SPECIES", 63, 69], ["people", "SPECIES", 186, 192], ["influenza viruses", "PROBLEM", 213, 230], ["global respiratory epidemics", "PROBLEM", 262, 290], ["influenza viruses", "OBSERVATION", 213, 230], ["respiratory epidemics", "OBSERVATION", 269, 290]]], ["Those under the age of 65 were severely affected by some of these, most notably the 1918 influenza pandemic [6].", [["influenza pandemic", "DISEASE", 89, 107], ["severely affected", "PROBLEM", 31, 48]]], ["A high prevalence amongst children and young adults was observed in the H1N1 epidemic of 2009.", [["children", "ORGANISM", 26, 34], ["children", "SPECIES", 26, 34]]], ["One possible explanation for low H1N1 mortality amongst older people may has been immunity due to prior exposure to similar serotypes [7].", [["H1N1", "DISEASE", 33, 37], ["people", "ORGANISM", 62, 68], ["people", "SPECIES", 62, 68], ["low H1N1 mortality", "PROBLEM", 29, 47], ["similar serotypes", "PROBLEM", 116, 133], ["possible explanation for", "UNCERTAINTY", 4, 28]]], ["Alternative explanations include differences in cytokine storm responses [8] and antigenic imprinting between the age groups [6].", [["cytokine", "PROTEIN", 48, 56]]], ["The age distribution of typical annual seasonal influenza epidemics exhibits a different pattern, however.", [["influenza", "DISEASE", 48, 57], ["typical annual seasonal influenza epidemics", "PROBLEM", 24, 67], ["typical", "OBSERVATION_MODIFIER", 24, 31], ["annual", "OBSERVATION_MODIFIER", 32, 38], ["seasonal influenza", "OBSERVATION", 39, 57], ["different pattern", "OBSERVATION_MODIFIER", 79, 96]]], ["In 31 countries between 2002\u20132011, 67% of influenza deaths occurred in those 65 years of age or older, 26 times the mortality in those under 65 [9].Impact of past epidemics on older peopleThe novel coronaviruses SARS\u2013CoV1 and MERS\u2013CoV emerged in the last 20 years, causing severe acute respiratory syndrome and the Middle East respiratory syndrome.", [["deaths", "DISEASE", 52, 58], ["acute respiratory syndrome", "DISEASE", 280, 306], ["Middle East respiratory syndrome", "DISEASE", 315, 347], ["people", "ORGANISM", 182, 188], ["coronaviruses", "ORGANISM", 198, 211], ["people", "SPECIES", 182, 188], ["influenza deaths", "PROBLEM", 42, 58], ["severe acute respiratory syndrome", "PROBLEM", 273, 306], ["the Middle East respiratory syndrome", "PROBLEM", 311, 347], ["coronaviruses", "OBSERVATION", 198, 211], ["severe", "OBSERVATION_MODIFIER", 273, 279], ["acute", "OBSERVATION_MODIFIER", 280, 285], ["respiratory syndrome", "OBSERVATION", 286, 306], ["Middle", "ANATOMY_MODIFIER", 315, 321], ["respiratory syndrome", "OBSERVATION", 327, 347]]], ["These coronaviruses impacted older people disproportionately before subsiding [10].", [["coronaviruses", "ORGANISM", 6, 19], ["people", "ORGANISM", 35, 41], ["people", "SPECIES", 35, 41]]], ["No lessons were learnt about how to mitigate the impact of coronavirus epidemics on older people.Demographic determinants ::: COVID-19 and older people\u2014overlooked vulnerabilitiesBoth absolute numbers and the proportion of the older population who are especially at risk during epidemics have grown.", [["coronavirus epidemics", "DISEASE", 59, 80], ["coronavirus", "ORGANISM", 59, 70], ["people", "ORGANISM", 90, 96], ["people", "SPECIES", 90, 96], ["coronavirus epidemics", "PROBLEM", 59, 80], ["COVID", "TEST", 126, 131], ["epidemics", "PROBLEM", 277, 286], ["absolute", "OBSERVATION_MODIFIER", 183, 191], ["numbers", "OBSERVATION_MODIFIER", 192, 199]]], ["The global older population increased from 128 million in 1950 to more than 700 million in 2019.", [["global", "OBSERVATION_MODIFIER", 4, 10], ["older", "OBSERVATION_MODIFIER", 11, 16], ["population", "OBSERVATION_MODIFIER", 17, 27], ["increased", "OBSERVATION_MODIFIER", 28, 37]]], ["In the United States, older people constituted 4.1% of the population in 1900 and 15.2% in 2016 [11].", [["people", "ORGANISM", 28, 34], ["people", "SPECIES", 28, 34]]], ["The number of very old people is also increasing; in the United States, there were 6.4 million people over 85 years in 2016, 50 times more than in 1900 [12].", [["people", "ORGANISM", 23, 29], ["people", "ORGANISM", 95, 101], ["people", "SPECIES", 23, 29], ["people", "SPECIES", 95, 101], ["number", "OBSERVATION_MODIFIER", 4, 10], ["very", "OBSERVATION_MODIFIER", 14, 18], ["old", "OBSERVATION_MODIFIER", 19, 22], ["people", "OBSERVATION", 23, 29], ["increasing", "OBSERVATION_MODIFIER", 38, 48]]], ["Government policy, health and social care and wider society should therefore plan to meet the particular needs of older people during epidemics much more than previously.Biological determinants ::: COVID-19 and older people\u2014overlooked vulnerabilitiesSeveral biological mechanisms make older people more prone to the effects of infections.", [["infections", "DISEASE", 327, 337], ["people", "ORGANISM", 120, 126], ["people", "ORGANISM", 291, 297], ["people", "SPECIES", 120, 126], ["people", "SPECIES", 291, 297], ["COVID", "TEST", 198, 203], ["infections", "PROBLEM", 327, 337], ["vulnerabilities", "OBSERVATION", 235, 250], ["infections", "OBSERVATION", 327, 337]]], ["The immune system is critical to survival of a host against pathogens.", [["immune system", "ANATOMY", 4, 17], ["pathogens", "PROBLEM", 60, 69]]], ["Old age is associated with immuno-senescence, the decline in immune function with increasing age [13].", [["immuno-senescence", "PROBLEM", 27, 44], ["the decline", "PROBLEM", 46, 57], ["immune function", "OBSERVATION", 61, 76]]], ["Immuno-senescence is likely to be one of the main reasons for increased attack rates, higher hospitalisation and mortality due to COVID-19 [14].", [["COVID-19", "CHEMICAL", 130, 138], ["increased attack rates", "PROBLEM", 62, 84], ["COVID", "TEST", 130, 135]]], ["Similar evidence emerged in previous coronavirus epidemics too [15].Biological determinants ::: COVID-19 and older people\u2014overlooked vulnerabilitiesOlder people suffer more co-morbidities such as diabetes, hypertension, coronary heart disease, chronic obstructive pulmonary disease, renal disease and cancer.", [["coronary", "ANATOMY", 220, 228], ["heart", "ANATOMY", 229, 234], ["pulmonary", "ANATOMY", 264, 273], ["renal", "ANATOMY", 283, 288], ["cancer", "ANATOMY", 301, 307], ["coronavirus epidemics", "DISEASE", 37, 58], ["diabetes", "DISEASE", 196, 204], ["hypertension", "DISEASE", 206, 218], ["coronary heart disease", "DISEASE", 220, 242], ["chronic obstructive pulmonary disease", "DISEASE", 244, 281], ["renal disease", "DISEASE", 283, 296], ["cancer", "DISEASE", 301, 307], ["coronavirus", "ORGANISM", 37, 48], ["people", "ORGANISM", 154, 160], ["heart", "ORGAN", 229, 234], ["pulmonary", "ORGAN", 264, 273], ["renal", "ORGAN", 283, 288], ["cancer", "CANCER", 301, 307], ["people", "SPECIES", 154, 160], ["previous coronavirus epidemics", "PROBLEM", 28, 58], ["COVID", "TEST", 96, 101], ["diabetes", "PROBLEM", 196, 204], ["hypertension", "PROBLEM", 206, 218], ["coronary heart disease", "PROBLEM", 220, 242], ["chronic obstructive pulmonary disease", "PROBLEM", 244, 281], ["renal disease", "PROBLEM", 283, 296], ["cancer", "PROBLEM", 301, 307], ["vulnerabilities", "OBSERVATION", 133, 148], ["diabetes", "OBSERVATION", 196, 204], ["hypertension", "OBSERVATION", 206, 218], ["coronary heart", "ANATOMY", 220, 234], ["disease", "OBSERVATION", 235, 242], ["chronic", "OBSERVATION_MODIFIER", 244, 251], ["obstructive", "OBSERVATION_MODIFIER", 252, 263], ["pulmonary", "ANATOMY", 264, 273], ["disease", "OBSERVATION", 274, 281], ["renal", "ANATOMY", 283, 288], ["disease", "OBSERVATION", 289, 296], ["cancer", "OBSERVATION", 301, 307]]], ["A 2016 study from Hubei, China, reported the prevalence of one or more non-communicable diseases amongst older people to be 74% [16].", [["non-communicable diseases", "DISEASE", 71, 96], ["people", "ORGANISM", 111, 117], ["people", "SPECIES", 111, 117], ["A 2016 study", "TEST", 0, 12], ["more non-communicable diseases", "PROBLEM", 66, 96]]], ["These co-morbidities could both exacerbate immuno-senescence and render compromised organs more vulnerable to the virus.", [["organs", "ANATOMY", 84, 90], ["organs", "ORGAN", 84, 90], ["These co-morbidities", "PROBLEM", 0, 20], ["immuno-senescence", "PROBLEM", 43, 60], ["render compromised organs", "PROBLEM", 65, 90], ["the virus", "PROBLEM", 110, 119]]], ["Related to, but distinct from, the effects of multimorbidity are the effects of frailty\u2014the loss of homeostatic reserve that renders many older people disproportionately vulnerable to the impact of even relatively minor stressors.", [["multimorbidity", "DISEASE", 46, 60], ["frailty", "DISEASE", 80, 87], ["people", "ORGANISM", 144, 150], ["people", "SPECIES", 144, 150], ["multimorbidity", "PROBLEM", 46, 60], ["the loss of homeostatic reserve", "PROBLEM", 88, 119], ["distinct", "OBSERVATION_MODIFIER", 16, 24]]], ["Recovery from any illness is less likely when frailty is present, recovery takes longer and those recovering are more prone to further episodes of illness.Biological determinants ::: COVID-19 and older people\u2014overlooked vulnerabilitiesOlder people are less likely to display typical disease symptoms than their younger counterparts.", [["illness", "DISEASE", 147, 154], ["people", "ORGANISM", 241, 247], ["people", "SPECIES", 241, 247], ["any illness", "PROBLEM", 14, 25], ["illness", "PROBLEM", 147, 154], ["COVID", "TEST", 183, 188], ["typical disease symptoms", "PROBLEM", 275, 299], ["less likely", "UNCERTAINTY", 29, 40], ["vulnerabilities", "OBSERVATION", 220, 235], ["less likely", "UNCERTAINTY", 252, 263], ["typical", "OBSERVATION_MODIFIER", 275, 282], ["disease", "OBSERVATION", 283, 290]]], ["Notably, fever is often absent, but case definition in viral epidemics often includes fever.", [["fever", "DISEASE", 9, 14], ["fever", "DISEASE", 86, 91], ["fever", "PROBLEM", 9, 14], ["viral epidemics", "PROBLEM", 55, 70], ["fever", "PROBLEM", 86, 91], ["fever", "OBSERVATION", 9, 14]]], ["Standard tests, such as X-rays, may initially fail to detect pneumonia [17].", [["pneumonia", "DISEASE", 61, 70], ["Standard tests", "TEST", 0, 14], ["pneumonia", "PROBLEM", 61, 70], ["pneumonia", "OBSERVATION", 61, 70]]], ["Atypical presentations such as decreased appetite or functional status, dehydration, falls or delirium may lead to missed or late diagnosis, increasing the likelihood of morbidity, mortality and transmission of the virus [18].Biological determinants ::: COVID-19 and older people\u2014overlooked vulnerabilitiesIatrogenic harm remains high amongst older people requiring healthcare, including nosocomial infection due to urinary catheters, feeding tubes and other invasive devices and to exposure to pathogens in healthcare settings [19].", [["urinary", "ANATOMY", 416, 423], ["dehydration", "DISEASE", 72, 83], ["falls", "DISEASE", 85, 90], ["delirium", "DISEASE", 94, 102], ["Iatrogenic harm", "DISEASE", 306, 321], ["nosocomial infection", "DISEASE", 388, 408], ["people", "ORGANISM", 349, 355], ["urinary", "ORGANISM_SUBDIVISION", 416, 423], ["people", "SPECIES", 349, 355], ["Atypical presentations", "PROBLEM", 0, 22], ["decreased appetite", "PROBLEM", 31, 49], ["functional status", "PROBLEM", 53, 70], ["dehydration", "PROBLEM", 72, 83], ["falls", "PROBLEM", 85, 90], ["delirium", "PROBLEM", 94, 102], ["morbidity", "PROBLEM", 170, 179], ["the virus", "PROBLEM", 211, 220], ["COVID", "TEST", 254, 259], ["Iatrogenic harm", "PROBLEM", 306, 321], ["nosocomial infection", "PROBLEM", 388, 408], ["urinary catheters", "TREATMENT", 416, 433], ["feeding tubes", "TREATMENT", 435, 448], ["other invasive devices", "TREATMENT", 453, 475], ["vulnerabilities", "OBSERVATION", 291, 306], ["high amongst", "OBSERVATION_MODIFIER", 330, 342], ["urinary", "ANATOMY", 416, 423], ["catheters", "OBSERVATION", 424, 433], ["feeding tubes", "OBSERVATION", 435, 448]]], ["Older people are also more likely to suffer side effects and adverse consequences from drug therapy, and adverse effects of the healthcare environment.Behavioural determinants ::: COVID-19 and older people\u2014overlooked vulnerabilitiesPhysical activity and nutrition are important lifestyle determinants for risk of disease.", [["people", "ORGANISM", 6, 12], ["people", "SPECIES", 6, 12], ["side effects", "PROBLEM", 44, 56], ["drug therapy", "TREATMENT", 87, 99], ["COVID", "TEST", 180, 185], ["disease", "PROBLEM", 313, 320], ["more likely", "UNCERTAINTY", 22, 33], ["vulnerabilities", "OBSERVATION", 217, 232], ["disease", "OBSERVATION", 313, 320]]], ["A high proportion of older people in both high- and low-middle income nations are sedentary [20].", [["people", "ORGANISM", 27, 33], ["people", "SPECIES", 27, 33], ["high", "OBSERVATION_MODIFIER", 2, 6], ["proportion", "OBSERVATION_MODIFIER", 7, 17], ["high", "OBSERVATION_MODIFIER", 42, 46], ["middle", "ANATOMY_MODIFIER", 56, 62]]], ["Only a minority consume the recommended five servings a day of fruits and vegetables [21].", [["fruits", "ANATOMY", 63, 69], ["vegetables", "ANATOMY", 74, 84], ["fruits", "ORGANISM_SUBDIVISION", 63, 69]]], ["Smoking and alcohol use, and reduced cessation efforts with age, predispose to risk during epidemics [22].", [["Smoking", "DISEASE", 0, 7], ["alcohol", "CHEMICAL", 12, 19], ["alcohol", "CHEMICAL", 12, 19]]], ["Stress and fear associated with an epidemic compound the already high prevalence of insomnia with a variety of proposed adverse health consequences [23].Behavioural determinants ::: COVID-19 and older people\u2014overlooked vulnerabilitiesHealth literacy is a strong psychosocial determinant of health.", [["Stress and fear", "DISEASE", 0, 15], ["insomnia", "DISEASE", 84, 92], ["Stress and fear", "PROBLEM", 0, 15], ["an epidemic compound", "PROBLEM", 32, 52], ["insomnia", "PROBLEM", 84, 92], ["COVID", "TEST", 182, 187], ["vulnerabilities", "OBSERVATION", 219, 234]]], ["It varies by age and older people risk being further marginalised during pandemics due to inadequate or inconsistent health communication [24].", [["people", "ORGANISM", 27, 33], ["people", "SPECIES", 27, 33]]], ["Health communication strategies need to account for sensory impairments, older people\u2019s preferences for specific communication styles, take account of the prevalence of dementia and mild cognitive impairment in the older population and dependence on carers and family members [25,26].", [["sensory impairments", "DISEASE", 52, 71], ["dementia", "DISEASE", 169, 177], ["cognitive impairment", "DISEASE", 187, 207], ["people", "ORGANISM", 79, 85], ["people", "SPECIES", 79, 85], ["sensory impairments", "PROBLEM", 52, 71], ["dementia", "PROBLEM", 169, 177], ["mild cognitive impairment", "PROBLEM", 182, 207], ["dementia", "OBSERVATION", 169, 177], ["mild", "OBSERVATION_MODIFIER", 182, 186]]], ["Poor pandemic communication may contribute to increased risks for older people, particularly around seeking healthcare when this is restricted by competing demands, isolation or distancing restrictions [27].Social determinants ::: COVID-19 and older people\u2014overlooked vulnerabilitiesIn the United Kingdom, 34% of older people live in homes that do not provide an appropriate standard of warmth, comfort and hygiene [28].", [["people", "ORGANISM", 72, 78], ["people", "ORGANISM", 319, 325], ["people", "SPECIES", 72, 78], ["people", "SPECIES", 319, 325]]], ["The winter predilection of most epidemic respiratory viruses places older people living in inadequate homes or experiencing fuel poverty at heightened risk.", [["respiratory viruses", "DISEASE", 41, 60], ["people", "ORGANISM", 74, 80], ["people", "SPECIES", 74, 80], ["most epidemic respiratory viruses", "PROBLEM", 27, 60], ["most", "OBSERVATION_MODIFIER", 27, 31], ["epidemic", "OBSERVATION_MODIFIER", 32, 40], ["respiratory viruses", "OBSERVATION", 41, 60]]], ["Social isolation and loneliness exacerbate physical and mental health problems [30].", [["loneliness", "DISEASE", 21, 31]]], ["Reports highlight a profound impact of the current lockdown on older people\u2019s physical, social and mental health [31].", [["people", "ORGANISM", 69, 75], ["people", "SPECIES", 69, 75], ["profound", "OBSERVATION_MODIFIER", 20, 28]]], ["The United Nations in its policy brief on the impact of COVID-19 has warned that, \u2018Lockdowns and concentration of health resources on COVID-19 may marginalise older persons and create barriers to obtaining health services for their existing underlying conditions, some of which may increase their vulnerability to COVID-19\u2019 [32].Care delivery ::: COVID-19 and older people\u2014overlooked vulnerabilitiesMany older people require personal care delivered by paid carers.", [["COVID-19", "CHEMICAL", 314, 322], ["people", "ORGANISM", 410, 416], ["persons", "SPECIES", 165, 172], ["people", "SPECIES", 410, 416], ["COVID", "TEST", 314, 319], ["COVID", "TEST", 347, 352]]], ["An estimated 540,000 older people in the UK receive home care at least weekly.", [["people", "ORGANISM", 27, 33], ["people", "SPECIES", 27, 33], ["home care", "TREATMENT", 52, 61]]], ["Epidemics pose a challenge in ensuring that such care is still deliverable without increasing the risk of infection either directly from care staff or by cross-transmission between clients.", [["infection", "DISEASE", 106, 115], ["a challenge", "TREATMENT", 15, 26], ["infection", "PROBLEM", 106, 115], ["infection", "OBSERVATION", 106, 115]]], ["This depends on an adequate supply of personal protective equipment, robust and frequent staff testing, processes that enable exposed or infected staff to stop work and isolate without financial penalty and adequate staff in reserve to enable services to continue when staff are ill.", [["personal protective equipment", "TREATMENT", 38, 67], ["frequent staff testing", "TEST", 80, 102]]], ["Epidemics pose similar challenges for older people living in care homes, assisted living facilities, foster and group homes and chronic disease wards, who are known to be vulnerable to seasonal influenza and norovirus outbreaks.Healthcare determinants ::: COVID-19 and older people\u2014overlooked vulnerabilitiesOlder people are more likely to attend hospital, as an inpatient, outpatient or visitor [33].", [["chronic disease", "DISEASE", 128, 143], ["influenza", "DISEASE", 194, 203], ["norovirus outbreaks", "DISEASE", 208, 227], ["people", "ORGANISM", 44, 50], ["people", "ORGANISM", 314, 320], ["people", "SPECIES", 44, 50], ["people", "SPECIES", 314, 320], ["chronic disease wards", "PROBLEM", 128, 149], ["seasonal influenza", "PROBLEM", 185, 203], ["norovirus outbreaks", "PROBLEM", 208, 227], ["COVID", "TEST", 256, 261], ["chronic", "OBSERVATION_MODIFIER", 128, 135], ["disease", "OBSERVATION", 136, 143], ["influenza", "OBSERVATION", 194, 203], ["norovirus", "OBSERVATION", 208, 217]]], ["Exposure of older people to healthcare environments risks bringing them into contact with pathogens.", [["people", "ORGANISM", 18, 24], ["people", "SPECIES", 18, 24]]], ["Seasonal influenza vaccine coverage of older people has improved in recent years, but in some countries at least, it is far from universal.", [["people", "ORGANISM", 45, 51], ["people", "SPECIES", 45, 51], ["Seasonal influenza vaccine coverage", "TREATMENT", 0, 35], ["improved", "OBSERVATION_MODIFIER", 56, 64]]], ["Vaccination, even when available, often provides only partial protection to older people [34].", [["people", "SPECIES", 82, 88], ["Vaccination", "TREATMENT", 0, 11]]], ["New vaccines are often tested on healthy volunteers, and their safety and usefulness for older people requires specific testing, and this is likely to be the case for candidate COVID-19 vaccines.", [["volunteers", "ORGANISM", 41, 51], ["people", "ORGANISM", 95, 101], ["people", "SPECIES", 95, 101], ["New vaccines", "TREATMENT", 0, 12], ["specific testing", "TEST", 111, 127], ["COVID-19 vaccines", "TREATMENT", 177, 194]]], ["In lower-income nations, healthcare access for older people remains limited both in quantity and quality, even during normal times [35].", [["people", "ORGANISM", 53, 59], ["people", "SPECIES", 53, 59]]], ["COVID-19 has already provoked a debate on \u2018who should get a ventilator?\u2019", [["COVID-19", "CHEMICAL", 0, 8], ["a ventilator", "TREATMENT", 58, 70]]], ["Older people (and those who care for them) are at risk of being considered at \u2018low priority\u2019 for a variety of healthcare interventions that are in short supply [36].", [["people", "ORGANISM", 6, 12], ["people", "SPECIES", 6, 12], ["healthcare interventions", "TREATMENT", 110, 134]]], ["It is reasonable to assume that impoverished communities will see a further reduction of the resources available for the care of older people during epidemics.ConclusionThe risks for older people in epidemic situations are varied and of serious concern.", [["people", "ORGANISM", 135, 141], ["people", "ORGANISM", 189, 195], ["people", "SPECIES", 135, 141], ["people", "SPECIES", 189, 195], ["epidemics", "PROBLEM", 149, 158]]], ["Risk of both infection and poor health outcomes can be influenced by demographic, biological, behavioural, social and healthcare access factors.", [["infection", "DISEASE", 13, 22], ["both infection", "PROBLEM", 8, 22], ["poor health outcomes", "PROBLEM", 27, 47], ["both", "OBSERVATION_MODIFIER", 8, 12], ["infection", "OBSERVATION", 13, 22]]], ["Direct and indirect effects of pandemics contribute to increased and premature mortality, infection-associated morbidity, neglected co-morbid conditions and impaired well-being and quality of life for older people.ConclusionAmongst all the epidemics encountered so far, COVID-19 has especially highlighted the vulnerabilities and needs of older people.", [["infection", "DISEASE", 90, 99], ["impaired well-being", "DISEASE", 157, 176], ["people", "ORGANISM", 207, 213], ["people", "ORGANISM", 345, 351], ["people", "SPECIES", 207, 213], ["people", "SPECIES", 345, 351], ["pandemics", "TREATMENT", 31, 40], ["increased and premature mortality", "PROBLEM", 55, 88], ["infection", "PROBLEM", 90, 99], ["associated morbidity", "PROBLEM", 100, 120], ["neglected co-morbid conditions", "PROBLEM", 122, 152], ["increased", "OBSERVATION_MODIFIER", 55, 64], ["premature", "OBSERVATION_MODIFIER", 69, 78], ["infection", "OBSERVATION", 90, 99], ["morbidity", "OBSERVATION_MODIFIER", 111, 120]]], ["Health professionals and policymakers must work with older people to ensure inclusion of their special needs in preparedness and action plans.", [["people", "ORGANISM", 59, 65], ["people", "SPECIES", 59, 65]]], ["This requires leadership and guidance from national geriatrics societies, healthcare professionals, civil society and academia.ConclusionIntersectoral programmes that recognise the special needs of older people and in unique contexts such as care homes must be developed and implemented, with the full participation and agreement of older people at all stages.", [["people", "ORGANISM", 204, 210], ["people", "ORGANISM", 339, 345], ["people", "SPECIES", 204, 210], ["people", "SPECIES", 339, 345], ["academia", "PROBLEM", 118, 126]]], ["Such programmes should include: (i) need-based health awareness programmes in areas such as self-care and prevention; (ii) increasing the availability and accessibility of essential basic healthcare services (including telehealth) for addressing both acute infections and co-morbidities and (iii) enhancing education programmes for healthcare professionals to include topics that remain neglected in traditional curricula and (iv) strengthening the collection and analysis of data to guide programmes and policies for the protection and care of older people.ConclusionCOVID-19 has created upheaval, challenging humanity and threatening the lives, rights, and well-being of older people.", [["infections", "DISEASE", 257, 267], ["people", "ORGANISM", 551, 557], ["people", "ORGANISM", 679, 685], ["people", "SPECIES", 551, 557], ["people", "SPECIES", 679, 685], ["both acute infections", "PROBLEM", 246, 267], ["co-morbidities", "PROBLEM", 272, 286], ["the collection", "TEST", 445, 459], ["ConclusionCOVID", "TEST", 558, 573], ["acute", "OBSERVATION_MODIFIER", 251, 256], ["infections", "OBSERVATION", 257, 267]]], ["We must ensure that we remain an age-friendly society and make the world a better place for all including older people.", [["people", "ORGANISM", 112, 118], ["people", "SPECIES", 112, 118]]]], "PMC7228483": [["IntroductionCoronavirus disease 2019 (COVID-19), first detected late December 2019,1 2 is the first coronavirus (CoV) pandemic of the 21st century.", [["IntroductionCoronavirus disease", "DISEASE", 0, 31], ["coronavirus (CoV) pandemic", "DISEASE", 100, 126], ["coronavirus", "ORGANISM", 100, 111], ["CoV", "ORGANISM", 113, 116], ["IntroductionCoronavirus disease 2019 (COVID-19", "SPECIES", 0, 46], ["CoV", "SPECIES", 113, 116], ["IntroductionCoronavirus disease", "PROBLEM", 0, 31], ["COVID", "TEST", 38, 43]]], ["It is the most serious CoV outbreak in history with 266 073 cases and 11 183 deaths as of 21 March 2020,3 outnumbering both the 2003 severe acute respiratory syndrome epidemic (8096 cases, 774 deaths) and the 2012 Middle East respiratory syndrome outbreak (2494 cases, 858 deaths).4 5", [["deaths", "DISEASE", 77, 83], ["acute respiratory syndrome", "DISEASE", 140, 166], ["deaths", "DISEASE", 193, 199], ["Middle East respiratory syndrome", "DISEASE", 214, 246], ["deaths", "DISEASE", 273, 279], ["CoV", "ORGANISM", 23, 26], ["severe acute respiratory syndrome", "PROBLEM", 133, 166], ["Middle East respiratory syndrome outbreak", "PROBLEM", 214, 255], ["severe", "OBSERVATION_MODIFIER", 133, 139], ["acute", "OBSERVATION_MODIFIER", 140, 145], ["respiratory syndrome", "OBSERVATION", 146, 166], ["Middle", "ANATOMY_MODIFIER", 214, 220], ["respiratory syndrome", "OBSERVATION", 226, 246]]]]}